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In recent years, differential sensing has become an increasingly popular approach 
to molecular recognition.  Mimicking the mammalian senses of taste and smell, arrays of 
semi-selective sensors generate a fingerprint for each analyte.  Pattern recognition 
algorithms allow these arrays to be used for discriminating analytes and for predicting the 
identity of unknowns.  Arrays of cross-reactive receptors have found use in a variety of 
sensing applications, including the differentiation of biologically-relevant analytes 
(Chapter 1).   
Serum albumin has previously been used in an array format for the discrimination 
of hydrophobic analytes such as terpenes, plasticizers, and fatty acids.  This protein is a 
versatile cross-reactive receptor because of its ability to bind hydrophobic analytes with 
different affinities and in different modes.  In Chapter 2, the use of serum albumin to pattern 
hydrophobic analytes was further expanded to include glycerides.  Glycerides are 
challenging analytes because they are structurally similar to one another.  Due to 
difficulties in identifying the regio- and stereochemistry of the unsaturated glycerides, a 
sample pretreatment consisting of olefin cross metathesis was used prior to array analysis. 
Using the array, twenty glycerides were discriminated, including stereo- and regioisomeric 
pairs.  Further, glycerides in mixtures were quantitated.  
 vi 
Due to the success with using serum albumins as receptors for hydrophobic 
analytes, it was hypothesized that serum albumin could be used in a different way to 
develop receptors for other types of analytes.  The serum albumin functions as a scaffold 
onto which species dynamically assemble through hydrophobic interactions.  In Chapter 3, 
the use of fatty acid-appended recognition units was explored as a way of building such 
receptors.  While these conjugates did not bind to the protein as well as expected, an 
alternative strategy was explored in Chapter 4 with squaraines and thiols.  As a starting 
point toward this goal, a series of squaraines were synthesized, and their reactivity to thiols 
and affinity for serum albumin were investigated.  Finally, in Chapter 5, the reversible 
covalent attachment of recognition units to serum albumin with thia-Michael chemistry 
was explored.  A bifunctional conjugate acceptor was used to reversibly label proteins with 
thiols as well as to generate resin-bound dynamic combinatorial libraries.  
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Chapter 1: Array Sensing Using Optical Methods for Chemical Analysis1 
1.1 INTRODUCTION 
Nearly all biological systems employ a lock-and-key approach to molecular 
recognition in the form of antibodies and enzymes.1  Nature’s high specificity approach 
has been used successfully for synthetic receptor design in some cases, but it has several 
drawbacks that limit its applicability to many sensing challenges.  Firstly, the rational 
design of receptors is impractical for analytes that have not been fully characterized, such 
as many large biomolecules.  Furthermore, even if an analyte’s structure is known and a 
highly specific receptor can be designed, the synthetic work required to actually make the 
receptor can be an overwhelming task in itself.  Finally, analyzing complex mixtures of 
analytes using a lock-and-key approach requires the design and synthesis of receptors for 
each component in the mixture, which is often an incredibly time-consuming undertaking.   
For these reasons, an increasingly popular approach that also mimics biology is 
differential sensing.  Mammalian olfaction and gustation employ cross-reactive receptors 
that interact differentially with odorants and tastants.2, 3, 4  Instead of identifying an odorant 
or tastant molecule by its strong affinity for one particular receptor, recognition is achieved 
by the composite response of the odorant or tastant to the entire array of semi-selective 
receptors in the nose or on the tongue.5  The result is a characteristic pattern – or 
fingerprint– for that odor or taste that the brain can perceive and store in an organism’s 
memory.6   An important advantage of this approach to molecule identification is that the 
system is limited by the number of different patterns possible for an array of receptors 
rather than by the number of different receptors.  Hence, the different receptors need not 
be designed to be highly specific for any one analyte.  Additionally, this array approach 
                                                 
1 Parts of this chapter were adapted from Diehl, K. L.; Anslyn, E. V. Chem. Soc. Rev. 2013, 42, 8596–8611.  
Katharine Diehl wrote the review, and Eric Anslyn edited the review. 
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allows the discrimination of analytes or analyte mixtures that have not been exhaustively 
characterized.    
In the laboratory, the differential sensing approach described above is 
accomplished using sets of cross-reactive receptors and pattern recognition algorithms to 
process the large amount of data generated from this method (Figure 1.1).  Both vapors 
and solutions can be exposed to the sensor array by either an active flow system that 
samples an analyte at a particular point in time (e.g. headspace sampling) or a static system 
that allows for equilibration between the receptors and analyte (e.g. microtiter plates).7 
Whatever method is used to introduce the analyte to the sensor array, a measurable signal 
is generated upon the interaction of an analyte with the receptors.  Many different kinds of 
signals can be employed, but most can be classified as electrical, gravimetric, or optical.1 
 
 
Figure 1.1 General outline of array sensing process. (Reproduced from Ref. 42: © 
Royal Society of Chemistry, 2013) 
1.1.1 Chemometrics 
Regardless of the type of signal output, array approaches produce a large amount 
of data across multiple axes.  This type of data is usually not interpretable by visual 
inspection of the data set or by using basic calibrations like a simple linear regression.  
Therefore, more advanced chemometric methods are routinely used to reduce the 
dimensionality of the data and present it in graphical form for visual interpretation.  There 
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are many statistical analysis tools available to process the data, but four common methods 
are principal component analysis (PCA), linear discriminant analysis (LDA), hierarchical 
cluster analysis (HCA), and artificial neural networks (ANN).   
1.1.1.1 Principal Component Analysis 
PCA is a cluster analysis method that reduces the dimensionality of a data set by 
decomposing the data into eigenvectors and eigenvalues.8, 9  The magnitudes of the 
eigenvalues represent the variance in the data.  The variance can then be displayed 
graphically with principal component (PC) axes with the first principal component axis 
expressing the most variance in the data (Figure 1.2).   The subsequent PCs are, by 
definition, orthogonal to one another.  This orthogonality is particularly important when 
large numbers of input variables are used that may be correlated with one another.10  
Requiring the PCs to be orthogonal to one another prevents redundant information in the 
data set from biasing the visualization of the data in the new space.   
PCs are often referred to as latent variables because they represent relevant factors 
that may not be apparent in the original data space.  For example, multiple chemical 
receptors in the array may respond to a similar property of the analytes, such as degree of 
hydrophobicity or charge state.  Sometimes the PCs can be assigned to physical properties.  
However, depending on the array, it is not always possible to clearly connect each latent 
variable to one particular chemical property, nor is it necessary to do so in order to effect 
an accurate classification of an analyte. 
When a visual inspection of a PCA plot detects not only close clustering between 
data points that represent repetitions of the same analyte class but also good separation 
between data points that represent different analyte classes, one can conclude that 
discrimination of the analytes has been successful.  Loading values for each receptor 
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represent the contribution of that receptor to each PC axis.  These can be used to evaluate 
the importance of the different receptors in an assay.  Since PCA considers only the 
variance in the data matrix and not any a priori information about groupings or classes, 
this method is often referred to as unsupervised.  Thus, in addition to dimensionality 
reduction and data visualization, PCA can be employed as an exploratory analysis method 
to try to identify latent variables as described above or to discover groupings that are not 
apparent in a data set.   
 
 
Figure 1.2 Principal component analysis.  PCA displays the variance in the data set 
with PC 1 representing the largest variance.  Subsequent PCs are orthogonal 
to one another. (Reproduced from Ref. 42: © Royal Society of Chemistry, 
2013) 
1.1.1.2 Linear Discriminant Analysis 
LDA is a classification method typically used to assign an unknown analyte to its 
appropriate class.8  Both the data from the array (i.e. the optical responses from all of the 
receptors) and the analyte classes are used as inputs, making LDA a supervised method.  
From these inputs, discriminant functions, which are linear combinations of these input 
variables, are calculated with the goals of maximizing separation between classes and 
 5 
minimizing separation within classes (Figure 1.3).  The resultant variable space is 
described by new factor axes that are orthogonal to one another.  These factor axes are 
similar in principle to the PCs in PCA and can also be thought of as latent variables.  
As with PCA, a successful LDA plot shows good separation between different 
classes.  The quality of the model built by LDA can be tested in several ways.  Within a 
single data set, a cross validation can be employed that iteratively removes random 
segments of the data set, recalculates a model from the remaining data, and then uses the 
new model to assign the left-out data points to classes.  When each data point is individually 
excluded, it is called a leave-one-out cross validation.  The output from the cross validation 
is the accuracy of the assignments obtained through this process, which can be used as a 
metric for the stability and the quality of fit of the model.  For prediction between two data 
sets, a training set is provided to the algorithm that includes the responses of all of the 
analytes of interest to the array in order to teach the algorithm.  Since the classes (i.e. 
analyte identities) in the training set are known, an analyte of unknown identity can then 
be assigned to one of the classes based on the similarity of its response to the responses of 
the analytes in the training set.  In this way, the predictive power of an array can be 
determined by the frequency of correct versus incorrect classifications. 
 
 
 6 
 
Figure 1.3 Linear discriminant analysis.  In LDA, the algorithm finds the axis that best 
separates the given classes.  The axis chosen in the example on the right 
separates the classes better than the axis chosen on the left. (Reproduced 
from Ref. 42: © Royal Society of Chemistry, 2013) 
1.1.1.3 Hierarchical Cluster Analysis 
HCA is a method that clusters data points based on the relative distances between 
all pairs of data points in the data set.8,11  This end can be achieved either by an 
agglomerative (“bottom up”) approach in which the algorithm begins with all of the data 
in separate clusters and works to merge clusters based on their similarity (Figure 1.4) or 
by a divisive (“top down”) approach in which the algorithm begins with all of the data in 
a single cluster and works to separate the clusters until each data point is in its own cluster.  
The Euclidean distance is typically used as the distance metric between data points.  The 
Euclidean distance metric calculates the distance between two data points with N 
dimensions (N usually being the number of different sensor responses).  The graphical 
result is a dendrogram.   When using this method with data from an array, it is up to the 
researcher to make determinations about the meaningfulness of the clustering, since the 
algorithm will always eventually place all of the data into either one cluster in the case of 
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an agglomerative method or into as many clusters as there are data points in the case of a 
divisive method. 
 
 
Figure 1.4 Agglomerative clustering. Illustration of how agglomerative clustering uses 
the Euclidean distance between data points as the basis for grouping the data 
points. (Reproduced from Ref. 42: © Royal Society of Chemistry, 2013) 
1.1.1.4 Artificial Neural Networks 
 An ANN is a system of layer functions that can be “trained” to give a desired 
response pattern.8, 12  It consists of layers including the input, “hidden,” and output layers.  
The input layer is usually the data from the array (e.g. fluorescence counts or RGB color 
values), while the output layer is the desired analysis of the system (e.g. analytes).  The 
“hidden” layers are user determined and can be adjusted to suit the system.  The training 
process adjusts the hidden layers in order to maximize the number of times the desired 
output is achieved from the given inputs (Figure 1.5).  Then, the system can be used to 
predict the identity of an analyte given the data set for that unknown.  The hidden layers 
need not be linear functions, so this method is useful when trends in the data are expected 
to be non-linear.10  However, ANNs can easily overfit data and generate an unstable and 
overly narrow model.   
 8 
A related method to ANNs that has found increasing popularity in chemometrics is 
a support-vector machine.  Like an ANN, this method can also model non-linear trends in 
data.  It does so by performing a non-linear transformation of the data into a higher 
dimensional space where it is possible to determine the best linear separators of the classes 
in the data.   
 
 
Figure 1.5 The layers of ANN.  The inputs are the response data from the array, while 
the outputs are the different analyte identities.  The hidden layers are 
adjusted during training to maximize the accuracy of the analyte 
identification. (Reproduced from Ref. 42: © Royal Society of Chemistry, 
2013) 
1.1.2 Optical Detection in Chemical Sensing 
Another major component of a chemosensor array is the mechanism by which the 
interaction of the receptor and the analyte generates a measurable signal.  Each receptor 
and analyte interact with one another through covalent, non-covalent, and/or reversible-
covalent interactions.  This recognition event must be transduced by some means, such as 
spectroscopic, electrochemical, or calorimetric methods.  The signal transduction might be 
inherent to the recognition event between the two molecules, such as a chemical shift 
change in a 1H-NMR spectrum upon binding, or it might be an indirect consequence of the 
specific receptor/analyte interaction, such as the displacement of a fluorescent dye from 
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the receptor by the analyte.13  The detection method should be sufficiently selective that it 
can be attributed to the binding event.   
Optical methods in general are desirable for many sensing applications because of 
the potential for high sensitivity, good selectivity, rapidity of analysis, portability of 
instrumentation, and overall cost-effectiveness.14  Spectroscopic detection is possible with 
vapor-, solution-, and solid-phase sensing systems.  Optical sensing assays are most 
commonly colorimetric or fluorescence-based.  
1.1.2.1 Colorimetric Detection 
Colorimetric sensors detect the change in color of a pigment upon interaction with 
an analyte vapor or solution.  The dyes most commonly used are solvatochromic, Lewis 
base sensitive, pH sensitive, or redox reactive.  These chromophores exhibit a change in 
their absorption of light of ultraviolet or visible wavelengths.  This color change can 
sometimes be detected visually for rapid qualitative analysis.   
For quantitative detection in the solution phase, a spectrophotometer is used to 
measure changes in the absorbance of the chromophore at one or more wavelengths 
compared to a blank sample.  For the array format, the solutions are usually placed in 
microtiter plates rather than in cuvettes to improve the efficiency of the data collection 
process.   
With printed arrays, quantitative colorimetric detection can be accomplished by 
reflectance detection.15 In this method, a desktop scanner or digital camera is used to 
capture the light reflected off the surface of the colored sensor regions on the printed array.  
The red, green, blue (RGB) values of the images of the spots are determined by standard 
digital image analysis software.  This detection method is particularly desirable because 
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cameras and scanners are widely available and familiar technologies outside the context of 
scientific instrumentation. 
1.1.2.2 Fluorescence Detection 
 Measuring fluorescence is perhaps the more popular optical detection method for 
array sensing.  Most commonly, fluorescence quenching of an intrinsically fluorescent 
molecule in the presence of an analyte is measured.  Quenching arises either from a static 
process (e.g. the quenching of a bound complex) or a dynamic process (e.g. bimolecular 
quenching of the excited state) and is described by the Stern-Volmer equation.16   In 
fluorescence measurements, the output is light emitted, which yields a better signal-to-
noise ratio than absorbance measurements, where the output is the ratio of light absorption.  
The detection limits of fluorescence methods are usually one to three orders of magnitude 
lower than absorption methods.17  However, in the case of an analyte quenching the 
fluorescence of the sensor, a subtraction from the large background signal of the 
fluorescent molecule in the absence of analyte can translate to low sensitivity, especially if 
the effect of quenching is small.  In array methods, this large background is generally less 
problematic. Usually the comparison being made is between the fluorescence responses of 
different sensors to an analyte and not to the emission of the sensor alone. 
Nevertheless, a turn-on fluorescence approach is an increasingly popular signaling 
method that involves the use of a fluorescent molecule that increases the intensity of its 
emission in the presence of an analyte.   Because the signal measured is relative to a dark 
background (i.e. the sensor alone exhibits relatively low to no emission), this method has 
good sensitivity.18  Changes in fluorescence lifetime, emission wavelength, and spectral 
shape can also be used as sensor responses.   
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Fluorescence detection can have some drawbacks, including photodegradation of 
the fluorophores, slow response times, and a lack of selectivity for the analyte of interest.  
However, in the case of successful differential arrays, this lack of specificity of 
fluorescence response is overcome by employing multiple different receptors in 
combination with pattern extraction techniques (LDA, PCA, etc.). 
For solution-phase assays, microtiter plates with 96 or more wells per plate used in 
combination with a spectrophotometric plate reader are used for high-throughput signal 
quantitation.  Plate readers consist of a series of optical components that provide excitation 
light of a wavelength or wavelengths to each sample well and detect emission light of a 
wavelength or wavelengths from each sample well.  For vapor-phase assays, the sensors 
are immobilized on a surface like a glass slide or the distal ends of optical fibers.  In optical 
fibers, the excitation light travels up to the immobilized sensors on the distal end containing 
the sensors from the other end of the fiber, and the emitted light from the sensors is sent 
back through the fiber to a detector. 19  This convenient setup allows for easier remote 
sensing of analytes because the sensors need not be placed in close proximity to the 
excitation source and emission detector, as is necessary for interrogating sensors on glass 
slides. 
1.2 ARRAYS FOR SMALL BIOMOLECULES 
 Cross-reactive arrays have been designed that target a wide range of small 
molecules.  Biologically relevant small molecules such as sugars, amino acids, and 
nucleotides have been of particular interest as analytes.  This section details some examples 
of systems that were developed to target such molecules.   
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1.2.1 Sugars 
Since sugars contain hydroxyl groups as the only functional handles, the detection 
of carbohydrates by chemosensors in aqueous solution has been a challenging task.  
Differential sensing of sugars has primarily employed boronic acid-based receptors, as the 
following examples illustrate.  Boronic acids reversibly form cyclic boronate esters with 
diols, including the diols found in carbohydrates (Scheme 1.1).20,21   
 
 
Scheme 1.1 Boronic acid-diol binding.  Relationship between phenylboronic acid 
and its boronate ester with a diol.  (Adapted from Ref. 20: © Elsevier, 
2002)  
For example, Chang and coworkers used an array consisting of boric acid and 
phenylboronic acid mixed with various pH indicators to discriminate 23 mono-, di-, and 
trisaccharides in aqueous solution.22  The sugars have different affinities for boric acid and 
phenylboronic acid, and thus modulate the pH of the solution differently based on these 
affinities (Scheme 1.1).  The pH indicators report on this pH change by measurable 
changes in their absorption.  PCA of the data from their array showed good differentiation 
of the sugars (Figure 1.6).  However, nearly all of this discrimination is displayed along 
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F1 (95%), indicating that the receptors interact similarly to one another with the sugars. In 
a low-dimensionality case such as this one, an array format is likely unnecessary because 
all of the receptors are more or less providing the same information about the analyte.  
Nevertheless, this work demonstrates how commercially available components can be 
readily combined to generate arrays with good discriminatory power.   
 
 
Figure 1.6  Discrimination of saccharides by boronic acids/pH indicators by Chang et 
al.  PCA plot showing PC1 (95.4%) and PC2 (3.4%) for the identification of 
23 carbohydrates based on six combinations of boric acid and phenylboronic 
acid each with three pH indicators.  (Reproduced from Ref. 22: © Wiley-
VCH, 2006) 
 Suslick and coworkers developed a similar array consisting of 3-
nitrophenylboronic acid and several pH indicators printed as sol gel formulations to 
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distinguish a panel of fifteen sugars and sweeteners.23  The printed arrays were exposed to 
the solutions of sugar and boronic acid for five minutes to allow for equilibration, resulting 
in visible color changes of the pH indicators (Figure 1.7).  The authors asserted that the 
modulation of the responses by the dyes was due not just to pH changes, but also to Lewis 
acid-base and hydrogen bonding interactions of the sugars and sugar-boronic acid adducts 
with the dyes.   Their assertion that multiple different types of interactions were occurring 
between the saccharides and receptors was evidenced by the LDA classification of the 
sugars requiring F1-F6 to achieve complete accuracy. 
 
 
Figure 1.7 Color difference maps of the array by Suslick and coworkers.  The sugars 
were discriminated by the responses of the pH indicators in the presence of 
3-nitrophenylboronic acid. (Reproduced from Ref. 23: © American 
Chemical Society, 2008) 
 In order to improve the discriminatory power of boronic acids for carbohydrates, 
researchers have appended other functionalities to boronic acids.  For instance, Singaram 
and coworkers attached boronic acids to cationic benzyl viologens (BBVs) in order to 
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incorporate fluorescent indicator displacement signaling in their array.24  The cationic BBV 
interacts with an anionic fluorescent indicator.  Upon formation of the negatively-charged 
boronate ester with a sugar, the affinity of the anionic indicator for the BBV diminishes 
and turns on its fluorescence (Figure 1.8).    Six different BBV receptors and an anionic 
fluorophore were exposed to each of twelve saccharides in aqueous solution, and the 
fluorescence data from each solution was collected to generate an LDA plot (Figure 1.9).  
The sugars were successfully differentiated at a concentration of 2 mM, which is an order 
of magnitude lower than the concentrations used by Chang and Suslick in their systems.  
The lower detection limit could be attributed, at least in part, to the use of fluorescence 
rather than colorimetric detection.  
 
 
Figure 1.8 Proposed indicator displacement mechanism for the BBV receptor.  
(Reproduced from Ref. 24: © Wiley-VCH, 2007) 
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Figure 1.9 LDA plot for the discrimination of twelve sugars by the BBV- based system 
of Singaram et al.  Key: 1) D-ribose, 2) D-arabinose, 3) L-rhamnose, 4) D-
xylose, 5) D-lyxose, 6) D-glucose, 7) D-mannose, 8) D-galactose, 9) D-
fructose, 10) L-sorbose, 11) melibiose, and 12) lactulose. (Reproduced from 
Ref. 24: © Wiley-VCH, 2007) 
Similarly, Anslyn and coworkers appended boronic acids to resin-bound peptides 
to build immobilized sugar receptors that generate a signal through an indicator 
displacement event.25  In addition to the boronate ester formation, the peptides themselves 
interact with the carbohydrates through hydrogen bonding and hydrophobic interactions, 
which was hypothesized to improve differentiation of the sugars compared to boronic acids 
alone.  The boronic acid-peptide receptors were generated in a combinatorial fashion on 
beads (Scheme 1.2), and these resin-bound receptors were exposed to solutions of 
saccharide (80 µM), washed, and then exposed to a solution of colorimetric indicator.  As 
the indicator solution was applied, the beads were interrogated with a CCD camera to 
measure the change over time of the indicator color.  The data collected was analyzed by 
LDA (Figure 1.10) and had a cross validation of 100%, indicating complete discrimination 
of each of the sugars or sugar-derivatives.  To further demonstrate the robustness and 
generality of the system, the researchers went on to use this system and the training set data 
from the analysis of the pure saccharide samples to identify sucralose in a real-world 
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beverage sample.  Overall, this work demonstrates the advantages of incorporating 
additional interaction opportunities between a receptor and analyte as well as incorporating 
indicator displacement for colorimetric signaling.   
 
 
Scheme 1.2 General structure of pentapeptides from combinatorial library. 
(Reproduced from Ref. 25: © American Chemical Society, 2007) 
 
 
Figure 1.10 Discrimination of sugars with a boronic acid-peptide receptor array.  LDA 
plot for the array by Anslyn et al.  Cross validation: 100%.  (Reproduced 
from Ref. 25: © American Chemical Society, 2007) 
1.2.2 Amino Acids 
In contrast to sugars, amino acids consist of a variety of functional groups, 
including hydrophobic, positively-charged, negatively-charged, and aromatic side chains.  
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These functionalities allow for perhaps simpler discrimination by chemosensors compared 
to sugars.  For example, Severin and coworkers developed a system for differentiating 
twenty natural amino acids using indicator displacement-based sensors from commercially 
available components.26  A rhodium cyclopentadiene species was employed as the receptor 
to which the amino acids bind. Three dyes were used as colorimetric indicators that 
compete with the amino acid for the rhodium species, which modulates the absorbance of 
the indicators (Scheme 1.3).  
 
 
Scheme 1.3 Rhodium species and dyes.  (Reproduced from Ref. 26: © American 
Chemical Society, 2005) 
 Different pH solutions of each amino acid/dye combination were also used. Since the 
binding affinity of dye and amino acid changes with pH, this provided additional 
discriminating information about each amino acid.  The absorbance data from the array 
was subjected to LDA and PCA.  In the LDA, the cross validation showed good 
classification of each amino acid with some misclassifications occurring between valine 
and isoleucine.  These amino acids both contain alkyl side chains, so it is unsurprising that 
 19 
they would be difficult to distinguish.  In the PCA plot (Figure 1.11), good visual 
separation of the amino acids was obtained.  Furthermore, the authors noted that amino 
acids with similar classes of side chain were placed near one another on the plot.  For 
example, the aromatic amino acids phenylalanine, tryptophan, and tyrosine are close to one 
another on the scoreplot as are serine and threonine.  This work highlights how simple 
arrays can be constructed from commercially available components that have good 
discriminatory power for structurally similar analytes. 
 
 
Figure 1.11  Discrimination of natural amino acids by IDA-based array by Severin et al.  
PCA plot from array data.  (Reproduced from Ref. 26: © American 
Chemical Society, 2005) 
 Anslyn and coworkers also used an IDA-based array for amino acid differentiation 
that was further able to distinguish enantiomers.27  The array was constructed from Cu(II) 
complexes derived from bidentate N-donor ligands and salicylate-derived chromophores 
that are modulated in their absorbance upon metal coordination.  Since the Cu(II) 
complexes are themselves chiral, the complexes exhibit a preference for L or D amino 
acids, allowing for enantioselective determination of the amino acids.  The absorbance data 
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from the array was subjected to PCA, which showed complete separation of each amino 
acid, primarily along PC1, as well as the L and D forms of each amino acid, primarily along 
PC2.   
1.2.3 Nucleotides 
Nucleotides, the components that make up DNA and RNA, are perhaps more 
challenging analytes for chemosensor targeting compared to amino acids.  Nucleotides 
consist of aromatic cores and hydrogen bond donor and acceptor functionalities.  Hence, 
the chemical and structural differences between nucleotides are subtle and difficult to 
target. 
One example of an approach to nucleotide sensing was developed by Mirsky and 
coworkers using molecularly imprinted polymers (MIPs) to synthesize semi-selective 
receptors for nucleotides.28  The receptors are synthesized by adsorbing an alkanethiol 
matrix onto a gold surface.  The image of the analyte is imprinted within the alkanethiol 
matrix using a thiol derivative of the analyte.  The resulting template is an MIP that is 
selective for detection of adenine, cytosine, thymine, and uracil.  The binding of the 
nucleotides to the MIPs was monitored electrochemically, and the data was analyzed by 
PCA.  The PCA plot (Figure 1.12) shows good separation of each nucleotide.  This work 
demonstrates a powerful approach to generate semi-selective receptors for subtly different 
analytes.   
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Figure 1.12  Discrimination of nucleotides by an array of MIPs by Mirsky et al.  The 
PCA plot distinguishes 1) caffeine, 2) uracil, 3) adenine, 4) cytosine, 5) 
thymine, and 6) uric acid with X1 and X2 comprising 75% of the total 
variance.  (Reproduced from Ref. 28: © Royal Society of Chemistry, 2003) 
Another macromolecule-based strategy for nucleotide detection was investigated 
by Prins and coworkers.29  In this approach, a gold nanoparticle was mixed with several 
different anionic fluorescent dyes that bind to the nanoparticle’s surface monolayer and 
can be displaced differentially by nucleotides.  The cationic counterion for the gold 
nanoparticle was also varied between Zn(II) and Cu(II) to obtain additional discriminatory 
information.  By subjecting eight nucleotides to the array at two different concentrations, 
the PCA plot showed complete separation of all nucleotides and concentrations (Figure 
1.13).  This study demonstrates how the nonspecific and complex interactions that occur 
on the nanoparticle monolayer surface can be exploited for distinguishing structurally 
similar analytes. 
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Figure 1.13  Differentiation of nucleotides by the gold nanoparticle/fluorescent dye array 
of Prins et al.  The PCA plot discriminates eight nucleotides at 50 µM and 
100 µM concentrations.  (Reproduced from Ref. 29: © Royal Society of 
Chemistry, 2013) 
1.3 ARRAYS FOR PROTEINS 
Receptors for proteins must be able to target the relatively large, solvent-exposed 
surface of these molecules.  Hence, larger supramolecular scaffolds or macromolecular 
structures have often been employed for protein detection in cross-reactive arrays.   
For instance, Hamilton and coworkers synthesized a library of fluorescent 
porphyrin receptors with four peptidic arms in a combinatorial fashion to target proteins.30  
The peptide arms contained a variety of sequences with aromatic, acidic, and basic amino 
acids, resulting in a library of 35 porphyrin receptors with varying hydrophobicity, charge, 
size, and symmetry (Scheme 1.4).  From the 35-member library, eight porphyrin receptors 
were chosen for an array to target cytochrome c, ferredoxin, cytochrome c551, and 
myoglobin.   
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Scheme 1.4  Structure of porphyrin scaffold.  R groups were TyrAsp, Lys, TyrLys, 
Asp, or Lys1,5-pentane-diamine.   
The fluorescence of the porphyrin is differentially quenched in the presence of the proteins.  
The authors found that the proteins were bound most strongly by receptors with 
complementary characteristics such as charge.  The fluorescence responses from the array 
clearly distinguished each protein (Figure 1.14).  The authors went on to refine this array 
to differentiate metal and metal-free proteins.31  In this study, they employed PCA to 
process the array data and obtained good discrimination of ten protein analytes.   
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Figure 1.14  Protein fingerprints from porphyrin receptor array by Hamilton et al.  Key: 
2) cytochrome c, 3) ferredoxin, 4) cytochrome c551, and 5) myoglobin.  The 
bars represent the fluorescence modulation of the solutions with protein 
(Gprot) compared to solutions without protein (Gref).  (Reproduced from Ref. 
30: © American Chemical Society, 2004) 
 Rotello and coworkers developed an array of water-soluble, conjugated polymers 
with terminally-charged residues to discriminate a panel of 17 proteins.32  The polymers 
were poly(p-phenylene ethynylene)s (PPEs) and were chosen because their emission is 
highly sensitive to environmental changes and because these large polymers have the 
potential for multivalent interactions with the protein analytes.  They chose six polymers 
with different charge characteristics and molecular weights (Scheme 1.5).  In most cases, 
the proteins quenched the fluorescence of the polymers upon binding, implying that the 
protein binding stimulates a modulation of the electronic state of the polymer.  The array 
was able to discriminate the 17 proteins (Figure 1.15), demonstrating the generalizability 
of these receptors for targeting a variety and large number of analytes. 
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Scheme 1.5 Structures of the PPEs used by Rotello et al.  (Reproduced from Ref. 32: 
© American Chemical Society, 2007) 
 
 
Figure 1.15  Differentiation of 17 proteins by a fluorescent polymer array by Rotello et 
al.  PCA plot generated from fluorescence data from the array. (Reproduced 
from Ref. 32: © American Chemical Society, 2007) 
 Based on a similar strategy to Hamilton et al. of using peptide-based receptors, 
Anslyn and coworkers generated a combinatorial library of receptors with different 
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peptidic arms on a substituted benzene scaffold (Scheme 1.6).33  The peptides contained 
boronic acid moieties to target glycoproteins.  From the library, 29 receptors were chosen 
at random to use in the array in conjunction with the bromopyrogallol red chromophore as 
a reporter based on indicator displacement (see 1.2.1).  Five proteins, including two 
glycoproteins, were exposed to the array, and the data was analyzed using PCA, which 
showed discrimination of the proteins.  The 29 receptors were then sequenced to determine 
their identities.  Based on the PCA data and the structures of the receptors, the authors 
determined that subtly different receptors were able to distinguish the proteins. 
 
 
Scheme 1.6 Boronic acid-functionalized peptides.  (Reproduced from Ref. 33: © 
Wiley-VCH, 2005) 
 Perhaps a more challenging task than targeting a wide range of proteins and protein 
classes is targeting several proteins within a single class that are structurally similar to one 
another.  For instance, Anslyn and coworkers patterned mitogen-activated protein kinases 
(MAPKs) using an array of SOX-peptides.34  The peptide sequences were selected, based 
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on previous literature, to have docking sites for the various kinases in the analyte panel 
(Scheme 1.7) so that the peptide will be phosphorylated by the kinase.  The adjacent SOX 
fluorophore increases in its fluorescence upon phosphorylation of the peptide, acting as the 
reporter.  The proteins studied were nine isoforms of MAPK, and they were applied to the 
solutions of SOX-peptide, and the fluorescence of the solution was monitored over time.  
The fluorescence data was analyzed by LDA (Figure 1.16) and PCA, both of which 
showed good separation of the kinases.  The PCA plot revealed cross-reactivity between 
the SOX-peptides and kinases, which was surprising considering that some of the peptide 
sequences were chosen to be selective for a particular kinase.  Additionally, the authors 
used their array for quantitative analysis of kinases using SVM analysis.  Overall, the 
approach used in this study demonstrates that employing receptors with more selectivity, 
rather than simply targeting general structural characteristics such as charge or 
hydrophobicity, can be used to detect subtle differences in a class of very similar and large 
analytes.   
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Scheme 1.7 SOX-peptides with the kinase docking sites indicated. Linker = three 6-
aminohexanoic acid moieties.  (Reproduced from Ref. 34: © Wiley-
VCH, 2014) 
 
Figure 1.16 Discrimination of MAPK isoforms by SOX-peptide receptors by Anslyn et al.  
LDA plot with cross validation of 94.4%.  (Reproduced from Ref. 34: © 
Wiley-VCH, 2014) 
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1.4  ARRAYS FOR WHOLE CELLS 
 Perhaps the ultimate challenge in the area of array-based biological sensing is 
discrimination of whole cells based on their surface features or on the volatile organic 
compounds (VOCs) they emit.  Cell surfaces are covered in a variety of lipids, 
carbohydrates, and proteins.  The number and type of these molecules can differ based on 
the cell type or on the health state of the cell,35,36 so there is an interest in detecting these 
subtle differences.  Furthermore, bacteria produce a variety of gaseous metabolites that 
could be used to identify a particular species or strain.  Since the surfaces and emitted 
VOCs of cells consist of many different compounds, a major advantage of using an array-
based approach to cell surface sensing is that high specificity is not necessary. Additionally, 
array detection does not require that the constituent compounds be fully characterized. 
1.4.1 Prokaryotic cells 
Rapid identification of different species and strains of human pathogenic bacteria 
remains an important sensing challenge.37  Differential sensing methods have been applied 
to bacteria sensing, mostly utilizing headspace analysis of mature cultures and “electronic 
nose” array technologies that make use of electrochemical signals.   Some efforts toward 
array-based methods with optical detection have been undertaken.  The colorimetric sensor 
array used by Suslick and coworkers has been applied to headspace analysis of bacterial 
cultures.37  Several species and strains of bacteria were cultured and monitored over time 
by a 36-dye array and flatbed scanner to digitize the array image.  Based on the changing 
color of the array, it was concluded that the nature of the volatile compounds emitted by 
the culture changes over time.   Data collected from monitoring of the bacteria was 
analyzed using several pattern recognition methods.  Using simple Euclidean distances, 
which compare only the overall response of the array, correct classification of 162 out of 
164 instances was achieved.  The only exception was misclassification between E. faecalis 
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and vancomycin resistant mutant (VRE).  HCA had a similar success rate and misclassified 
only three instances, all of which were between E. faecalis and vancomycin resistant 
mutant (VRE) as well.  PCA showed high dimensionality, with the first three dimensions 
accounting for only 79% of total variance.  Finally, the PCA space (Figure 1.17) was used 
to classify new inputs (i.e. unknown cultures of one of the 11 types studied) based on their 
array responses.  Using the first seven PCs, 99.2% correct classification was achieved.   
Since the full extent of these volatile metabolites are not known and would be difficult to 
fully characterize for every species of bacteria at every time point, it is clear that this 
detection challenge is well-addressed by array-based methods compared to developing 
specific sensors for each volatile metabolite.  Versions of Suslick’s colorimetric sensor 
array have been commercialized by Metabolomx as disposable breath analyzers for cancer 
and bacterial metabolite detection. 
 
 
Figure 1.17 PCA plot from response of array by Suslick et al. to ten bacterial strains.  
Key: black, S. aureus; red, MRSA; dark green, S. epidermidis; purple, S. 
sciuri; orange, P. aeruginosa; white, E. faecium; light blue, E. faecalis; 
gray, E. faecalis VRE; yellow, E. coli 25922; light green, E. coli 53502; 
dark blue, control. (Reproduced from Ref. 37: © American Chemical 
Society, 2011) 
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An approach to bacteria detection that does not involve headspace analysis of 
cultures instead targets the lipopolysaccharides (LPS) of Gram negative bacteria.38 
Lipopolysaccharides are glycolipids found in the outer membrane of Gram negative 
bacteria.  The sugar portion differs for different bacterial species and strains, so it provides 
a target analyte for differentiation of bacteria.  The sensors employed in this assay were 
diacetylene liposomes.  The functionalization of these liposomes (e.g. with tryptophan) 
was chosen to be generic for interactions with sugars instead of highly specific, as is 
normally the case when liposomes are used as sensors.  These diacetylene liposomes are 
known to change color from blue to red upon analyte binding, providing an assay signal 
(Figure 1.18).  The LPS harvested from five strains of bacteria were exposed to three 
different liposomes, and the color change of the solution was quantified from absorbance 
spectra of the solutions before and after exposure to analyte.  To add more variables to the 
array, measurements were taken in the presence of a detergent (SDS) and a metal chelating 
agent (EDTA).  The resulting response patterns were found to be unique for each bacterial 
species upon visual inspection.  While the need to harvest the LPS from bacteria samples 
probably limits the use of this method as a rapid detection system, the authors indicate that 
further avenues of study will include development of a version of this approach that 
performs detection of intact bacteria, which would greatly expand the method’s 
applicability. 
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Figure 1.18 Color response of liposome solution in the presence of LPS.  Left: visible 
color change of liposome upon addition of LPS.  Right: Graph of liposome 
sensor conditions to different bacteria.  (Reproduced from Ref. 38: © 
American Chemical Society, 2004) 
Finally, Bunz and coworkers have targeted the bacterial cell surface with their gold 
nanoparticle-conjugated polymer sensors.39 Initially, anionic polymers are associated with 
cationic gold nanoparticles and thus are quenched in their fluorescence.  Upon exposure to 
a negatively-charged bacterial cell surface, the gold nanoparticles associate with the cell 
surface, releasing the polymers and turning on the fluorescence of the polymers (Figure 
1.19).   Three hydrophobic ammonium-functionalized nanoparticles were employed in the 
array as well as one anionic fluorescent polymer.  Twelve different kinds of bacteria were 
exposed to the array, with each exhibiting a unique fluorescence response to the array.  The 
twelve bacteria were successfully discriminated from one another, including different 
strains of E. coli.  Identification of randomly selected solutions of one of the twelve bacteria 
was accomplished with 95% accuracy.  Since it targets whole bacteria, this method has 
good potential applicability for screening of bacteria.  Furthermore, this assay also benefits 
from the high sensitivity characteristic of turn-on fluorescence signals. 
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Figure 1.19 Schematic of fluorescent polymer/gold nanoparticle array for bacterial cell 
surfaces.  a) Fluorescence turn on occurs upon displacement of polymers 
from the nanoparticle surface, b) Differential displacement of polymers by 
differing affinity of the nanoparticle for the cell surface leads to 
fluorescence modulation. (Reproduced from Ref. 39: © American Chemical 
Society, 2011) 
1.4.2 Eukaryotic cells 
Mammalian cell surfaces are of particular interest as sensing targets because these 
surfaces are known to be indicative of disease states, such as cancer.  An example of an 
array-based approach by Rotello and coworkers differentiated cell lines and health states 
of genetically identical cells.40  The array consisted of PPE-derived polymers like those 
used in the arrays described in section 1.3 for proteins and in section 1.4.1 for bacterial 
cells.  In this study, eight polymers were chosen with varying charge characteristics and 
degrees of polymerization in order to provide diversity in the receptors.  In the presence of 
cells, the polymers aggregated differentially, resulting in modulation of their intrinsic 
fluorescence.  Of the eight polymers, four were found by LDA analysis to contribute most 
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to the differentiation of the cell lines.  From the fluorescence responses of these four 
polymers to four cancer cell lines: HeLa (cervical), MCF7 (breast), HEPG2 (liver), and 
NT2 (testicular), an LDA plot was constructed (Figure 1.20) that showed good 
differentiation of the cell lines.  Most of the discrimination is along F1 (96.7%), indicating 
that the receptors are providing similar information to the analysis.  Three of the four 
polymers selected for the array were cationic, which suggests that F1 could represent 
varying degrees of negative charge on the cell surfaces.  The authors went on to study the 
ability of the array to distinguish healthy from unhealthy cells.  Three genetically identical 
cell lines that were healthy (CDBgeo), cancerous (TD), and metastatic (V14) were 
subjected to the array.  The LDA analysis of the data from this assay was able to separate 
the three health states, although the dimensionality of the data was also low (F1 96.3%). 
 
 
 
Figure 1.20 Discrimination of cancer cell lines with the array from Rotello et al.  LDA 
plot discriminating the four cell lines.  (Reproduced from Ref. 40: © 
American Chemical Society, 2010) 
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Another recent example of the application of array sensing to cancer cell surfaces 
was executed by Yan and coworkers.  In this study, dual-ligand nanoparticles were used in 
an array to differentiate three cancer cell lines that all overexpress folate receptors.41  The 
gold nanoparticles were coated with two different recognition units in order to achieve 
multivalent binding interactions with the cell surfaces.  One of the ligands on all of the 
nanoparticles was folic acid, which they expected to interact with all of the cell lines’ folate 
receptors.  The second ligand was varied as shown in Table 1.1 in a combinatorial fashion 
to yield 30 unique nanoparticle receptors.  The cells were exposed to the array of 
nanoparticles and then were washed to remove unbound material. The binding of the 
particles to the cells was determined by quantifying the gold content of the samples by 
inductively-coupled plasma spectrometry (ICP-MS).  The authors expressed their data as 
a heat map (Figure 1.21).  The heat map shows a wide range of interactions between the 
dual-ligand nanoparticles and the cell lines.  Significantly, the binding of the dual-ligand 
particles was enhanced compared to mono-ligand particles and blank control samples.  This 
finding suggested that the authors were correct in their hypothesis that the dual-ligand 
feature would allow for multivalent binding to the surfaces.     
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Table 1.1 Structures of the 30 dual-ligand nanoparticles.  FA= folic acid, TA = 1,2-
dithiolan-3-yl pentanamide moiety, Tyr = tyrosine.  (Reproduced from Ref. 
41: © American Chemical Society, 2011) 
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Figure 1.21 Discrimination of cell lines with array by Yan et al.  Heat maps calculated 
from gold content of cells.  Top: HeLa cells, Middle: KB cells, Bottom: 
HepG2 cells.  The darker colors indicate a higher gold content and stronger 
binding compared to lighter colors.  (Reproduced from Ref. 41: © American 
Chemical Society, 2011) 
1.5 SUMMARY AND OUTLOOK 
Array-based methods have demonstrated their usefulness in addressing many 
sensing challenges.  By using collections of semi-selective receptors along with 
chemometric analysis, arrays can be designed to discriminate various structurally similar 
analytes and analyte mixtures.  The approaches described in this chapter focused on assays 
that utilize optical signals because, in general, colorimetric and fluorescence sensors have 
good sensitivity and tunability as well as great practical potential in terms of ease of use 
and price of instrumentation.  While this approach to sensing has had success in highly 
controlled environments, there are still challenges to overcome before many of these 
methods could be implemented outside the research laboratory.  The ultimate usefulness 
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of array sensing for practical applications lies in its predictive power.  The predictive ability 
of an assay in a controlled laboratory environment can differ significantly from diagnostic 
capability in the field for a number of reasons.   
Olfactory and gustatory systems in mammals provide mostly qualitative 
information about odors and tastes.   The response to a particular odor or taste is apparently 
unique enough that the concentration of the odorant or tastant is not very important to 
correctly identifying it; rather we perceive at most that the odorant or tastant is present in 
a high, medium, low, or trace amount.  However, many artificial arrays have a significant 
concentration dependence, which could lead to misidentification of analytes if the system 
is not properly trained at multiple concentrations.  Also, if the response pattern is not unique 
enough for each analyte over the desired range of possible concentrations, then the assay 
is likely to confuse analytes.   In addition, the identification of complex mixtures is an 
important advantage of differential sensing over the use of highly specific receptors 
designed for particular molecules.  The mixture need not be fully characterized in order to 
be detected, which is particularly useful when dealing with analyte mixtures that are 
impossible or difficult to characterize extensively such as explosive mixtures or bacterial 
metabolites.   However, when the array is presented with the complex mixture, it can be 
trained to identify that mixture but not the components of the mixtures.   Changing the 
mixture slightly (e.g. different relative concentrations of the same components or adding 
new components) may also confuse the system.  In general, interferents can be problematic 
for analyte identification if they are not anticipated and included in the training process.   
Data from the responses of the analytes to the array sensors and the analyte 
identities or classes are presented to the system as a training set.  When the system is 
presented with responses from an unknown analyte, it has only the information it was given 
to base its prediction on.  In order to create array-based assays that can accurately predict 
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the identity of the desired analytes under conditions that are reasonable for a specific 
application, several conditions must be achieved.  The response of analytes to the array 
should be reproducible.  The system has to be able to match responses from unknowns to 
responses from a training set of analytes.  Hence, these responses have to be similar enough 
from exposure to exposure of the same analyte to the array in order to do this successfully.  
The sensor array should have sufficient semi-selectivity for the range of analytes of 
interest.  If the sensors are less selective, then low dimensionality in the data is achieved, 
and the system will have fewer bases on which to discriminate analytes correctly.   Each 
analyte must have a distinct enough pattern of response to be identified from other analytes 
that the system is trained to identify. Appropriate training of the system is vital, as the assay 
will only be capable of doing what it has been trained to do.  The specific chemometric 
method used may also have to be optimized for a particular system.  A balance between 
accuracy and time/cost of the overall sensing system will still have to be struck based on 
the application. Overall, the studies described in this chapter represent progress toward the 
application of array-based sensing methodologies to important sensing challenges.  
1.6 ADDITIONAL INFORMATION 
Portions of this chapter were adapted from a review published in Chemical Society 
Reviews.42 
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Chapter 2: Differential Sensing For the Regio- and Stereoselective 
Identification of Glycerides: A Qualitative Fingerprinting and 
Quantitative Analysis Study 
2.1 GLYCERIDES 
Glycerides are the primary component of animal fats and vegetable oils.1  They 
consist of one, two, or three fatty acids esterified on glycerol, and hence are referred to as 
mono-, di-, and triglycerides, respectively (Scheme 2.1).  The structural diversity of 
glycerides derives in part from their fatty acid alkyl groups, which can differ in carbon 
number (i.e. chain length), the degree of unsaturation, the position of olefins, and the 
configuration of the olefins (i.e. cis/trans).  Furthermore, these fatty acid alkyl groups can 
be connected to the sn-1, -2, or -3 carbons on glycerol.  Hence, a variety of regio- and 
stereoisomers can exist for glycerides, posing a challenge for mass spectrometry.2  Further, 
because the differences in chain length primarily result from the presence of greater or 
fewer methylene groups, NMR spectroscopy can be ambiguous.3 
 
 
Scheme 2.1 Structure of glycerol, a fatty acid, and a triglyceride.  The sn-1, -2, and -
3 positions of glycerol are labeled.  
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2.1.1 Importance of Glyceride Determination 
The analysis of glycerides is primarily important to the food and nutrition industries 
for tasks such as authenticating edible oils,4 designing foods with certain physical 
properties,5 and studying how fats are digested and absorbed.6  In particular, classifying all 
the various kinds of regio- and stereoisomers of glycerides is biologically important 
because lipases, enzymes that catalyze the hydrolysis of glycerides into fatty acids and 
glycerol, exhibit selectivity based on these features of the glyceride substrates. For 
instance, the position and configuration of olefins, the identity of fatty acid alkyl groups, 
as well as their position on glycerol (i.e. sn-1,3 versus sn-2), all contribute to differing 
biological activity.7,8 For example, hormone-sensitive lipase (HSL), which plays a role in 
mobilizing free fatty acids from acylglycerols in stored fat, prefers 2,3-sn-diacylglycerols 
over 1,3-sn-diacylglycerols as substrates.9  Studying the selectivity of these lipases has 
important applications in understanding diseases, including fat malabsorption disorders, 
hypercholesterolemia (i.e. high blood cholesterol levels), atherosclerosis, and diabetes.10, 
11 
2.1.2 Glyceride Determination Methods 
The most common method of glyceride identification is mass spectrometry (MS).2, 
12 However, as alluded to above, this approach has drawbacks.  Because glycerides are 
neutral molecules, they must be ionized to be analyzed by mass spectrometry.   
Saponification can be used to obtain the fatty acids, which are both volatile and charged, 
thereby facilitating MS analysis, but information about the glyceride structure is lost in this 
process.12  Electrospray ionization (ESI) and atmospheric pressure chemical ionization 
(APCI) can be used to ionize glycerides directly; however, the ion yields are low compared 
to preionized lipid fatty acids.13, 14  Furthermore, the ability of a glyceride to be ionized 
using these methods often varies.  For example, ion abundance generally increases with 
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increasing number of double bonds in the fatty acid alkyl chain and can also depend on 
fatty acid alkyl chain length.15  These significant variations in ion abundance means that 
ionization methodologies must be developed and tailored to a specific application to 
satisfactorily detect each glyceride of interest.13  Finally, these variations render the 
quantification of glycerides, particularly in a complex mixture, quite challenging when 
using mass spectrometry.16 
Regio- and stereoisomers further confound the discrimination of glycerides by mass 
spectrometry, since isomers share the same mass.  Other techniques such as chemical 
derivitization of the glycerides, ion fragmentation, and specialized HPLC must be coupled 
with mass spectrometry to differentiate isomeric species.  For example, ozonolysis has 
been used to cleave the double bonds in unsaturated glycerides prior to ionization in order 
to deduce the positions of double bonds.17  Non-aqueous reverse phase (NARP)-HPLC can 
resolve cis/trans isomers of triacylglycerols and double bond positional isomers after 
treatment of the olefins with bromine.18  Silver ion chromatography has been used to 
separate triacylglycerol positional isomers under specifically-developed solvent and 
column temperature conditions.19  Silver cationization as a post-column treatment in 
conjunction with NARP-HPLC and ion fragmentation has also been employed for 
triglyceride positional isomer determination (Figure 2.1).20, 21   
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Figure 2.1 MS5 experiment with silver cationization to discriminate regioisomers.  
Triglyceride isomers 1(3),2-dioleoyl-3(1)-palmitoyl-sn-glycerol (POO) and 
1,3-dioleoyl-2-palmitoyl-sn-glycerol (OPO) were distinguished by repeated 
fragmentation that was able to yield a unique ion for POO (m/z 313) that 
was not observed with OPO.  (Reproduced from Ref. 20: © Wiley-VCH 
2010) 
When analyzing complex, real world fat mixtures such as vegetable oils by 
chromatography, researchers have employed statistical analysis protocols like principal 
component analysis (PCA) in order to process the large amount of data generated and to 
build predictive models.22,23  Thus, while these current approaches to glyceride isomer 
analysis are successful, they are complicated, labor intensive, time-consuming, and often 
inconsistent in their results.20   
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2.2 AN ARRAY-BASED APPROACH TO GLYCERIDE DETECTION 
Because glycerides are very structurally similar to one another and lack variety in 
terms of functional groups, we believed that a differential sensing array-based approach 
would be most suitable for their classification.  Our hypothesis was that if a cross-reactive 
array could be created that is responsive to the subtle structural differences inherent in 
glycerides, it could be used to pattern individual glycerides, identify structural features of 
unknown glycerides, and potentially quantitate glycerides in a mixture. Cross-reactive 
arrays have been successfully employed in a number of sensing applications, such as the 
examples described in Chapter 1.24–29 In the laboratory, chemometric routines such as 
principle component analysis (PCA) and linear discriminant analysis (LDA) are used to 
extract the relevant information from the array (see Chapter 1). Therefore, the goal of this 
project was to develop an array of cross-reactive receptors that could discriminate 
glycerides.  The glycerides selected for the development of this array are shown in 
Schemes 2.2, 2.3, and 2.4.  The panel includes commercially available mono-, di-, and 
triacylglycerols with fatty acid alkyl groups that are relevant to mammalian biology.30  
Moreover, the panel consists of examples of each of the following stereo- and 
regioisomers: 1) cis/trans olefins (D1 and D2; T2 and T3), 2) differing position of the 
olefin (T3 and T4), and 3) differing position of the fatty acid alkyl groups on glycerol (D5 
and D6).  Clearly, it would be extremely challenging to create highly-selective receptors 
for each individual glyceride, and thus a differential sensing method seems the only 
reasonable approach to creating an optical sensing routine to identify and classify such 
structures. 
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Scheme 2.2 Triglyceride structures. 
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Scheme 2.3 Diglyceride structures. 
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Scheme 2.4 Monoglyceride structures. 
Thus, herein we describe a method using serum albumins to fingerprint glycerides, 
which classifies them as mono-, di-, or triglycerides.  The glycerides were further classified 
based on fatty acid chain length, ester positions on glycerol, and olefin regio- and 
stereochemistry. For the unsaturated glycerides in the panel, differentiation based on olefin 
position and stereochemistry was achieved by the use of a pretreatment olefin metathesis. 
Using the protocols described herein, structural features of unknown glycerides were 
identified. Furthermore, the quantitation of trilinolein in a mixture of triglycerides was 
achieved by application of the standard addition method using a net analyte signal 
(SANAS) technique presented herein.   
2.3 SERUM ALBUMIN 
Because glycerides are extremely hydrophobic analytes, we postulated that serum 
albumins (SAs) would be suitable cross-reactive receptors with which to test our 
hypothesis.  Serum albumin is a common plasma protein that performs several important 
functions in the bodies of vertebrates.31  The protein plays a major role in stabilizing the 
osmotic pressure of plasma.  Additionally, serum albumin binds hydrophobic molecules in 
order to transport them through the hydrophilic environment of blood.  The protein shuttles 
long-chain fatty acids from the intestines to the liver, from the liver to muscle, and to and 
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from adipose tissue.  In addition to fatty acids, serum albumin transports other endogenous 
compounds like copper, bile acids, hormones, and vitamins.  Albumin also binds toxins 
and delivers them to the liver for excretion.  As part of its role as transporter, serum albumin 
has also been linked to metabolic effects, such as stimulating lipoprotein lipase activity in 
adipose tissue.   
2.3.1 General Properties 
Serum albumin is an approximately 66 kDa protein consisting of about 580 amino 
acids.  Other than cobra albumin, all albumins have 35 cysteine residues that participate in 
17 disulfide bridges, which contribute to the superior stability of the protein.  The primary 
sequences of bovine (BSA) and human serum albumin (HSA) have been determined by 
Edman degradation, cDNA analysis, and mass spectrometry.  The crystal structures of 
bovine32 (Figure 2.2) and human albumin33 (Figure 2.3) have been solved as well, 
showing a heart-shaped structure for both species’ albumins.  In solution, BSA is 
ellipsoidal in shape with dimensions of approximately 40 x 140 Å.34  BSA and HSA are 
both highly helical molecule (67% in HSA and 68% in BSA), with a low content of β-turns 
(10% in HSA and 17% in BSA).33,35  Albumin consists of three domains (I, II, and III), 
which are each further divided into two subdomains (IA, IB, IIA, IIB, IIIA, and IIIB) as 
shown in Figure 2.3.   
The primary sequence of albumin differs depending on the organism it comes from.  
For instance, BSA and HSA have a 24% difference in sequence.31  Since albumins have 
different sequences and thus can exhibit different binding properties, multiple species’ 
serum albumins can be employed in a differential array to obtain cross-reactive interactions 
with analytes. 
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Figure 2.2 Crystal structure of bovine serum albumin.  The amino acids in the fatty 
acid binding pockets are highlighted.  (Reproduced from Ref. 32: © Wiley-
VCH, 2012) 
 
Figure 2.3 Crystal structure of human serum albumin.  The subdomains and drug 
binding sites (I and II) are labeled.36  (Reproduced from Ref. 36: © Royal 
Society of Chemistry, 2009) 
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2.3.2 Ligand Binding 
Serum albumins bind a number of endogenous compounds, including long-chain 
fatty acids (Ka = 10
6-107 M-1),37 bile acids (Ka = 10
3-105 M-1),38 steroids (Ka = 10
3-105 M-
1),39–41 and bilirubin (Ka = 10
7 M-1).42  In addition, a variety of exogenous fluorophores and 
drugs are known to bind to the protein.  These types of ligands typically bind in Sudlow 
Site I or II, also known as drug binding sites I and II.43,44  Sudlow Site I is located in the 
subdomain IIA, and Sudlow Site II is located in subdomain IIIA (Figure 2.3).  Some 
ligands show clear specificity for one site over the other, and some ligands bind in both to 
some extent.31,45  In general, Site I ligands are heterocyclic anions with centrally-distributed 
charge, while Site II ligands are usually aromatic and neutral or anionic with a peripherally-
located charge.  Examples of Site I ligands include warfarin, digitoxin, salicylate, 
bromocresol green, methyl orange, and dansyl amide.  Examples of Site II ligands include 
diazepam, ibuprofen, naproxen, medium-chain fatty acids, and dansyl proline. Despite 
being composed of fatty acid alkyl groups, glycerides bind less tightly to SAs and in a 
different location than their fatty acid counterparts.46  
2.4 PREVIOUS WORK USING SERUM ALBUMIN AS A CROSS-REACTIVE RECEPTOR 
Our group has used arrays of serum albumins (SAs) for the differentiation of 
hydrophobic analytes including fatty acids,47 terpenes,48 and plasticizers.49  In each study, 
two to three different serum albumins, BSA, HSA, and rabbit serum albumin (RSA), were 
used in conjunction with fluorescent indicators such as fluorescein, PRODAN, 2-
anthracene carboxylate (2-AC), and dansyl amide (DNSA) to build an array.  In the terpene 
and plasticizer studies, the use of non-fluorescent additives like deoxycholate and ascorbic 
acid in the array was investigated to determine if the additive could improve discrimination 
of the analytes (Figure 2.4).  It was determined that such dopants can improve the cross-
reactivity of the serum albumin/fluorophore receptors and aid in distinguishing structurally 
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similar analytes.  In each case, complex mixtures that contain the targeted analytes were 
also tested with the arrays.  For the fatty acid array, samples of edible vegetable oils were 
discriminated.  The terpene array was used to discriminate sample of Masaki perfume that 
had been spiked with various terpenes.  Finally, the plasticizer array was tested with 
simulated plastic explosive mixtures that contained RDX and PETN simulants mixed with 
the plasticizers.  The array was even able to differentiate the explosive mixtures after they 
had been contaminated with soil (Figure 2.5).   
 
 
Figure 2.4 Schematic of the sensing ensemble of serum albumin, PRODAN, and a 
hydrophobic additive in the presence of terpene. 
 55 
 
Figure 2.5 Discrimination of contaminated explosive mixtures by the serum albumin 
array.  LDA plot generated from the array data with a cross validation of 
96.5%.  P1-5 are the different plasticizers.  Semtex 1A, H, and 2P are 
different compositions of Semtex.  (Reproduced from Ref. 49: © Royal 
Society of Chemistry, 2012). 
Nevertheless, these previous studies did not involve differences between the 
analyte structures as subtle as with glycerides, nor had we challenged our methods to 
identify structural aspects of an unknown.  We had also never implemented a quantitation 
assay in a complex mixture.   Nevertheless, because the binding of ligands to SAs is known 
to depend on subtle differences in their structure,31 we anticipated that success could be 
achieved with glyceride discrimination but would be highly dependent upon the signaling 
modality and potentially also on analyte prederivitization. 
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2.5 DEVELOPMENT OF AN ARRAY FOR GLYCERIDES 
2.5.1 Indicator Uptake Experiments with Serum Albumin and Triglyceride 
The optical signaling approach we envisioned required that fluorophores bind to 
the SAs, and signal the addition of glycerides upon binding. In order to identify appropriate 
fluorophores for the sensing ensemble, several candidates were screened for their 
fluorescence modulation both in the presence of bovine serum albumin and triglycerides.  
The triglycerides are insoluble in water but dissolve in the presence of serum albumin, 
presumably due to binding in the hydrophobic sites of the protein.  Indicator uptake 
experiments were undertaken in which a serum albumin/triglyceride solution was titrated 
with a fluorescent indicator.50  The change in emission of the indicator in the presence of 
the triglyceride was compared with the indicator’s change in emission when it was added 
to serum albumin alone.  This protocol revealed which fluorophores bind the SAs and 
modulate in the presence of glycerides. The fluorophores screened (Scheme 2.5) included 
dansyl amide (DNSA), 2-anthracenecarboxylate (2-AC), 1-anilinonapthalene sulfonic acid 
(ANS), and a nitrobenzoxadiazole fatty acid (NBD-FA).   The first three compounds were 
known previously to bind to serum albumin.31  NBD-FA was synthesized by a literature 
procedure (Scheme 2.6),51 and the binding of this fluorophore to SA was studied.50   
 
 
 
 57 
 
Scheme 2.5 Structures of the fluorophores screened for use in the array. 
 
Scheme 2.6 Synthesis of NBD-FA. 
An example of these indicator uptake experiments is shown in Figure 2.6 for NBD-
FA, while the titrations for the other indicators can be found in reference 50.  When NBD-
FA is added to serum albumin, its emission increases (“BSA” in Figure 2.6); however, 
when trimyristin (T6) is present with the BSA, this increase in emission is smaller 
(“BSA/T6” in Figure 2.6), indicating that the binding of T6 to serum albumin is inhibiting 
the binding of NBD-FA.  It should be noted that the decrease in emission at concentrations 
above 100 uM NBD-FA is attributed to self-quenching as multiple NBD-FAs bind to the 
SA.  
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Figure 2.6 NBD-FA uptake.  Addition of NBD-FA (0-155 µM) to BSA (100 µM) and 
to BSA (100 µM)/T6, (90 µM) in 10 mM phosphate buffer, pH 7.0, 0.02% 
NaN3, alone; < 0.3% THF; λex = 470 nm, λem = 540 nm.   (Reproduced from 
Ref. 50: © University of Texas at Austin, 2013) 
From these experiments, DNSA and NBD-FA were inhibited in their binding to 
serum albumin in the presence of triglycerides and therefore were suitable for use in the 
array.  The other indicators, 2-AC and ANS, did not demonstrate significant inhibition in 
binding to serum albumin in the presence of trimyristin. However, we chose to include 
ANS in the cross-reactive array because it is commonly used to probe the folding of SAs 
since it binds in the crevices between domains,31 and we anticipated it would respond to 
other glycerides even if our initial tests with trimyristin did not reveal emission 
modulations.  
2.5.2 First Iteration of the Well Plate Array 
The cross-reactive array was constructed using 96-well plates. As a preliminary test 
of the array’s ability to differentiate the glycerides, an assortment of eight mono-, di-, and 
triglycerides from the total panel were selected.  Each glyceride was mixed with individual 
combinations of the three indicators (DNSA, NBD-FA, and ANS) and bovine and human 
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serum albumin (six combinations) in a 96-well plate with eight replicates for each 
glyceride, and the emission of each well was recorded.  
An LDA score plot of the fluorescence data collected from this array is shown in 
Figure 2.7, which has a 98% cross-validation analysis.   While the eight glycerides were 
differentiated by this array with high accuracy, there was significant visual overlap along 
the F1 and F2 axes of three of the glycerides.  D1 and D2, which are cis/trans isomers of 
one another, were not well discriminated, and T5 was also poorly separated.  The fact that 
our approach demonstrated overlap of unsaturated glycerides with only eight of the twenty 
total targets in the panel caused us to reconsider the approach.  Because differences 
between the unsaturated glycerides were the hardest to discriminate, we anticipated even 
further problems when attempting to classify the position of the double bonds, their 
stereochemistry, and the numbers of double bonds. 
 
 
Figure 2.7 Discrimination of eight glycerides by the six-receptor array.  LDA plots of 
data collected from 96-well plates: BSA and HSA (100 µM), glyceride (90 
µM), DNSA (60 µM), ANS (60 µM), and NBD-FA (60 µM) in phosphate 
buffer with < 2% THF (see Table 2.7 for read parameters).  Cross validation 
= 98%. 
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2.6 OLEFIN METATHESIS OF GLYCERIDES 
One strategy to discriminate the differences in the olefins would be through 
derivitization.  We contemplated the use of bromination and dihydroxylation, but 
ultimately chose olefin metathesis. Metathesis reactions of glycerides and fatty acids have 
been previously explored with the intent of using these compounds to make chemical 
products more sustainably.52,53 Such a prior derivitization approach is similar, in principle, 
to the use of other olefin reactions, such as halogen addition18 and silver cationization, that 
are able to resolve stereo- and regioisomers of glycerides when combined with NARP-
HPLC-MS methods.20 
Olefin metathesis was chosen for several reasons. First, using a metathesis reaction 
results in products of differing length depending upon the positions of the olefins in the 
glycerides, thus potentially making the products from such glycerides unique.  Second, 
olefin metathesis catalysts have differing reactivity toward cis and trans stereoisomers,54 
thus potentially leading to different extents of metathesis depending upon the 
stereochemistry of the starting fatty acid chains.  Third, the reaction conditions are 
relatively mild, and the reaction mixture can be used directly in the SA array without any 
purification.  This factor allows the cross metathesis reactions of multiple glycerides to be 
performed in parallel in a polypropylene well-plate for efficient workflow.  Lastly, this 
reaction could be used to introduce an additional fluorophore for optical analysis.  Our 
strategy therefore utilized fluorescein conjugated to an olefin, resulting in mixed olefin 
products. 
2.6.1 Synthesis of Allyl Fluorescein 
With these goals in mind, the allyl fluorescein derivative AF was synthesized 
according to a literature procedure (Scheme 2.7).55,56   
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Scheme 2.7 Synthesis of allyl fluorescein (AF). 
2.6.2 Optimizing the Metathesis Reaction with Monoerucin 
As a model, we then screened several different reaction conditions for cross 
metathesis between AF and monoerucin (M1) (Scheme 2.8) in order to optimize the 
reaction conditions.   LC-MS analysis of the reaction mixtures confirmed the conversion 
of AF to mixed glyceride- and AF-containing compounds.   
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Scheme 2.8 Olefin metathesis of monoerucin. 
The conditions that were screened are summarized in Table 2.1.  The application 
of vacuum to the reaction was found to be unnecessary (reaction #1), so the reactions were 
run at atmospheric pressure to simplify the reaction setup.  Although the reaction also 
worked in dichloroethane (DCE), chloroform (CHCl3) was preferred as the solvent because 
it is non-flammable and hence can be heated more safely in a plastic well plate.  The 
reaction did not proceed when tetrahydrofuran (THF) was used as the solvent.  The 
presence of even very small amounts (<10%) of THF appeared to hinder or entirely halt 
the reaction (e.g. reaction #12).  The addition of copper57 provided no significant 
improvement in the reaction, so it was ultimately excluded.   
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The origin of reaction #2’s failure is unclear.  THF was not used as the solvent 
during the reaction, but the reagents were first dissolved in THF, and then the THF was 
removed by rotary evaporation.  Perhaps the presence of a trace amount of THF was enough 
to affect the reaction.  Using more M1 compared to AF did improve the yield of the M1-
AF mixed products, but we did not want to use more material than necessary, so an excess 
of glyceride was not used in the array.  Pre-reacting M1 with the catalyst before adding AF 
hindered the formation of any M1-AF mixed products (reaction #11).  Moreover, 
inconsistent results were obtained when repeating the metathesis reaction with an old batch 
of catalyst.   New batches of catalyst purchased from Sigma gave reproducible results.  The 
conditions that were selected to be optimal for our purposes are shown in Scheme 2.8.  
 
Table 2.1 Reaction conditions for the metathesis reaction and AF and M1. 
 Solvent Temperature 
(°C) 
Reaction 
time 
M1 
(equiv) 
AF 
(equiv) 
G2*** 
(mol%) 
CuI 
(mol%) 
Reaction 
success 
1* CHCl3 55, vacuum 24 hr 1.1 1.0 0.1 NA Yes 
2 CHCl3 55 24 hr 1.1 1.0 0.1 NA No 
3 THF 50 24 hr 1.1 1.0 0.1 NA No 
4 DCE 70 2 hr 1.0 15 1.5 NA Yes 
5 DCE 75 24 hr 1.0 15 2.0 3.0 Yes 
6 DCE 75 24 hr 1.0 5.0 20 25 Yes 
7 CHCl3 50 2 hr 1.0 2.0 20 25 Yes 
8 CHCl3 50 2 hr 1.0 1.1 20 30 Yes 
9 CHCl3 50 6 hr 2.0 1.1 50** NA Yes 
10 CHCl3 50 2 hrs 3.0 1.0 20** NA Yes 
11 CHCl3 50 24 hrs 1.0 1.1, added 
after 2 hrs 
20** NA No 
12 CHCl3 50 2 hr 1.0, 
prepared 
from a 
THF stock 
of M1 
1.1 20** NA No 
13 CHCl3 50 2 hr 1.0 1.1 20** NA Yes 
* Reactions 1-8 were performed by Michelle Adams Ivy and published in ref 50 
**New batch of catalyst was used from Sigma  
***G2 = Grubbs 2nd Generation Catalyst 
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2.6.3 Evaluating the Olefin Metathesis with All of the Unsaturated Glycerides in 
the Panel 
Once the optimal conditions were identified for M1, all of the unsaturated 
glycerides in the panel were subjected to the cross metathesis reaction in parallel in a well 
plate, and the reaction mixtures were analyzed by LC-MS to determine that AF was 
metathesizing with the glycerides and that the conversion was the same for each repetition 
of the reaction with each glyceride.  In these experiments, the AF-glyceride products 
observed in the LC-MS analysis contained the alkyl portion of the glyceride, as in 2.1 
(Schemes 2.8 and 2.9), and smaller amounts of products such as 2.3.   Table 2.2 
summarizes the percent conversion of AF to the corresponding mixed product (2.1 type) 
for each unsaturated glyceride. The chromatogram for absorption at 280 nm was used to 
quantitate the conversion, and we assumed that the extinction coefficient at that wavelength 
for AF and AF-glyceride species did not differ significantly.  In each reaction, some 
unreacted AF remained, and some of product 2.2, which results from the catalyst loading 
used, was also observed.  Finally, it is highly likely that olefin combinations that did not 
involve AF (i.e. self-metathesis of the glyceride) are also generated in the reaction.  
However, these species were not observable using conventional LC-MS analysis because 
they neither absorb light at any unique wavelength nor do they ionize readily.  Although 
the conversion differed for each glyceride, all of the glycerides were found to metathesize 
with AF.  
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Scheme 2.9 Metathesis products detected by mass spectrometry from reaction of AF 
with each of the unsaturated glycerides.  The exact mass of each 
compound is given along with the corresponding glyceride from which 
each product originates. 
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Table 2.2 Summary of the olefin metathesis reaction for the unsaturated glycerides 
and AF. 
Glyceride Cis or 
Trans* 
m/z (M+1) of mixed 
metathesis product 
Percent conversion of AF to 
mixed product (%) 
T1- Tripalmitolein cis 457.2 68 
T2- 1,3-Dioleoyl-2-
palmitoyl glycerol 
cis 485.2 52 
T3- Trielaidin trans 485.2 65 
T4- Tripetroselaidin trans 527.3 54 
T5- Trilinolein cis 443.2 49 
cis 483.2 23 
D1- 1,3-Dipalmitelaidin trans 457.2 55 
D2- 1,3-Dipalmitolein cis 457.2 56 
D3- 1,2-Diolein cis 485.2 59 
D5- 1,3-Diarachidonin cis 443.2 33 
cis 483.2 16 
cis 523.2 9 
cis 563.3 10 
M1- Monoerucin cis 485.2 8 
*Configuration of the double bond in the original glyceride 
2.6.4 Binding Studies of AF and 2.1 to Serum Albumin 
In order to investigate the binding of 2.1 to serum albumin, the compound was 
isolated by HPLC to obtain a pure sample.  BSA was titrated into AF and 2.1, separately.50  
AF is fluorescent alone in solution, and this fluorescence is quenched in the presence of 
serum albumin.  On the other hand, 2.1 has relatively lower emission alone but increases 
in its emission upon addition of serum albumin.   The lower emission in solution indicates 
that the alkyl tail quenches the fluorescence of the fluorescein intramolecularly.   
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2.6.5 Exploring FRET with Dansyl Amide and Allyl Fluorescein 
Dansyl and fluorescein moieties have been reported to act as a Förster Resonance 
Energy Transfer (FRET) pair,58,59 and therefore we investigated this property with the 
metathesized glycerides. FRET would be advantageous to the chemometric patterning 
because it would add an additional facet of cross-reactivity to the array. To test whether 
FRET occurred between DNSA and 2.1 in the presence of BSA, we measured the emission 
spectra of solutions of DNSA/BSA, 2.1/BSA, and DNSA/2.1/BSA by exciting at 350 nm 
(Figure 2.8).   This data supports FRET because the DNSA/2.1/BSA sample exhibits 
emission at the λmax of 520 nm for fluorescein that was much higher in intensity than the 
2.1/BSA sample.  We also performed a titration in which DNSA was titrated into BSA/2.1 
while exciting at 350 nm (for dansyl) and observed an increase in emission of fluorescein 
with a λmax at 520 nm,50 which supports FRET between dansyl amide and 2.1 when they 
are both bound to BSA.   
 
 
Figure 2.8 Evidence of FRET between DNSA and 2.1.  Fluorescence spectra for 
DNSA/BSA (250 µM/100 µM), 2.1/BSA (90 µM/100 µM), and 
DNSA/2.1/BSA (250 µM/ 90 µM/ 100 µM) in 10 mM phosphate buffer, pH 
7.00, 0.02% NaN3; λex = 350 nm.  (Reproduced from Ref. 50: © University 
of Texas at Austin, 2013) 
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However, we knew from the analysis of the metathesis reaction mixtures that a 
significant amount of AF remained in the solution.  AF has a broad excitation spectrum 
compared to 2.1 (Figure 2.39) and can be excited directly at 350 nm.  Furthermore, we 
titrated DNSA into AF/BSA and observed a small decrease in emission (Figure 2.40), 
which is not indicative of FRET.  Therefore, we expected to observe a mixture of these two 
effects for the FRET parameter in the array, since both AF and species like 2.1 could both 
be present in the well.   
2.6.6 Second Iteration of the Well-Plate Array 
Once we had established that the olefin metathesis reaction was successfully 
mixing AF with fragments of the unsaturated glycerides in our panel, we were ready to 
incorporate this reaction into the well plate array with SA.  To do so, we performed the 
metathesis reaction on the glycerides in a well plate in chloroform. However, because 
chloroform is immiscible with buffered SA solutions, after metathesis the chloroform was 
allowed to evaporate and the residues were taken up in THF.  The THF solutions of the 
glyceride metathesis reactions were then exposed to BSA and HSA, separately, in a 96-
well plate.  Dansyl amide (DNSA) was added to one set of BSA and HSA plates and buffer 
was added to another set of BSA and HSA plates.  For the plates that contained DNSA, the 
emission of fluorescein, DNSA, and the FRET pair between the two fluorophores was 
measured.  For the plates without DNSA, only the emission of the fluorescein was 
measured.  We wanted to measure the fluorescein emission both in the absence and 
presence of DNSA to see if there was a significant difference in this signal and thus an 
additional variable in our array.  The first iteration of the well plate array was also 
performed exactly as described above for each glyceride.  Both sets of fluorescence data 
were used in the pattern recognition algorithm for a total of fourteen variables. 
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The LDA plot generated for eight glycerides is shown in Figure 2.9.  The cross-
validation was 100%.  The clustering within replicates of the same glyceride in this plot 
(B) is much tighter than in the plot generated using only the first iteration of the well plate 
array (A), and the separation between different glycerides is more marked.  In particular, 
compared to Figure 2.7, the cis isomer D2 is discriminated from its trans isomer D1, and 
T5 no longer overlaps with D1 and D2.  
From the factor-loading plot (Figure 2.10), we can conclude that the metathesis 
parameters contributed significantly to the discrimination.  A factor-loading plot shows the 
contribution of each of the original input variables to each factor axis in the reduced 
variable space.  The loading plot in Figure 2.10 shows that the metathesis variables, which 
are marked in red, contribute significantly to F1 and F2. This result supports our hypothesis 
that the metathesis reaction would improve the differentiation of a panel of glycerides 
containing unsaturated species. 
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Figure 2.9 Discrimination of eight glycerides by the fourteen-receptor array.  LDA 
plots of data collected from 96-well plates with olefin metathesis.  BSA and 
HSA (100 µM), glyceride (90 µM), DNSA (60 µM), ANS (60 µM), and 
NBD-FA (60 µM), metathesized glyceride (90 µM), AF (100 µM), and 
DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 2.8 for read 
parameters).  Cross validation = 100%. 
 
Figure 2.10 Loading plot corresponding to the LDA in Figure 2.9.  DNSA1 refers to the 
non-metathesis part of the assay, while DNSA2 refers to the measurement of 
the DNSA emission in the presence of the metathesized glycerides.  AF1 
refers to the fluorescein emission in the absence of any DNSA, while AF2 
refers to the fluorescein emission in the presence of DNSA. 
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2.7 ARRAY REPRODUCIBILITY 
Next, we wanted to be sure that we could replicate the results of array.  In other 
words, we wanted to know if we would get essentially the same pattern for the glycerides 
each time we performed an independent repetition of the entire experiment, including 
repeating the metathesis reaction and starting from newly prepared stock solutions of all of 
the array components. Such a complete reproduction has rarely, if ever, been discussed in 
papers describing differential sensing routines.  Hence, we performed an independent 
repetition of the array on those same eight glycerides two more times for a total of three 
data sets (Figure 2.11).  The relative position of all eight glycerides was essentially the 
same for each plot, and we concluded that the array is reproducible.   
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Figure 2.11 LDA plots of data collected from 96-well plates in three independent 
repetitions. BSA and HSA (100 µM), glyceride (90 µM), DNSA (60 µM), 
ANS (60 µM), and NBD-FA (60 µM), metathesized glyceride (90 µM), AF 
(100 µM), and DNSA (60 µM) in phosphate buffer with < 5% THF (see 
Table 2.8 for read parameters). The fluorescence counts were express as a 
percentage of the total fluorescence for each receptor/variable. 
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In order to further test the consistency of the array, we used LDA as a predictive 
tool.  Since LDA entails that the classes be given as inputs, one can take two sets of data, 
in our case the independent repetitions of the array on those eight glycerides, and assign 
one as a training set and the other as a prediction set.  The training set teaches the algorithm 
which responses from the array correspond to which glyceride, and then the algorithm can 
assign the glyceride identity to the sets of array responses in the prediction set.  Hence, we 
alternately treated each of the three repetitions as the training set or the prediction set.  For 
64 data points in each set (8 replicates of 8 glycerides), the average accuracy was 87% for 
the six combinations of the three independent replications (Table 2.3).   
Table 2.3 Summary of prediction accuracy for the six combinations of the three 
repetitions in Figure 2.11. 
Training Set Prediction Set % Correct Classification (of 64 cases) 
Rep 1 Rep 2 75 
Rep 1 Rep 3 84 
Rep 2 Rep 1 80 
Rep 2 Rep 3 100 
Rep 3 Rep 1 84 
Rep3 Rep 2 100 
 
2.8 ANALYSIS OF THE FULL GLYCERIDE PANEL 
Finally, we performed the full fourteen-variable array on all twenty glycerides in 
the panel.  An LDA plot was obtained with a cross-validation of 98% (Figure 2.12).  The 
only error in classification in the cross validation was between one replicate of the saturated 
triglyceride T7, which was misclassified as another saturated triglyceride T8.  In general, 
the unsaturated di- and triglycerides are on the right side of the plot, while the saturated 
glycerides are on the left side.  Within the unsaturated glycerides, there is very clear 
separation between all of the mono-, di-, and triglycerides.  The unsaturated monoglyceride 
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M1 is associated more closely with the saturated glycerides on the left side of the plot.  
However, this result is reasonable because M1 metathesizes poorly (see Table 2.2).  The 
two glycerides that consist of fatty acid alkyl groups with multiple double bonds (T5, D4) 
are found near one another at the bottom center of the plot.   
 
 
Figure 2.12 Discrimination of twenty glycerides by the array.  LDA plot of data 
collected from 96-well plates.  The array components consisted of BSA and 
HSA (100 µM), glyceride (90 µM), DNSA (60 µM), ANS (60 µM), NBD-
FA (60 µM), metathesized glyceride (90 µM), AF (100 µM), and DNSA (60 
µM) in phosphate buffer with < 5% THF (see Table 2.8 for read 
parameters).  Cross validation: 98%. 
Moreover, the stereo- and regioisomers of the unsaturated di- and triglycerides are 
successfully distinguished by the array.  Within the unsaturated diglycerides, the cis/trans 
isomers D1 and D2 are discriminated from one another.  Within the unsaturated 
triglycerides, the olefin positional isomers T3 (olefin between carbons 9 and 10) and T4 
(olefin between carbons 6 and 7) are also clearly separated.  Furthermore, T2 contains fatty 
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acid alkyl groups that are stereoisomeric (cis) to the fatty acid alkyl groups in T3 (trans), 
and these species are also clearly differentiated from one another. 
All the saturated glycerides are also well discriminated, although the separation is 
less marked than between the unsaturated glycerides.  This finding is unsurprising since 
the metathesis reaction does not occur with the saturated glycerides, and hence their 
discrimination would not be expected to be as significantly improved by the pretreatment 
step.  Within the saturated mono-, di-, and triglycerides, the difference between the 
compounds is simply the number of carbons in the fatty acid alkyl chains; however, the 
panel does contain one regioisomer pair, D5 and D6.  D5 is esterified at the sn-1 and sn-3 
positions of glycerol, while D6 is esterified at the sn-1 and sn-2 positions of glycerol.  The 
array is able to differentiate these regioisomers as well.  
The PCA plot (Figure 2.13) also shows good discrimination of the glycerides and 
similar groupings of glycerides based on their structural features to the LDA plot.  In PCA, 
the identities of the glycerides are not given as inputs, so the analysis only takes the 
variance in the variables (i.e. emission signals for each receptor) into account without 
knowing what the classes (i.e. identities of the glycerides) are supposed to be.   It is apparent 
in the PCA plot that the serum albumin-based receptors respond to the glycerides in a 
differential manner.   In other words, the receptors behave differently from one another 
with each analyte.  When receptors in an array behave similarly to one another, the PCA 
shows low dimensionality (i.e. most of the variance is described by one or two factor axes).  
For example, if the receptors all display their highest emission values in the presence of 
analyte 1 and the lowest emission values in the presence of analyte 2, the PCA would be 
able to describe the bulk of the variance in the data along a single factor axis.  In our case, 
the first five factor axes (F1-F5) describe 90% of the variance in the data.  The high 
dimensionality in the data is indicative of receptors that respond differently from one 
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another to the analytes in the panel.  High dimensionality in the data is indicative of a truly 
cross-reactive array of receptors.   
 
 
Figure 2.13 Discrimination of twenty glycerides using PCA.  PCA plot of data collected 
from 96-well plates.  The array components consisted of BSA and HSA 
(100 µM), glyceride (90 µM), DNSA (60 µM), ANS (60 µM), NBD-FA (60 
µM), metathesized glyceride (90 µM), AF (100 µM), and DNSA (60 µM) in 
phosphate buffer with < 5% THF (see Table 2.8 for read parameters).  
2.9 PREDICTION OF GLYCERIDE STRUCTURAL FEATURES 
Since glycerides that share structural features are grouped in the LDA and PCA 
plots, we hypothesized that our array could be used to identify these features in unknown 
glycerides.  As a way of testing this hypothesis, an independent reproduction of the array 
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was performed on all twenty glycerides (Figure 2.14), and the predictive feature of LDA 
was used.  The data set from one experiment was used as the training set, and the other data 
set was used as the prediction set.  The analyte classes that were provided to the algorithm 
were structural features of the glycerides: unsaturated triglyceride, saturated triglyceride, 
polyunsaturated triglyceride, unsaturated diglyceride, saturated diglyceride, 
polyunsaturated diglyceride, unsaturated monoglyceride, and saturated monoglyceride 
(Figure 2.15).  
 
 
Figure 2.14 Independent repetition of array discrimination of twenty glycerides.  LDA 
plot of data collected from 96-well plates in an independent repetition of the 
array on all twenty glycerides.  The array components consisted of BSA and 
HSA (100 µM), glyceride (90 µM), DNSA (60 µM), ANS (60 µM), NBD-
FA (60 µM), metathesized glyceride (90 µM), AF (100 µM), and DNSA (60 
µM) in phosphate buffer with < 5% THF (see Table 2.8 for read 
parameters).  Cross validation: 98% 
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Figure 2.15 LDA plots of training sets with glyceride classes designated as structural 
features.  The array components consisted of BSA and HSA (100 µM), 
glyceride (90 µM), DNSA (60 µM), ANS (60 µM), NBD-FA (60 µM), 
metathesized glyceride (90 µM), AF (100 µM), and DNSA (60 µM) in 
phosphate buffer with < 5% THF (see Table 2.8 for read parameters).  The 
fluorescence counts were expressed as a percentage of the total fluorescence 
for each receptor/variable.  Cross validation: 100% (top) and 98% (bottom). 
LDA correctly assigned the glycerides in the training set to its structural feature 
class in an average of 89% of 160 cases.  Since our array is primarily designed to target 
differences between unsaturated glycerides through the metathesis pretreatment, we 
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postulated that separating the saturated and unsaturated glycerides from one another first 
would improve the accuracy of the predictions.  The analyte classes were assigned more 
generally to either saturated, unsaturated, or polyunsaturated (Figure 2.16).  LDA correctly 
assigned the glycerides in the training set according to these classes in an average of 96% 
of 160 cases.   
 
Figure 2.16  LDA plots of the training sets with glyceride classes designated as 
saturated, unsaturated, and polyunsaturated.  The array components 
consisted of BSA and HSA (100 µM), glyceride (90 µM), DNSA (60 µM), 
ANS (60 µM), NBD-FA (60 µM), metathesized glyceride (90 µM), AF (100 
µM), and DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 
2.8 for read parameters).  The fluorescence counts were expressed as a 
percentage of the total fluorescence for each receptor/variable. Cross 
validation:  99% (left) and 100% (right). 
Once it was known whether the glycerides were saturated or unsaturated, then whether they 
were mono-, di-, or triglycerides could be determined.  The training and prediction sets 
were split into saturated and unsaturated.  Within the unsaturated set, the analyte classes 
were triglyceride, diglyceride, monoglyceride, polyunsaturated diglyceride, and 
polyunsaturated triglyceride (Figure 2.17).   
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Figure 2.17 LDA plots of the training sets of unsaturated glycerides with classes 
designated as shown in the key.  The array components consisted of BSA 
and HSA (100 µM), glyceride (90 µM), DNSA (60 µM), ANS (60 µM), 
NBD-FA (60 µM), metathesized glyceride (90 µM), AF (100 µM), and 
DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 2.8 for read 
parameters).  The fluorescence counts were expressed as a percentage of the 
total fluorescence for each receptor/variable. Cross validation:  100% (left) 
and 100% (right). 
With the saturated set, the analyte classes were triglyceride, diglyceride, and 
monoglyceride (Figure 2.18).  For the unsaturated set, the glycerides were assigned 
correctly in an average of 95% of the 80 cases, while for the saturated set, the glycerides 
were assigned correctly in an average of 73% of the 80 cases.  The lower accuracy of the 
prediction for the saturated glycerides is unsurprising since it is apparent in the LDA plot 
that the saturated glycerides are less clearly separated from one another compared to the 
unsaturated glycerides.  However, overall, the array shows a good ability to predict the 
structural features of glycerides using LDA.   
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Figure 2.18 LDA plots of the training sets of saturated glycerides with analyte classes 
designated as shown in the key.  The array components consisted of BSA 
and HSA (100 µM), glyceride (90 µM), DNSA (60 µM), ANS (60 µM), 
NBD-FA (60 µM), metathesized glyceride (90 µM), AF (100 µM), and 
DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 2.8 for read 
parameters).  The fluorescence counts were expressed as a percentage of the 
total fluorescence for each receptor/variable.  Cross validation:  100% (left) 
and 100% (right). 
2.10 ADIPOCYTES 
 Adipocytes store dietary fat in the form of glycerides.1  Triglycerides are ingested 
and converted into free fatty acids by pancreatic lipases.  These free fatty acids are absorbed 
by the body and transported to adipocytes, hepatocytes, and muscle cells.  The adipocytes 
reesterify the fatty acids to obtain triglycerides that remain in the cells until the glycerides 
are needed for energy production.  When energy is needed, glycerides are mobilized by the 
process of lipolysis, in which lipases hydrolyze the glycerides to yield free fatty acids that 
can be catabolized (Figure 2.19). 
 There is a recent interest in investigating the lipid patterns of diabetic individuals 
compared to non-diabetic individuals as a potential diagnostic tool.60–63 Several enzymes, 
including adipocyte triglyceride lipase (ATGL), hormone sensitive lipase (HSL), and 
monoglyceride lipase (MGL), carry out lipolysis by hydrolyzing the ester bonds in tri-, di-
, and monoglycerides in adipocytes, respectively (Figure 2.19).64  These enzymes are in 
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turn regulated by hormones like insulin and epinephrine. Many biochemists and biologists 
are seeking to illuminate the complex interplay of these enzyme and regulatory pathways 
in order to better understand metabolic diseases like diabetes.51,65,66  For example, the 
inhibition of HSL by insulin is known to lead to an increase in diglyceride content in 
adipocytes.67   Furthermore, it is known that lipolytic enzymes exhibit substrate 
preferences,11,68,69 such as the preference of HSL for 2,3-diglycerides over 1,3-
diglycerides.9  The different preferences of the enzymes in conjunction with their 
regulation by different hormones could lead to changes in glyceride profiles in adipocytes 
in hormonal disorders.64 
 
 
Figure 2.19 Lipolysis in an adipocyte under basal and stimulated conditions.  ATGL = 
adipocyte triglyceride lipase, HSL = hormone sensitive lipase, MGL = 
monoglyceride lipase, TAG = triglyceride, DAG = Diglyceride, MAG = 
monoglyceride, FA = fatty acid, P = phosphate group.  The other 
components are additional cofactors.  (Reproduced from Ref. 64: © Nature 
Publishing Group, 2012) 
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2.10.1 Extracts from Human and Rat Adipocytes 
 We hypothesized that our array could be applied to extracts from mammalian 
adipocytes to detect differences in these glyceride mixtures.   Hence, our collaborators at 
Sanofi-Aventis and the Helmholtz Institute provided us with extracts from human and rat 
adipocytes.  The fat cells were harvested from the respective organisms and then were 
exposed to three different types of in vitro conditions: no treatment (control), insulin 
treatment, or isoproterenol treatment (Table 2.4 and 2.5, Scheme 2.10).  Insulin and 
isoproterenol are known to regulate lipolysis.67  Specifically, insulin inhibits HSL, while 
isoproterenol stimulates HSL activity (Figure 2.19).  Thus, these exposures were 
hypothesized to induce glyceride profile changes in the cells: affecting the activity of the 
substrate-specific HSL while leaving other lipases at their normal level of activity should 
cause changes in the mobilization of some types of glycerides compared to other types.  
After treatment, the fat cells were lysed and centrifuged, and the lipid droplet, which is 
essentially a mixture of glycerides, was collected and provided to us.  The fat material was 
further treated by taking up the samples in ethyl acetate and washing with brine solution.  
The ethyl acetate portion of each sample was collected, filtered to remove any insoluble 
material remaining, and placed in a pre-weighed vial to obtain an accurate weight of the 
material.  The solvent was removed by rotary evaporation and then overnight drying on the 
high vacuum line.  The glyceride material was a clear, viscous liquid.  
 
 
Scheme 2.10 Isoproterenol.  It is structurally similar to epinephrine. 
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Table 2.4 Human fat samples.  HA1-HA8 were provided as a set and HA9-HA14 were 
provided as a set. 
Sample Treatment Sample Treatment 
HA1 Control HA8 Control 
HA2 + 10 nM insulin HA9 Control 
HA3 Control HA10 + 10 nM insulin 
HA4 Control HA11 + 1 µM isoproterenol 
HA5 Control HA12 Control 
HA6 + 10 nM insulin HA13 + 10 nM insulin 
HA7 + 10 nM insulin HA14 + 1 µM isoproterenol 
 
Table 2.5 Rat fat samples including time courses. 
Sample Treatment Sample Treatment 
1 control 16 + 10 nM insulin 
4 + 1 µM isoproterenol 37 + 10 nM insulin, 0 min 
28 + 1 µM isoproterenol, 0 hr 40 + 10 nM insulin, 30 min 
31 + 1 µM isoproterenol, 3 hr 43 + 10 nM insulin, 6 hr 
34 + 1 µM isoproterenol, 6 hr   
 
2.10.2 Application of the Array to the Human Fat 
Since the fat samples were mixtures of glycerides with different molecular weights, 
weight/volume concentrations were used instead of molar concentrations in order to 
introduce the same amount of material from each sample to the array.  Most of the 
glycerides in the mixture are expected to be triglycerides derived from myristic, palmitic, 
palmitoleic, oleic, linoleic, and stearic acids.1  These glycerides range in molecular weight 
from about 700-900 Da.  Thus, an average molecular weight of 800 Da was chosen to 
loosely correlate a weight/volume concentration to a molar one (e.g. 9 mM ≈ 7.2 mg/mL).  
The purpose of this calculation was to ensure that a similar concentration of glyceride was 
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being used in the array with these mixtures as was used successfully with the pure samples 
of glyceride.  
The fat samples were subjected to the array in the same manner as for the pure 
glyceride samples.  Samples HA1-HA8 were analyzed together (Figures 2.20 and 2.21).   
 
 
Figure 2.20 LDA plot of array data from analysis of HA1-HA8.  The insulin-treated 
samples are marked as triangles.  The array components consisted of BSA 
and HSA (100 µM), fat (0.072 mg/mL), DNSA (60 µM), ANS (60 µM), 
NBD-FA (60 µM), metathesized fat (0.072 mg/mL), AF (100 µM), and 
DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 2.8 for read 
parameters).  Cross validation: 98%. 
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Figure 2.21 PCA plot of array data from analysis of HA1-HA8.  The insulin-treated 
samples are marked as triangles.  Top: F1 versus F2.  Bottom: F2 versus F3.  
The array components consisted of BSA and HSA (100 µM), fat (0.072 
mg/mL), DNSA (60 µM), ANS (60 µM), NBD-FA (60 µM), metathesized 
fat (0.072 mg/mL), AF (100 µM), and DNSA (60 µM) in phosphate buffer 
with < 5% THF (see Table 2.8 for read parameters).  
The clustering in the LDA plot is quite good; however, the three insulin-treated 
samples are not grouped together, nor are the control samples.  The PCA plot is more 
revealing in that it shows very poor clustering and separation, which is not resolved even 
when considering F3.  Looking at F1 versus F2, the three insulin-treated samples are 
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overlapping one another.  The control samples are scattered around the insulin-treated 
samples and are not well separated from them.  We repeated the array on samples HA3-
HA8 again (Figures 2.22 and 2.23).  There was insufficient HA1 and HA2 material to 
analyze them again.   
 
 
Figure 2.22 LDA plot of array data from analysis of HA3-HA8.  The insulin-treated 
samples are marked as triangles.  The array components consisted of BSA 
and HSA (100 µM), fat (0.072 mg/mL), DNSA (60 µM), ANS (60 µM), 
NBD-FA (60 µM), metathesized fat (0.072 mg/mL), AF (100 µM), and 
DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 2.8 for read 
parameters).  Cross validation: 98%. 
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Figure 2.23 PCA plot of array data from analysis of HA3-HA8.  The insulin-treated 
samples are marked as triangles.  Top: F1 versus F2.  Bottom: F2 versus F3.  
The array components consisted of BSA and HSA (100 µM), fat (0.072 
mg/mL), DNSA (60 µM), ANS (60 µM), NBD-FA (60 µM), metathesized 
fat (0.072 mg/mL), AF (100 µM), and DNSA (60 µM) in phosphate buffer 
with < 5% THF (see Table 2.8 for read parameters).  
Similar results were obtained in the repetition of the analysis of HA3-HA8, which 
indicates good reproducibility in the method.  There is again poor clustering and separation 
in the PCA plot.  This data set represents a good example of why employing both PCA and 
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LDA is useful: PCA can sometimes reveal the apparently good clustering and separation 
in an LDA plot to be forced and potentially not meaningful.  In both repetitions, the insulin-
treated samples do seem to be associated with one another in the LDA and PCA plots, but 
the control samples are positioned all around the insulin-treated samples.  Normally, we 
would expect to see that two regions of a plot are separable by a boundary that can be 
drawn as a straight line (e.g. control samples on one side, insulin-treated samples on the 
other) rather than by a circle.  The meaning of this circular boundary between the two 
sample types is unclear.  Putting this inconclusive data aside, we next analyzed HA9-
HA14, which also contain isoproterenol-treated samples, with the array (Figures 2.24 and 
2.25).   
 
Figure 2.24 LDA plot of array data from analysis of HA9-HA14.  The array components 
consisted of BSA and HSA (100 µM), fat (0.072 mg/mL), DNSA (60 µM), 
ANS (60 µM), NBD-FA (60 µM), metathesized fat (0.072 mg/mL), AF (100 
µM), and DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 
2.8 for read parameters).  Cross validation: 98%. 
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Figure 2.25 PCA plot of array data from analysis of HA9-HA14.  The array components 
consisted of BSA and HSA (100 µM), fat (0.072 mg/mL), DNSA (60 µM), 
ANS (60 µM), NBD-FA (60 µM), metathesized fat (0.072 mg/mL), AF (100 
µM), and DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 
2.8 for read parameters). 
Again, similar results were obtained.  The LDA plot looks promising with good 
separation and clustering, and the treated samples seem to be associated properly (insulin 
with insulin, isoproterenol with isoproterenol).  However, the control samples are not 
grouped in their own region of the plot.  The PCA shows poor clustering and substantial 
overlap with no obvious groupings with respect to the sample treatment conditions.  At this 
point, we concluded that the array was not discriminating the treatment conditions of the 
human fat samples in any meaningful or useful way.  
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2.10.3 Application of the Array to the Rat Fat 
The rat fat was applied to the array at the same weight/volume concentration as the 
human fat.  For the first analysis, one sample of each treatment type was selected: 1 
(control), 4 (isoproterenol), and 16 (insulin) (Figures 2.26 and 2.27).  
  
 
Figure 2.26 LDA plot of array data from analysis of rat samples 1, 4, and 16.  The array 
components consisted of BSA and HSA (100 µM), fat (0.072 mg/mL), 
DNSA (60 µM), ANS (60 µM), NBD-FA (60 µM), metathesized fat (0.072 
mg/mL), AF (100 µM), and DNSA (60 µM) in phosphate buffer with < 5% 
THF (see Table 2.8 for read parameters).  Cross validation: 92%. 
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Figure 2.27 PCA plot of array data from analysis of rat samples 1, 4, and 16.  Top: F1 
versus F2.  Bottom: F2 versus F3.  The array components consisted of BSA 
and HSA (100 µM), fat (0.072 mg/mL), DNSA (60 µM), ANS (60 µM), 
NBD-FA (60 µM), metathesized fat (0.072 mg/mL), AF (100 µM), and 
DNSA (60 µM) in phosphate buffer with < 5% THF (see Table 2.8 for read 
parameters). 
Even though the LDA plot indicates good discrimination of the samples, the PCA 
plot shows substantial overlap between the three samples, even when considering a third 
dimension.  We decided to try performing the assay at a higher concentration of fat to see 
if this change would improve the results.  All of the rat samples were analyzed at a higher 
concentration (Figures 2.28 and 2.29). 
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Figure 2.28 LDA plot of array data from analysis of all of the rat samples.  The array 
components consisted of BSA and HSA (100 µM), fat (0.6 mg/mL), DNSA 
(60 µM), ANS (60 µM), NBD-FA (60 µM), metathesized fat (0.6 mg/mL), 
AF (100 µM), and DNSA (60 µM) in phosphate buffer with < 5% THF (see 
Table 2.8 for read parameters).  Cross validation: 100%. 
 
Figure 2.29 PCA plot of array data from analysis of all of the rat samples.  The array 
components consisted of BSA and HSA (100 µM), fat (0.6 mg/mL), DNSA 
(60 µM), ANS (60 µM), NBD-FA (60 µM), metathesized fat (0.6 mg/mL), 
AF (100 µM), and DNSA (60 µM) in phosphate buffer with < 5% THF (see 
Table 2.8 for read parameters).   
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At first, these results appeared more promising than the results from the human 
samples.  The LDA plot is dominated by the separation between isoproterenol (4) and the 
rest of the samples, but the PCA plot does not include this feature, so it is likely not truly 
significant.  While the PCA plot shows decent clustering within the different sample 
conditions, it is unclear what the relative position of the different groups could mean.  For 
example, the insulin-treated samples are just as close to one another as they are to 
isoproterenol-treated samples.   Our hypothesis that the insulin and isoproterenol would 
have very different effects on the glyceride profiles does not seem to be borne out by these 
results.  Hence, we cannot be confident that the discrimination of the rat fat samples in the 
LDA or PCA is based on real differences in the glyceride content.  Rather, the chemometric 
algorithms could be “discriminating” the samples based on small differences in 
concentration and other sample preparation imperfections.  To probe this question, we 
repeated the analysis of the rat samples in exactly the same way (Figures 2.30 and 2.31).  
There was insufficient sample 30 (insulin 30 min) to use in the array, so it was excluded. 
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Figure 2.30 LDA plot of array data from the repetition of the analysis of the rat samples.  
The array components consisted of BSA and HSA (100 µM), fat (0.6 
mg/mL), DNSA (60 µM), ANS (60 µM), NBD-FA (60 µM), metathesized 
fat (0.6 mg/mL), AF (100 µM), and DNSA (60 µM) in phosphate buffer 
with < 5% THF (see Table 2.8 for read parameters).  Cross validation: 95%. 
 
Figure 2.31 PCA plot of array data from the repetition of the analysis of the rat samples. 
The array components consisted of BSA and HSA (100 µM), fat (0.6 
mg/mL), DNSA (60 µM), ANS (60 µM), NBD-FA (60 µM), metathesized 
fat (0.6 mg/mL), AF (100 µM), and DNSA (60 µM)  in phosphate buffer 
with < 5% THF (see Table 2.8 for read parameters).   
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The results from the repetition of the array do not resemble the initial results in 
terms of the relative positioning of the sample types.  Furthermore, the scatter and overlap 
are worse in the repetition.  Since the results were not reproduced, the apparent 
differentiation of the analytes can likely be attributed to small errors in preparing the array 
(e.g. solution preparation, pipetting, and measuring of the fluorescence).  Our conclusion 
at this point was that the array was not successful in discriminating either the human or rat 
fat samples based on differences in their glyceride content.  Whatever differences in the 
type and number of glycerides may be present in the samples, this method is not sensitive 
enough to detect them reproducibly.  We next examined mass spectral and 1H-NMR data 
from the fat samples in order to determine if any differences could be detected with these 
methods. 
2.10.4 Mass Spectral and 1H-NMR Data from Fat Samples 
Since the glycerides do not ionize readily, it was not possible for us to obtain mass 
spectral data from the fat samples directly.  However, we were able to analyze the 
metathesis reactions with LC-MS to gain insight into the unsaturated species present in the 
sample.  In fact, this data was obtained routinely for each repetition of the array in order to 
ensure that the metathesis reaction was working each time.   
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Figure 2.32 Chromatograms of metathesis reactions of human fat samples.  Top: control 
(HA12), middle: insulin (HA13), bottom: isoproterenol (HA14).  
Absorbance detection at 280 nm.  From the corresponding ion 
chromatograms: A- AF, B- 2.2, C- linoleic acid-derived species, D- 
palmitoleic acid-derived species, E- oleic acid-derived species, and F- 
petroselaidic acid-derived species. 
The chromatograms for the metathesis of human fat samples that had been 
untreated, insulin-treated, or isoproterenol-treated were nearly identical (Figure 2.32).  
From the corresponding ion chromatograms, some of the species derived from unsaturated 
glycerides mixed with AF could be identified as indicated in the figure caption (A-F).  
Based on this data, it was unsurprising that our array could not discriminate the glycerides, 
since the array works best at differentiating unsaturated glycerides.  We performed the 
A 
B 
C 
D 
E 
F 
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same analysis on the metathesis reactions of the rat fat of the three types from the first 
repetition of the array with the rat samples (Figure 2.33).   
 
 
Figure 2.33 Chromatograms of metathesis reactions of rat fat samples.  Top: control (1), 
middle: insulin (16), bottom: isoproterenol (4).  Absorbance detection at 280 
nm.  From the corresponding ion chromatograms: A-linoleic acid-derived 
species, B- palmitoleic acid-derived species, and C- oleic acid-derived 
species. 
The control and insulin samples were identical in their unsaturated glyceride 
content based on the chromatograms.  Unreacted AF was not observed in those 
chromatograms because the rat fat was introduced at a much higher concentration to the 
metathesis reaction than with the human fat.   
The isoproterenol-treated sample shows only AF (peak at 7.66 min), indicating that 
there was no reaction.  This failure was probably due to some experimental error, like the 
A B 
C 
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presence of THF, rather than the absence of any unsaturated glycerides.  This finding 
explains the LDA plot obtained from the array analysis of these samples (Figure 2.28), 
which had the isoproterenol sample separated markedly from all of the others.  This feature 
was not seen again in the repetition of the experiment (Figure 2.30), which further 
indicates the failure of the metathesis reaction with the isoproterenol-treated sample was 
due to an error in setting up the reaction rather than an indication that the sample contained 
no unsaturated glycerides.    
Interestingly, while all of the human samples were identical, as were the rat 
samples, the human and rat samples are different from one another.  According to the LC-
MS data, the human and rat samples contain different amounts of linoleic, palmitoleic, and 
oleic acid-derived species.   
NMR data was also collected from the rat fat of the three sample types.  There was 
insufficient human fat to obtain NMR data.  The 1H-NMR spectra for the control, insulin, 
and isoproterenol rat samples were largely the same (Figure 2.38).  The only potentially 
significant difference was in the peaks from 4.0-4.5 ppm, which are the glycerol methylene 
peaks of the glycerides.  Additional small peaks in this region could be from mono- and 
diglyceride species.  
Overall, the MS and NMR data support the notion that the fat samples do not differ 
significantly in their glyceride composition based on sample treatment.  Hence, it is 
unsurprising that our array was unable to discriminate the samples.  In fact, this finding 
supports the validity of our array, since the array correctly detected no differences in the 
samples when there were none.   
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2.11 QUANTITATION OF TRILINOLEIN (T5) IN TRIGLYCERIDE MIXTURES USING 
STANDARD ADDITION 
2.11.1 Introduction to standard addition and net analyte signal (NAS) 
Since quantitation is one of the major challenges that mass spectrometric analysis 
faces in regard to glyceride analysis, we sought to demonstrate the use of our assay for 
quantitation of a glyceride of interest within a mixture of other glycerides.  Typically, 
mixtures of glycerides found in edible oils or adipocyte cell extracts are separated by HPLC 
or GC before being individually identified by mass spectrometry and quantified by 
standard calibration methods.2  However, we wanted to eliminate the need for an HPLC 
separation step in order to simplify the analysis by our assay, as this separation itself can 
be challenging to accomplish.19  Because the receptors in the array are semi-selective in 
nature, the presence of glycerides other than the species of interest in the mixture will 
interfere with the signal elicited from the receptor by that species.  Hence, we chose to use 
the “standard addition” method to minimize the influence of the other glycerides in the 
mixture on the quantitation of the glyceride of interest.   
Standard addition is a classic calibration method that is used when matrix effects 
are present in a sample that interfere with the signal the compound of interest elicits, 
confounding accurate quantitation of that compound.70  Ordinarily, the experimentalist 
tries to remove interferents from the sample whenever possible; however, when it is not 
facile to physically remove the interfering background matrix, standard addition can be 
employed to minimize the matrix’s effect on the analysis.   Standard addition is carried out 
by measuring the response of the mixture after successive additions of the pure analyte of 
interest.  By plotting the response against the amount of the pure analyte in each addition, 
the concentration of the analyte of interest in the sample is obtained by a linear fit of the 
data.  The x-intercept of the line is the original analyte concentration.   This data analysis 
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procedure is used when dealing with univariate data (i.e. one signal, y, describes the 
concentration, x, of the analyte); however, in the multivariate case (i.e. multiple signals, 
y1, y2,…yn, describe the concentration, x, of the analyte), the data analysis employed to 
determine the analyte concentration is necessarily more complicated.71   
In the literature, there are numerous examples of multivariate standard addition 
procedures,72–77 usually dealing with spectral or electrochemical data obtained from 
complex sample mixtures. Nevertheless, to our knowledge this is the first report in which 
a multivariate standard addition has been performed with a cross-reactive chemosensor 
array.  For our purposes, we chose to follow the mathematical procedure developed by 
Hemmateenejad and Yousefinejad, called standard addition by net analyte signal 
(SANAS), due to its simplicity and accuracy.78  The net analyte signal (NAS) is defined as 
the portion of the total signal that is directly related to the concentration of the analyte.79  
For some total signal elicited from a mixture, some portion of the signal is due to the 
component of interest and the rest is due to the background and other components of the 
mixture.  Lorber has shown that the contribution to the signal due to the component of 
interest, the NAS, can be computed because it is orthogonal to the contribution to the signal 
of the background and other components.80  Linear algebra is used to determine this 
orthogonal part of the signal as a vector.  In this way, the influence of the matrix as well as 
background noise can be removed.  
In SANAS, the data is first subjected to dimensionality reduction, commonly by 
principal component analysis (PCA) or partial least squares regression (PLS).  As described 
earlier in this report, these algorithms transform the data into a space described by new 
orthogonal axes, called factor axes, that are linear combinations of the original variables 
(i.e. the signals y1, y2,…yn).  These factor axes are chosen by the algorithm according to 
different criteria depending on the exact method used (e.g. PCA, LDA, or PLS), but in 
 102 
general these criteria lead to factor axes that are more information dense.  The first factor 
axis (F1) contains the most relevant information about the data, F2 the second most, and 
so on up to FN, where N = number of original variables.  With our data, we obtained better 
results using PLS rather than PCA.  PLS relates a matrix X (the emission data from our 
array) to a property y (concentration of the additions).81  PLS uses maximum covariance 
as its criterion for determining the new factor axes, unlike PCA which uses maximum 
variance.  The advantage of using covariance is that it includes both variance of X as well 
as correlation of X and y.   
By rebuilding the data set from fewer factor axes than the total number (for 
example, from F1-F3, discarding F4-F10), irrelevant information like noise, background, 
or interferences can be removed from X.  From the rebuilt data set (X’), the NAS for the 
analyte of interest is calculated by using a type of single value decomposition method 
called rank annihilation (see reference 78 for a detailed account of this series of 
computations).  The output is a vector that describes the NAS (||NAS||).  By plotting the 
Euclidean norm of this vector (i.e. its magnitude) against the concentrations of the 
additions, one obtains a plot that is equivalent to the one described for the univariate case 
described above.  The x-intercept of the linear fit has the same meaning as in the univariate 
case, that is, the concentration of the analyte of interest in the mixture.   
2.11.2 Applying SANAS to mixtures of glycerides 
The first step in performing the quantitative analysis with our array was to generate 
mixtures of triglycerides with a known composition to study the accuracy of the method.   
Mixtures consisting of T1, T3, T5, T6, and T7 were carefully prepared (Table 2.9).  
Weight/volume concentrations were used since the molecular weights differ for different 
glycerides.  The mixture solution was aliquoted into vials and each aliquot was spiked with 
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an increasing amount of pure T5 at a constant total volume for seven additions.  The eight 
resultant solutions were then subjected to the array, and the fluorescence data was obtained 
as described previously.  The final concentration of T5 from the mixture that was in the 
well plates of the array is shown in Table 2.6.  This concentration is the one that we are 
measuring with the array.  The data from the array was normalized and then subjected to 
PLS analysis as this method of dimensionality reduction was found to give a slightly more 
accurate result compared to PCA.   The data was rebuilt from F1 only (mixtures A, B, C) 
or from F1 and F2 (mixture D) to obtain the closest estimates.  In all cases, F1 described 
90% or more of the covariance in the data sets. 
From the rebuilt data matrix, the net analyte signal (||NAS||) was calculated and 
plotted against the additions to give SANAS plots (Figures 2.34-2.37).  From these plots, 
the concentration of T5 in the mixture was determined by finding the x-intercept of the 
linear fit (Table 2.6).  Good estimates of the concentration of T5 in the mixtures were 
obtained for mixtures B, C, and D; however, a larger overestimation of the concentration 
of T5 in mixture A was obtained.  We attribute this error to poor linearity in the response 
of the sensors to the additions of T5 that is evidenced by the lower correlation coefficient 
for the linear fit in the SANAS plot for mixture A (Table 2.6).  Some of the non-linearity 
is likely due to random experimental errors in solution and plate preparation.  However, 
some deviations from linearity of the responses to the additions to all of the mixtures are 
inherent to the experimental method.  The fluorescence signal collected from each well of 
the plate is mediated by the serum albumin, fluorophore, and glycerides in the solution and 
is an indirect measurement of the T5 content.  Hence, we expect that non-linearity in the 
response results from both the saturation behavior of ligand binding to serum albumin as 
well as binding competition from glycerides in the mixture that are not T5.  Nevertheless, 
for mixtures B, C, and D the array response showed a good linear dependence on the 
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additions of T5.  The SANAS method was able to provide quite accurate values for the T5 
content without the necessity for removing or otherwise separating out the other 
triglycerides in the mixture.   
Table 2.6 Results for T5 concentration in triglyceride mixtures from SANAS. 
Mixture Total 
concentration 
of the mixture 
(mg/mL) 
Actual T5 
concentration (mg/mL) 
Predicted 
concentration 
(mg/mL) 
R2 of SANAS 
plot 
A 0.04 0.0113 0.0338 0.7403 
B 0.04 0.0158 0.0160 0.9517 
C 0.01 0.0053 0.0056 0.9519 
D 0.01 0.0042 0.0047 0.9664 
 
 
Figure 2.34 SANAS plot generated from the standard addition of mixture A. 
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Figure 2.35 SANAS plot generated from the standard addition of mixture B. 
 
Figure 2.36 SANAS plot generated from the standard addition of mixture C. 
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Figure 2.37 SANAS plot generated from the standard addition of mixture D. 
2.12 CONCLUSIONS 
In this work, we developed an array of cross-reactive serum albumins and 
fluorescent indicators to discriminate a panel of structurally similar glycerides.  An olefin 
cross metathesis reaction with an allyl fluorescein species was used to pretreat the samples 
prior to array analysis in order to distinguish unsaturated glycerides.  Using this simple 
assay, we successfully discriminated twenty mono-, di-, and triglycerides, including stereo- 
and regioisomeric pairs.   These isomer types included cis/trans stereoisomers, double bond 
positional regioisomers, and positional regioisomers on the glycerol core.  Additionally, 
we used the array in conjunction with LDA to predict structural features of glycerides.  
However, the application of the array to adipocyte fat extracts from humans and rats did 
not result in reproducible discrimination of these samples.  It is unclear that the insulin and 
isoproterenol treatments were the appropriate concentration and length of time to stimulate 
differences in the cells.  Thus, there is a question as to whether the poor discrimination is 
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indicative of a sensitivity problem with the array or of a true lack of differences in the 
samples. 
We demonstrated the first use of multivariate standard addition with a cross-
reactive array of chemosensors.   We used our array to perform a standard addition of 
trilinolein to mixtures of triglycerides.  By applying the established standard addition by 
net analyte signal (SANAS) method, we were able to quantitate the trilinolein in the 
mixtures with good accuracy. 
2.13 FUTURE WORK 
While we have clearly demonstrated that our array can be used successfully for a 
number of applications, the method could be further improved to be applicable to a range 
of glyceride-based analytical challenges.  The array could be improved for discrimination 
of mono-, di-, and triglycerides by functionalizing the free hydroxyls of mono- and 
diglycerides to accentuate their differences.   While the array was not successful at 
distinguishing the adipocyte extracts, the treatment protocols could be improved or 
changed to ensure that there would be differences in the fat samples.  Other treatment 
conditions such as different diets or induced diabetic states in whole organisms could be 
used instead of just treatment of cells with insulin or isoproterenol.  A series of artificially 
prepared mixtures of glycerides could be used to test the sensitivity of the array to 
differences in composition.  Finally, the quantitation of glycerides of interest in a real world 
sample like an adipocyte fat extract could be tested.   
2.14 CONTRIBUTIONS 
The experiments that Michelle Adams Ivy performed for this work were indicated 
by citing her dissertation (Ref. 50) where her results can be found.  The adipocyte samples 
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were prepared by Günter Müller of the Helmholtz Institute München, formerly of Sanofi-
Aventis.  The SANAS code was written by Scott Rabidoux (UT Austin). 
2.15 EXPERIMENTAL METHODS 
2.15.1 General Information 
Human and bovine serum albumin were purchased fatty acid free from Sigma 
Aldrich.  Glycerides were purchased from Nu-Chek Prep (D1, D2, D4), Sigma Aldrich 
(T1, T2, T4, T8, D4, D7), ABCR (T3, T5, T6, M1, M2, M3, M4, M5), Acros (T7), 
Bachem (D6), and Zerenex (D5).  Grubbs Second Generation Catalyst and 1,8-
anilinonaphthalene sulfonic acid was purchased from Sigma Aldrich.  Dansyl amide and 
2-anthracene carboxylate were purchased from TCI America.  The cuvette experiments 
were performed with a PTI fluorimeter using an 814 photomultiplier detection system and 
a 75W xenon short arc lamp.  The arrays were prepared in Costar 96-well plates (#3915).  
The plates were analyzed using a Biotek Synergy 2 Multimode Microplate Reader or a 
Biotek Cytation 3 Microplate Reader.  LC-MS analysis was performed on an Agilent 1200 
Series HPLC with an Agilent 6130 single quadrupole mass spectrometer (ESI and APCI 
ionization).  NMR spectra were taken on a 500 mHz Varian NMR.  Linear discriminant 
analysis, principal component analysis, and data normalization were done using XLSTAT 
2011.  The SANAS code was run on MATLAB 2014. 
2.15.2 Synthesis 
2.15.2.1 Synthesis of NBD-FA 
To 100 mL methanol was added 12-aminododecanoic acid (5.61 mmol, 1.2 g) and 
Hünig’s base (10.6 mmol, 1.85 mL).  Then, 7-chloro-4-nitrobenzo-3-oxa-1,3-diazole ( 5.01 
mmol, 1.0 g) was dissolved in 50 mL of methanol.  This solution was added to the first 
one, and the reaction was stirred overnight at room temperature.  The reaction slowly 
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darkened from yellow to a brownish-red color.  The methanol was removed under vacuum 
leaving an oil.  The oil was taken up in dichloromethane and washed several times with 
aqueous 1M HCl.  Finally, the solvent was removed under vacuum to yield a reddish-brown 
powder (1.23 g, 65% yield).  No further purification was necessary.   1H-NMR (400 MHz, 
CDCl3, ppm): δ 8.50 (d, 1H, H-Ar), 6.37 (m, 1H, H-N), 6.17 (d, 1H, H-Ar), 3.48 (dt, 2H, -
CH2-NH2), 2.35 (t, 2H, -CH2-COOH), 1.8-1.25 (m, 18H, 9 –CH2).  MS (ESI): 377.2 (M-
1).   
2.15.2.2 Synthesis of allyl fluorescein 
Fluorescein (4 g, 12.0 mmol) and sodium hydroxide (1 g, 12.0 mmol) were 
dissolved in 50 mL of water to yield the disodium salt.  The water was removed by 
lyophilization or centrifugal evaporation.  The disodium salt was dissolved in 150 mL 
water/80 mL acetone.  Allyl bromide (2.4 mL, 27.6 mmol) was added to the reaction, and 
the reaction was refluxed for 2 hr.  The reaction mixture was poured into 150 mL of water, 
and this solution was basified to yield an orange precipitate.  A red oil remained in the 
reaction flask.  This oil was dissolved in acetone and then poured into 100 mL of water.  
This solution was also basified to form the orange precipitate.  The two orange precipitates 
were collected by filtration and combined.  The fluorescein diether was recrystallized in 
ethanol/dilute NaOH (aq).  Finally, the diether was dissolved in 30 mL acetone and heated 
to reflux.  Then 20 mL of 1 M NaOH (aq) was added, and the reflux was continued for 12 
min.  The reaction mixture was poured into 100 mL of water, and this solution was 
acidified, becoming yellow and cloudy.  The solution was extracted 3x with 
dichloromethane.  The dichloromethane was dried with magnesium sulfate and removed 
under vacuum.  The resulting product was a yellow powder (357 mg, 8% yield).  1H-NMR 
(400 MHz, CDCl3, ppm):  δ 8.00 (dt, 1H, H-Ar-COOH), 7.65 (td, 1H, H-Ar-COOH), 7.60 
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(td, 1H, H-Ar-COOH), 7.15 (dt, 1H, H-Ar-COOH), 6.76 (d, 1H, H-Ar), 6.71 (d, 1H, H-
Ar), 6.67-6.50 (m, 6H, H-Ar), 6.02 (m, 1H, CH2-CH=CH2), 5.40 (dq, 1H, geminal cis-
CH2-CH=CH2), 5.30 (dq, 1H, geminal trans- CH2-CH=CH2), 4.55 (dt, 2H, CH2-CH=CH2).  
MS (ESI):  373.2 (M+1). 
2.15.2.3 Synthesis of 1 
 Michelle Adams Ivy synthesized 1.50  
2.15.3 Array Procedures 
2.15.3.1 Glyceride Array (Part 1) 
Concentrated stock solutions of each glyceride were prepared in THF 
(concentrations on the order of millimolar).  Stock solutions of human and bovine serum 
albumin were prepared in 10 mM phosphate buffer (pH 7.0, 0.02% NaN3) at a 
concentration of 500-700 µM.   Serum albumin-glyceride solutions were prepared from 
these stocks at concentrations of 150 µM serum albumin and 135 µM glyceride (3% THF, 
97% 10 mM phosphate buffer, pH 7.0, 0.02% NaN3).  Concentrated stock solutions of 
dansyl amide and NBD-FA were prepared in DMSO.  A concentrated stock solution of 
ANS was prepared in 10 mM NaOH (aq).   Then solutions of each of the three indicators 
at a concentration of 180 µM in 10 mM phosphate buffer, pH 7.0, 0.02% NaN3 were 
prepared.  
The plates were made by placing 200 µL of each serum albumin-glyceride solution 
and 100 µL of the 180 µM indicator solution in each well (final concentrations: 100 µM 
serum albumin, 90 µM glyceride, 60 µM indicator, 2% THF).  Each plate contained a 
column of indicator alone and a column of indicator and serum albumin as controls.  Eight 
replicates were performed for each glyceride/serum albumin/indicator combination and for 
the controls.   
 111 
The parameters for the reading of the well plates can be found in Table 2.7.  The 
fluorescence data was normalized by first subtracting the emission of the control (indicator 
alone) from each data point, and then the data set was rescaled from 0 to 100.  
Table 2.7 Plate read parameters for part 1 of the glyceride array 
 NBD-FA DNSA ANS 
λex 485/20 360/40 380/20 
λem 540/25 485/20 485/20 
Mirror Top 510 Top 400 Top 400 
 
2.15.3.2 Well Plate Metathesis Reaction 
Concentrated stock solutions of each glyceride were prepared in chloroform 
(concentrations were on the order of millimolar).  Solutions of allyl fluorescein and Grubbs 
Second Generation Catalyst (G2) were also prepared in chloroform.  These solutions were 
applied to a deep well polypropylene plate such that each well contained 2 mM glyceride, 
2.2 mM allyl fluorescein, and 0.4 mM G2 in a total volume of 1 mL of chloroform.  Two 
controls were also included that contained only allyl fluorescein and G2.  The plate was 
placed in an oven and heated at 50°C for 2 hr.  Then the plate was removed and left in the 
fume hood to finish evaporating the chloroform overnight at ambient temperature and 
pressure.  The next day, the dry material that remained in each well was taken up in 1 mL 
of THF with thorough mixing via a glass pipette to completely dissolve all of the material 
in the THF.  
2.15.3.3 Glyceride Array with Metathesized Glycerides (Part 2) 
The solutions from the metathesis reaction in 1 mL of THF were used directly.  
Solutions of human and bovine serum albumin were prepared in 10 mM phosphate buffer 
(pH 7.0, 0.02% NaN3) at a concentration of 550 µM.   Serum albumin-glyceride solutions 
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were prepared from these stocks at concentrations of 150 µM serum albumin, 135 µM 
glyceride, 149 µM AF, and 27 µM G2 (6.8% THF, 93.2% 10 µM phosphate buffer, pH 
7.0, 0.02% NaN3).  A concentrated stock solution of dansyl amide was prepared in DMSO.  
Then a solution of dansyl amide at a concentration of 180 µM in 10 µM phosphate buffer, 
pH 7.0, 0.02% NaN3 was prepared.   
The plates were made by placing 200 µL of each serum albumin-glyceride solution 
and 100 µL of buffer or of the 180 µM dansyl solution in each well (final concentrations: 
100 µM serum albumin, 90 µM glyceride, 99 µM AF, 60 µM dansyl amide, 4.5% THF).  
Each plate contained a column of indicator alone and a column of indicator and serum 
albumin as controls.  Eight replicates were performed for each glyceride/serum albumin 
combination with either dansyl amide/AF or only AF and for the controls.   
The parameters for the reading of the well plates can be found in Table 2.8.  The 
fluorescence data was normalized by first subtracting the emission of the control (indicator 
alone) from each data point, and then the data set was rescaled from 0 to 100.  
Table 2.8 Plate read parameters for part 2 of the glyceride array 
 NBD-FA DNSA1 ANS AF1/2 FRET DNSA2 
λex 485/20 360/40 380/20 485/20 360/40 360/40 
λem 540/25 485/20 485/20 528/40 528/40 485/20 
Mirror Top 510 Top 400 Top 400 Top 510 Top 510 Top 400 
 
2.15.4 Application of the Array to Adipocyte Fat Extracts 
2.15.4.1 Preparation of the fat samples 
To the fat was added 500 µL of ethyl acetate and 500 µL of brine.  The solution as 
shaken for 5 min and then centrifuged at 5,000 x g for 30 min.  The ethyl acetate layer was 
removed by pipette, filtered, and placed in a weighed vial.  Another 500 µL was added to 
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the brine, and the process was repeated two more times.  The combined ethyl acetate layers 
were evaporated thoroughly by drying on the high vacuum line overnight.  The weights of 
the fat samples were determined carefully.  The presence of glyceride could be confirmed 
by TLC on a silica plate with 1:1 ethyl acetate/hexanes.  The Rf of triglycerides was about 
0.8.   
2.15.4.2 Use of the fat in the array 
The human fat was dissolved in THF at a concentration of 4.8 mg/mL (≈ 6 mM) 
for the non-metathesis part of the array and in CHCl3 at a concentration of 7.2 mg/mL (≈ 
9 mM) for the metathesis reaction.  In the array, the final concentration of human fat in the 
well plates was 0.072 mg/mL (≈ 90 µM).  The other array components were used at the 
same molar concentrations as already indicated.   
For the first analysis, the rat fat was used at the same concentrations as the human 
fat.  For the subsequent analyses, the final concentration of the rat fat in the well plates was 
0.6 mg/mL. 
2.15.4.3 1H-NMR Spectra of the Fat Samples 
The samples were dissolved in CDCl3. 
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Figure 2.38 1H-NMR spectra of control (top), insulin-treated (middle), and isoproterenol 
(bottom) rat fat samples in CDCl3.   
2.15.5 Quantitation of Trilinolein in Triglyceride Mixtures 
2.15.5.1 Preparation of the Glyceride Mixtures 
Mixtures of triglycerides were prepared by weighing out each component in a vial, 
dissolving each in chloroform, and consolidating the component solutions into a single 
weighed vial.  The chloroform was removed under vacuum. 
Table 2.9 Composition of glyceride mixtures by weight 
Mixture % T1 by 
weight 
% T3 by 
weight 
% T5 by 
weight 
% T6 by 
weight 
% T7 by 
weight 
Total weight 
of glyceride 
material (mg) 
A 11.61 26.47 22.13 16.01 23.79 17.49 
B 7.74 17.95 31.63 24.00 18.67 34.87 
C 0 16.34 52.81 30.86 0 23.69 
D 0 32.37 41.88 25.75 0 25.24 
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2.15.5.2 Standard Addition Procedure 
A fixed amount of each mixture was used for each analyte solution/metathesis 
reaction well.  To the constant quantity of mixture in each vial/metathesis reaction well 
was added increasing amounts of pure T5 as described in the text.  These solutions were 
then subjected to the same conditions as described for parts 1 and 2 of the array.  The final 
concentration of the glyceride mixture in the well plates of the array is given in Table 2.6 
as well as the final concentration within that mixture of T5.  The content of the other 
triglyceride components is detailed in Table 2.9.  For the additions, the final amount of T5 
added was 0, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, and 0.06 mg/mL for mixtures A and B and 
0, 0.003, 0.005, 0.01, 0.015, 0.02, 0.025, and 0.03 mg/mL for mixtures C and D. The raw 
fluorescence data was normalized by rescaling within each variable from values 0-100 
using XLSTAT.  The eight replicates collected for each addition were averaged after 
normalization, and this averaged data matrix was subjected to the SANAS calculation in 
MATLAB.   
2.16 ADDITIONAL FIGURES 
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Figure 2.39 Excitation spectra for AF and 2.1.  AF (30 µM) and 2.1 (30 µM) in 10 mM 
phosphate buffer, H2O, pH 7.00, 0.02% NaN3: λem = 515 nm. (Reproduced 
from Ref. 50: © University of Texas at Austin, 2013) 
 
Figure 2.40 Titration of DNSA into AF/BSA.  Addition of DNSA (0-253 µM) to AF (100 
µM) and BSA (100 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% 
NaN3: λex = 360 nm. 
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Chapter 3: Development of Dynamic Supramolecular Receptors from 
Serum Albumin and Fatty Acid-Appended Peptides 
3.1 INTRODUCTION 
 Due to our success with using serum albumins as receptors for hydrophobic 
analytes, we next considered how we could use serum albumin in a different way to develop 
receptors for other types of analytes.  The serum albumin could function as a scaffold onto 
which species dynamically assemble through hydrophobic interactions with the protein.  
These species would contain two parts: a hydrophobic portion to bind to serum albumin 
and a recognition unit to bind to the analyte.  In this way, the association of the recognition 
units with the scaffold would be reversible.  An advantage of dynamic receptors is that they 
can be templated to an analyte.1–4  In other words, the scaffold and a variety of recognition 
units are simply combined in solution, and in the presence of an analyte, the assembly or 
assemblies that bind the analyte best are selected for upon thermodynamic equilibration.  
We envisioned targeting large, multivalent analytes such as proteins or cell surfaces 
(Chapter 1) with these receptors, so we wanted the potential for multiple recognition units 
to assemble on a single protein scaffold.   
  To explore these ideas, we hypothesized that we could build dynamic assemblies 
from serum albumin and fatty acid-appended peptides.  The fatty acid portion binds in the 
hydrophobic pockets of the protein,5 leaving the peptidic portion protruding out into 
solution (Figure 1).  Human serum albumin has been shown to have at least seven binding 
sites for long-chain fatty acids (LCFAs),6 so there is the potential for multiple fatty acid-
peptides to bind.  Since the association of the fatty acids with the protein is non-covalent 
and reversible, the assembly can rearrange freely until thermodynamic equilibrium is 
reached.   
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Figure 3.1 Cartoon representation of the fatty acid-peptides assembled on the serum 
albumin scaffold.   
For the recognition unit part of the conjugate, peptides were chosen because they 
are easy to synthesize via solid-phase peptide synthesis (SPPS) and can be appended to 
compounds with an amine or carboxylic acid.  Furthermore, previous work in our group 
toward the development of receptors built from a DNA scaffold used pentapeptides 
conjugated to a DNA intercalator, so a similar concept had already been tested with 
peptide-based species.7  The same peptide motifs from the DNA study were used for initial 
testing of the serum albumin-based assembly.  These motifs were selected in the DNA 
study because they were known in the literature to bind to specific cancer cell types or 
cancer cell surface features, and the goal of that project was to make receptors to target 
cancer cell surfaces.  However, in this work, we simply wanted to begin by determining if 
we could build assemblies from serum albumin and fatty acids that were attached to some 
kind of generic recognition unit.  Hence, the choice of peptide was somewhat arbitrary at 
this point in the development of the receptors.  We postulated that, if the components 
assembled as we hypothesized, then a variety of different kinds of recognition units could 
be attached to the fatty acids.   
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3.2 SYNTHESIS OF FATTY ACID-PEPTIDES 
3.2.1 Attaching the Fatty Acid to the Resin 
First, 12-aminododecanoic acid was FMOC protected according to the literature 
procedure (Scheme 3.1).8 This medium-chain fatty acid (MCFA) was chosen because it is 
commercially available with the terminal amino group.   
 
 
Scheme 3.1 FMOC protection of 12-aminododecanoic acid.  
Next, the FMOC-protected fatty acid was coupled to a Wang resin by the Sieber method 
(Scheme 3.2).9 
 
 
Scheme 3.2 Loading of FMOC-protected 12-aminododecanoic acid to Wang resin. 
 126 
 The loading of the fatty acid on the resin was determined to be 0.6 mmol/g by 
quantitating the FMOC content with absorbance spectroscopy.10   
3.2.2 Synthesis of the Fatty Acid-Peptide Conjugates 
 The peptides were built on the fatty acid-Wang resin using SPPS (Scheme 3.3).  
The peptides were cleaved from the Wang resin.  After cleavage from the resin and 
deprotection of the side chains, ACKGGRK-FA was acetylated with acetic anhydride in 
order to try to control for the effect of hydrophobicity of the peptide on binding to serum 
albumin.  The crude material was purified by reverse-phase HPLC (RP-HPLC).  
 
 
Scheme 3.3 Structures of the fatty acid-peptides. 
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3.3 BINDING STUDIES OF FATTY ACID-PEPTIDES TO SERUM ALBUMIN 
 Once we had synthesized the fatty acid-conjugated peptides, we next performed a 
series of titrations to determine if the conjugates were binding to serum albumin.  Since the 
conjugates do not contain a chromophore, we used indicator displacement and uptake 
experiments to measure binding indirectly with several fluorescent probes (Scheme 3.4).   
 
 
Scheme 3.4 Structures of the fluorescent probes used in this work.  DP = dansyl 
proline, DNSA = dansyl amide, ANS = 1,8-anilinonaphthalene 
sulfonate, AC = 2-anthracenecarboxylate, NBD-FA = 
nitrobenzofurazan- fatty acid, and BSPOTPE = 1,2-Bis[4-(3-
sulfonatopropoxyl)phenyl]-1,2-diphenylethene. 
3.3.1 Indicator Displacement and Uptake Titrations with NBD-FA 
 The first fluorophore used to try to detect binding of KAGLK-FA to serum albumin 
was NBD-FA (see Chapter 2 for synthesis). NBD-FA is also derived from 12-
aminododecanoic acid, so we postulated that it would bind similarly to the fatty acid-
peptides.  KAGLK-FA was titrated into a mixture of BSA and NBD-FA, and the 
fluorescence of the NBD-FA was monitored (Figure 3.2). 
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Figure 3.2 Displacement of NBD-FA from BSA by KAGLK-FA.  Left: Addition of 
KAGLK-FA (0-101 µM) to BSA (33 µM) and NBD-FA (20 µM) in 10 mM 
phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 470 nm.  
Right: Corresponding binding isotherm for λem = 530 nm. 
The emission of NBD-FA decreased as the fatty acid-peptide was added, which is 
indicative of displacement of the fluorophore from the serum albumin.  However, the 
modulation of the emission was very small.  This small change could be indicative of very 
little displacement occurring or of some direct effect that KAGLK-FA was having on 
NBD-FA.  Thus, we performed an indicator uptake experiment with NBD-FA to attempt 
to clarify these results.  In this indicator uptake experiment, we compared the addition of 
NBD-FA to BSA to the addition of NBD-FA to BSA/KAGLK-FA to see if the presence of 
KAGLK-FA inhibits binding of NBD-FA to BSA (Figure 3.3). 
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Figure 3.3 Indicator uptake titrations with NBD-FA, BSA, and KAGLK-FA.  Left: 
Addition of NBD-FA (0-165 µM) to BSA (100 µM) in 10 mM phosphate 
buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 470 nm.  Right: 
Corresponding binding isotherm overlaid with isotherm from addition of 
NBD-FA (0-165 µM) to BSA (100 µM) and KAGLK-FA (90 µM), λex = 
470 nm and λem = 530 nm. 
The same self-quenching behavior of NBD-FA that was observed in other indicator 
uptake experiments (Figure 2.6) was also seen here.  There was essentially no difference 
in the uptake of NBD-FA in the absence or presence of KAGLK-FA.  This result indicates 
that the fatty acid-peptide is not binding to BSA or that it is binding to an extent and manner 
that does not affect the binding of NBD-FA.  We hypothesized that the peptidic portion of 
the conjugate was inhibiting binding of the fatty acid portion due to its positive charge, and 
it was at this point that we acetylated the crude KGGRK-FA to block the amine and 
guanidine groups to test this postulate.  The indicator uptake experiment was repeated with 
the acetylated KGGRK-FA (Figure 3.4). 
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Figure 3.4 Indicator uptake titrations with NBD-FA, BSA, and KGGRK-FA. Addition 
of NBD-FA (0-165 µM) to BSA (100 µM) and addition of NBD-FA (0-165 
µM) to BSA (100 µM) and KGGRK-FA (90 µM) in 10 mM phosphate 
buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 470 nm and λem = 
530 nm. 
Again, the fatty acid-peptide did not significantly inhibit the uptake of NBD-FA by 
BSA.  In fact, the uptake of NBD-FA appeared to be enhanced slightly by the presence of  
the acetylated KGGRK-FA.  According to these experiments, the fatty acid-peptides were 
not binding to BSA.  In order to ensure that these experiments with NBD-FA could provide 
evidence for ligand binding to BSA at all, we performed two positive controls.  The uptake 
of NBD-FA by BSA was measured in the presence of palmitic acid and of monopalmitin, 
which are both known to bind to serum albumin (Figure 3.5).5   
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Figure 3.5 Indicator uptake titrations with NBD-FA, BSA, palmitic acid (PA), and 
monopalmitin (MP).  Addition of NBD-FA (0-172 µM) to BSA (100 µM), 
of NBD-FA (0-165 µM) to BSA (100 µM) and palmitic acid (90 µM), and 
of NBD-FA (0-165 µM) to BSA (100 µM) and monopalmitin (90 µM) in 10 
mM phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 470 
nm and λem = 530 nm. 
The presence of palmitic acid and of monopalmitin inhibited the uptake of NBD-
FA by BSA as evidenced by the lower emission increases and maxima of those isotherms 
compared to isotherm for the addition of NBD-FA to BSA alone.  These positive controls 
confirmed our expectation of how inhibition of NBD-FA uptake would manifest in these 
experiments.  Thus, the titrations with the fatty acid-peptides were not indicative of these 
species binding to BSA.  We performed another control experiment with 12-
aminododecanoic acid, the fatty acid from which NBD-FA and the peptides are derived 
(Figure 3.6).  This fatty acid itself does not inhibit the uptake of NBD-FA by BSA.  Hence, 
the NBD moiety is contributing significantly to the affinity of NBD-FA for BSA and 
simply attaching other groups like peptides to 12-aminododecanoic acid will not 
necessarily result in good ligands for BSA.   
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Since palmitic acid clearly inhibited the uptake of NBD-FA while the fatty acid-
peptides and 12-aminododecanoic acid did not, we concluded that the conjugates were not 
binding in the same site(s) as long-chain fatty acids.  Medium-chain fatty acids (C6-C14) 
can bind in long-chain fatty acid sites of serum albumin but not nearly as strongly as long-
chain fatty acids bind (MCFA Ka = 10
3-5 M-1, LCFA Ka = 10
7-8 M-1).11  Having an amine 
or even an entire peptide attached to the MCFA could further diminish its binding affinity 
by making it more hydrophilic and positively-charged.  However, the conjugates could still 
bind in other parts of the protein.12  There is evidence that medium-chain fatty acids bind 
in Sudlow Site II.13  Thus, we undertook more indicator uptake experiments with different 
fluorophores to probe other potential modes of binding to serum albumin. 
 
 
Figure 3.6 Indicator uptake titrations with NBD-FA, BSA, and 12-aminododecanoic 
acid.  Addition of NBD-FA (0-172 µM) to BSA (100 µM) and of NBD-FA 
(0-165 µM) to BSA (100 µM) and 12-aminododecanoic acid (100 µM) in 10 
mM phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 470 
nm and λem = 530 nm. 
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3.3.2 Indicator Displacement and Uptake Titrations with Other Fluorophores 
3.3.2.1 Dansyl Amide 
Dansyl amide (DNSA) is a Sudlow Site I-specific ligand.14  Indicator uptake 
titrations were undertaken by adding DNSA to BSA, BSA/KGGRK-FA, and 
BSA/KAGLK-FA (Figure 3.7).  An indicator displacement assay was performed by 
adding KAGLK-FA to DNSA/BSA (Figure 3.8). 
 
   
Figure 3.7 Indicator uptake titrations with DNSA, BSA, ACKGGRK-FA, and KAGLK-
FA.  Left: Addition of DNSA (0-214 µM) to BSA (100 µM), of DNSA (0-
214 µM) to BSA (100 µM) and ACKGGRK-FA (90 µM), and of DNSA (0-
214 µM) to BSA (100 µM) and KAGLK-FA (90 µM) in 10 mM phosphate 
buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 350 nm. Right: 
Corresponding binding isotherms for λem = 490 nm. 
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Figure 3.8 Displacement of DNSA from BSA by KAGLK-FA.  Left: Addition of 
KAGLK-FA (0-233 µM) to BSA (20 µM) and DNSA (20 µM) in 10 mM 
phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 350 nm.  
Right: Corresponding binding isotherm for λem = 490 nm. 
The fatty acid-peptides are affecting the binding of DNSA to BSA, so perhaps the 
conjugates are binding in Sudlow Site I. 
3.3.2.2 Dansyl Proline 
Dansyl proline (DP) is a Sudlow Site II-specific ligand.14  An indicator 
displacement assay was performed by titrating ACKGGRK-FA into DP/BSA (Figure 3.9). 
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Figure 3.9 Displacement of DP from BSA by ACKGGRK-FA.  Left: Addition of 
ACKGGRK-FA (0-24 µM) to BSA (10 µM) and DP (10 µM) in 10 mM 
phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 350 nm.  
Right: Corresponding binding isotherm for λem = 484 nm.  
The fatty acid-peptides are also displacing DP.  The amount of modulation is lower 
than for DNSA by about an order of magnitude; however, fewer equivalents of conjugate 
are necessary to reach saturation, again by about an order of magnitude.  Therefore, it is 
unclear whether DNSA or DP is being more directly affected by the fatty acid-peptides, 
and hence whether the conjugates are binding to Sudlow Site I, II, or both. 
3.3.2.3 1,8-Anilinonaphthalene Sulfonate 
ANS binds between the domains of serum albumin and is used as a probe for 
denaturation of the protein.15  LCFAs are known to depress ANS emission as do MCFAs, 
although to a lesser extent.  Indicator uptake experiments were undertaken by adding ANS 
to BSA and to BSA/ACKGGRK-FA (Figure 3.10).  No inhibition of ANS uptake was 
detected. 
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Figure 3.10 Indicator uptake titrations with ANS, BSA, and ACKGGRK-FA.  Left: 
Addition of ANS (0-226 µM) to BSA (100 µM) and of ANS (0-226 µM) to 
BSA (100 µM) and ACKGGRK-FA (90 µM) in 10 mM phosphate buffer, 
140 mM NaCl, H2O, pH 7.40,  0.02% NaN3, λex = 350 nm.  Right: 
Corresponding binding isotherms for λem = 490 nm. 
3.3.2.4 2-Anthracenecarboxylate 
AC binds to serum albumin in four sites, including Sudlow Sites I and II and 
between subdomains IIA and IIB.16,17  Titration of KAGLK-FA into BSA/AC did not result 
in displacement of AC (Figure 3.11). 
 
Figure 3.11 Displacement experiment of AC from BSA by KAGLK-FA.  Addition of 
KAGLK-FA (0-200 µM) to BSA (10 µM) and AC (10 µM) in 10 mM 
phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 386 nm. 
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3.3.2.5 BSPOTPE 
BSPOTPE has been shown by computational modeling to bind in the cleft between 
subdomains IIA and IIIA.18  Indicator uptake experiments show a small depression of 
binding of BSPOTPE to BSA in the presence of ACKGGRK-FA (Figure 3.12).  Thus 
either the fatty acid-peptide can also bind in the cleft, or it binds elsewhere and causes 
allosteric changes in the protein that render the cleft a less attractive binding site for 
BSPOTPE.   
 
 
Figure 3.12 Indicator uptake titrations with BSPOTPE, BSA, and ACKGGRK-FA.  Left: 
Addition of BSPOTPE (0-221 µM) to BSA (100 µM) and of BSPOTPE (0-
221 µM) to BSA (100 µM) and ACKGGRK-FA (90 µM) in 10 mM 
phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 350 nm.  
Right: Corresponding binding isotherms for λem = 490 nm. 
3.3.3 Intrinsic Fluorescence 
Human and bovine serum albumin both have a tryptophan residue (Trp-214) in 
Sudlow Site I.5  The intrinsic fluorescence of this tryptophan has been used to measure 
binding of ligands to this site and to the protein in general.19–21  Thus, we investigated the 
effect of the fatty-acid peptide on the tryptophan fluorescence.  First, palmitic acid was 
titrated into BSA to determine the effect that this ligand would have on the intrinsic 
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fluorescence as a comparison (Figure 3.13).  Then, ACKGGRK-FA was titrated into BSA 
(Figure 3.14). 
 
 
Figure 3.13 Titration of palmitic acid into BSA monitoring intrinsic fluorescence of BSA.  
Left: Addition of palmitic acid (0-33 µM) to BSA (3 µM) in 10 mM 
phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, 0.3% THF, λex 
= 280 nm.  Right: Corresponding binding isotherm for λem = 340 nm. 
 
Figure 3.14 Titration of ACKGGRK-FA into BSA monitoring intrinsic fluorescence of 
BSA. Left: Addition of ACKGGRK-FA (0-33 µM) to BSA (3 µM) in 10 
mM phosphate buffer, 140 mM NaCl, H2O, pH 7.40, 0.02% NaN3, λex = 280 
nm.  Right: Corresponding bind isotherm for λex = 340 nm 
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For the addition of palmitic acid, the fluorescence is quenched at first, but then at 
about four equivalents, the fluorescence begins to increase.  A gradual shift in the λmax 
occurs from 340 nm to 330 nm as palmitic acid is added. For the addition of ACKGGRK-
FA, the fluorescence decreases slightly upon the addition of about 0.5 equivalents of fatty 
acid-peptide and then increases continuously as more is added.  There is no change in the 
λmax.  These results are consistent with the indicator displacement and uptake experiments 
in that the fatty acid-peptides do seem to be binding to some extent to serum albumin, but 
they are not binding to the same extent and in the same manner as LCFAs. 
3.4 CONCLUSIONS AND FUTURE WORK 
The goal of this project was to determine if multivalent, dynamic receptors could 
be made from serum albumin and fatty acid-appended recognition units.  We hypothesized 
that multiple fatty acids would self-assemble by binding in the LCFA sites of the protein, 
leaving the recognition units out in solution to interact with analytes.  To test this 
hypothesis, we synthesized fatty acid-peptides and performed a series of fluorescence 
experiments to measure the binding of these conjugates to bovine serum albumin.  Through 
these experiments, we determined that the fatty acid-peptides seem to bind to the protein.  
However, the binding strength, stoichiometry, and mode are clearly different from the 
binding of LCFAs.   
It is uncertain whether this difference in binding is due to the fatty acid portion of 
the conjugate, a MCFA, or to the hydrophilic peptide portion of the conjugate (or to both).  
A LCFA-appended peptide could be synthesized to test whether the fatty acid alone is the 
problem.  Perhaps a longer-chain fatty acid would also provide a better spacer between the 
binding part of the conjugate and the peptide part, so that the peptide interferes less with 
binding.  Finally, it is also possible that these conjugates, due to their hydrophobic and 
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hydrophilic ends, adopt stable structures in solution like micelles that diminish the driving 
force behind the binding of the fatty acid to serum albumin. In this case, less hydrophilic 
recognition units than peptides would need to be employed to try to avoid micelle 
formation.  While there are conceivably other experiments that could be attempted to try 
to reach our goal, we instead decided to change direction away from fatty acids and toward 
squaraines (Chapter 4).   
3.5  EXPERIMENTAL METHODS 
3.5.1 General 
 Unless otherwise indicated, chemicals and reagents were obtained from Sigma 
Aldrich and used without further purification.  The Wang resin, amino acids, and coupling 
reagents were obtained from NovaBioChem.  Dansyl amide, dansyl proline piperidinium 
salt, and 2-anthracene carboxylic acid were obtained from TCI America.  NBD-FA was 
synthesized according to the literature procedure described in Chapter 2.  BSPOTPE was 
provided by Ben Zhong Tang (Hong Kong University of Science and Technology).   
HPLC-grade solvents were prepared with 0.1% TFA (v/v) and filtered through 0.2 
micron filter.  HPLC was performed on a Shimadzu instrument with a preparative C-18 
column using a water and acetonitrile mobile phase.  LC-MS analysis was performed on 
an Agilent 1200 Series HPLC with an Agilent 6130 single quadrupole mass spectrometer 
(ESI and APCI ionization). 
The titration experiments were performed with a PTI fluorimeter using an 814 
photomultiplier detection system and a 75W xenon short arc lamp.   
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3.5.2 Synthesis 
3.5.2.1 Fmoc-Protected 12-Aminododecanoic Acid 
 A 1:1 mixture of THF and 5% NaCO3 (aq) was prepared and added to 12-
aminododecanoic acid (1.5 g, 6.97 mmol, 1.0 eq).  The solution was stirred for 30 min and 
then poured into a separatory funnel.  The THF (top layer) was collected.  To this solution 
was added fluorenylmethyl chloroformate (2.0 g, 7.73 mmol, 1.1 eq).  The reaction was 
stirred at room temperature for 48 hr.  Then the reaction was acidified with 1M HCl (aq) 
and extracted three times with diethyl ether.  The ether was dried with MgSO4, filtered, 
and removed under reduced pressure.  The crude product was purified by silica column 
with chloroform and 0-10% methanol.  The product was a white solid (0.95 g, 31% yield).  
LRMS (ESI): 438.2 (M+1).   
3.5.2.2 Loading Fmoc-Fatty Acid to Wang Resin 
The Wang resin (100-200 mesh, 1.1 mmol/g, 1.0 g, 1.09 mmol, 1.0 eq) was placed 
in a fritted peptide flask with the Fmoc-fatty acid (0.95 g, 2.17 mmol, 2.0 eq) in 10 mL of 
DMF.  The flask was shaken for 15 min.  Then pyridine (0.26 mL, 3.27 mmol, 3.3 eq) and 
2,6-dichlorobenzoyl chloride (0.31 mL, 2.17 mmol, 2.0 eq) were added, and the reaction 
was shaken for 20 hr.  The flask was drained, and the resin was washed with DMF, DCM, 
and methanol.  The resin was dried slightly under nitrogen, and then 35 mL dichloroethane, 
3 mL pyridine, and 3 mL benzoyl chloride were added. The reaction was shaken for 2 hr.  
Then flask was drained, and the resin was washed with DMF, DCM, and methanol.  The 
resin was washed with dichloroethane, and then 10 mL dichloroethane, 2 mL pyridine, and 
2 mL benzoyl chloride were added.  The reaction was shaken for 30 min, and the draining 
and washes were repeated again.  The resin was dried thoroughly on the high vacuum line.   
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The loading of the resin was measured by first carefully weighing out a small 
portion of dry resin (10.3 mg).  To the resin was added 2 mL of a 2% DBU in DMF solution.  
The solution was shaken for 30 min and then diluted with 10 mL of acetonitrile.  A 2-mL 
portion of this solution was taken and diluted to a total volume of 25 mL.  A reference 
solution was prepared in the same way without the resin.  The sample and reference 
solutions were placed in cuvettes, and the absorbance at 304 nm was read three times and 
averaged.  From the following equation, the loading was calculated to be 0.60 mmol/g.   
 
𝐹𝑀𝑂𝐶 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (
𝑚𝑚𝑜𝑙
𝑔
) =
(𝐴𝑏𝑠𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏𝑠𝑟𝑒𝑓) × 16.4
𝑚𝑔 𝑟𝑒𝑠𝑖𝑛
 
3.5.2.3 Peptide Synthesis 
The peptides were synthesized on an automated peptide synthesizer (Protein 
Technologies) using Fmoc chemistry and the Wang resin pre-loaded with Fmoc-12-
aminododecanoic acid.  For a 200 µmol-scale reaction, the Wang resin was swelled in 
DMF and then deprotected with 20% piperidine in DMF twice.  In between the resin was 
washed with DMF and DCM.  Each amino acid was dissolved in DMF (100 mM) and 
introduced to the resin after the deprotection step.  PyBOP (300 mM) and DIPEA (1.2 M) 
in DMF were added along with the amino acid to perform each coupling (twice).  The final 
residue was deprotected at the end.  The resin was then removed from the synthesizer.   
The resin was washed with DMF, DCM, MeOH, and glacial acetic acid and then 
dried overnight on the high vacuum line.  The peptides were cleaved from the resin with 
95% TFA, 2.5% TIPS, and 1% H2O for 4 hr.  The TFA solution was filtered from the resin, 
and the TFA was removed.  To the residue was added diethyl ether to precipitate the 
peptides.   
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3.5.2.4 Acetylation of ACKGGRK-FA 
The crude ACKGGRK-FA was dissolved in 5 mL of acetic anhydride and 200 µL 
of DIPEA.  The solution was stirred for 18 hr.  Then another 2 mL of acetic anhydride and 
100 µL of DIPEA were added, and the reaction was stirred for another 5 hr.  The acetic 
anhydride was quenched by adding a few milliliters of water, and the solution was 
concentrated.   
3.5.2.5 Peptide Purification 
The crude peptides were dissolved in water/DMSO (no more than 50% DMSO) 
and purified by HPLC.  Fractions containing the desired peptide were verified by LC-MS, 
combined, and evaporated.   
KAGLK-FA: 40.6 mg (39% yield); LRMS (ESI): 713.2 (M+1); HRMS (ESI): 
expected 713.53, found 713.53 (M+1) 
ACKGGRK-FA: 16.1 mg (18% yield);   LRMS (ESI): 907.8 (M-1), 910.0 (M+1); 
HRMS (ESI): expected 901.57, found 910.57 (M+1) 
3.5.3 Titrations 
Details about the titrations can be found in the captions of the figures in this chapter 
including the concentrations, buffer used, and excitation/emission wavelengths. 
The KAGLK-FA stock was prepared in 10 mM phosphate buffer, 140 mM NaCl, 
H2O, pH 7.40, 0.02% NaN3 at a concentration of 770 µM.  The KGGRK-FA stock was 
prepared in DMSO (100%) at a concentration of 3.54 mM.   
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3.5.4 Additional Figures 
 
 
Figure 3.15 Titration of BSA into NBD-FA.  Addition of BSA (0-79 µM) to NBD-FA 
(15 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex = 470 
nm. 
 
Figure 3.16 Titration of BSA into AC.  Addition of BSA (0-39 µM) to AC (10 µM) in 10 
mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex = 386 nm. 
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Figure 3.17 Titration of BSA into ANS.  Addition of BSA (0-52 µM) to ANS (10 µM) in 
10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex = 400 nm. 
  
Figure 3.18 Titration of BSA into BSPOTPE.  Addition of BSA (0- 36µM) to BSPOTPE 
(20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex = 350 
nm. 
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Chapter 4: Investigation of Serum Albumin Binding and Thiol Addition 
to Water-Soluble Squaraines 
4.1  INTRODUCTION 
Since the fatty acid-peptides did not bind to serum albumin as we had postulated, 
we became interested in using squaraines as part of an alternative strategy.  The first 
squaraine was reported in 1965 by Treibs and Jacob, who synthesized the dye by reacting 
pyrrole and squaric acid (3,4-dihydroxy-3-cyclobutene-1,2-dione).1  Despite being known 
in the literature for fifty years, squaraines have not been researched as extensively as other 
organic dye classes.  A SciFinder search of the term “squaraine” yields only about 1,200 
references, while searches for other dye classes like “rhodamine” or “cyanine” yield 
upwards of 25,000 references.  Despite the comparative dearth of research on squaraines, 
they have found application in imaging,2–4 photovoltaics,5–7 ion sensing,8–12 and other 
areas.13,14 
4.1.1 Synthesis, Structure, and Optical Properties of Squaraines 
Squaraines are prepared by the reaction of squaric acid with electron rich aromatic 
or heterocyclic molecules such as N,N-dialkylanilines, benzothiazoles, phenols, and 
pyrroles with azeotropic removal of water (Scheme 4.1).2  The structure of a squaraine is 
a resonance-stabilized zwitterion (Scheme 4.2).  The central four-membered ring is 
electron deficient, while the oxygen atoms and the two aniline groups are electron donating, 
leading to a donor-acceptor-donor (D-A-D) structure.  From theoretical calculations, 
Bigelow and Freund showed that during the S0  S1 transition there is a charge transfer 
that is largely from the oxygen atoms to the four-membered ring with some minor donation 
from the aniline groups.15  This intramolecular charge transfer and the extended 
conjugation of the molecule lead to absorption in the visible to near-IR region with narrow 
bands (half bandwidth ~ 750 cm-1)2 and large extinction coefficients (ε ≥ 105 cm-1 M-1).16  
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In the solid state, squaraines are microcrystalline powders that are often highly 
photoconductive.2  They exhibit broad absorption between 700-850 nm and fluorescence 
quenching due to aggregation.  For the aniline-derived squaraines, the absorption band is 
usually between 500-700 nm in solution.  
 
 
Scheme 4.1  Examples of squaraines derived from different electron-rich aromatic 
and heterocyclic molecules.  From left to right, top to bottom: aniline-
derived, benzothiazole-derived, pyrrole-derived, phloroglucinol-derived, 
and indolenine-derived squaraines. 
 
 
Scheme 4.2 Resonance of the squaraine zwitterion. 
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4.1.2 Aggregation Behavior of Squaraines in Solution 
Squaraines can exist in solution as monomers, dimers, or higher order aggregates.  
The distribution of these species in solution is dependent on the structure of the squaraine 
as well as the solvent and pH.17,18   Squaraines can form H-type aggregates, which exhibit 
a hypsochromic shift relative to the monomer and are less or non-fluorescent than the 
corresponding monomer, or J-type aggregates, which exhibit a bathochromic shift and have 
a higher quantum yield of fluorescence than the monomer.19,20    H-type aggregates are 
stacked vertically like a deck of cards, while J-type aggregates are in a “slipped stack” 
arrangement (Figure 4.1).  Squaraines in solution most commonly form H-type 
aggregates.16 
 
 
Figure 4.1  Simple schematic of H- and J-type aggregates.  a) J and H dimer 
orientations b) Energy level splitting of J and H dimers.21  (Reproduced 
from Ref. 21: © World Scientific Publishing Co. Pte. Ltd., 2012) 
4.1.3 Reaction of Squaraines with Nucleophiles 
Martinez-Manez and coworkers first demonstrated in 2002 that the electron 
deficient four-membered ring in a squaraine is susceptible to nucleophilic attack.22  They 
used a squaraine as a cyanide probe in acetonitrile/water solutions buffered at pH 9.5.   The 
addition of a nucleophile to a squaraine (Scheme 4.3) breaks up the extended conjugation 
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of the molecule, which switches off the distinctive absorbance and fluorescence of the 
molecule.  This property allows for simple visual or spectroscopic detection.  The sensor 
was selective for cyanide over other insufficiently nucleophilic anions, including halides, 
nitrate, acetate, thiocyanate, dihydrogen phosphate, and bisulfate.  The researchers also 
used their squaraine as a probe for thiols.23  The squaraine was exposed to ten equivalents 
of amino acid in acetonitrile/water solutions buffered at pH 6.  Only the solution containing 
cysteine decolored (Figure 4.2), indicating that at pH 6 the probe is selective for thiols 
over amines and alcohols.   
 
 
Scheme 4.3 Thiol addition to a squaraine. 
 
 
Figure 4.2 Solutions of squaraine and ten equivalents of amino acids.  Addition 
performed in acetonitrile/water, 20:80 v/v, at pH 6.  From left to right and 
top to bottom: no amino acid, phenylalanine, threonine, arginine, histidine, 
asparagine, leucine, alanine, proline, valine, glycine, lysine, glutamine, 
methionine, isoleucine, serine, cysteine, tryptophan, glutamic acid, and 
aspartic acid.  (Reproduced from Ref. 23: © American Chemical Society, 
2004).   
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Since this report, Martinez-Manez and other researchers have published further studies on 
squaraines as thiol probes including the detection of volatile thiols,24 detection of thiols at 
physiological pH,25 and a dual chromophore squaraine for thiol detection.26 
 The addition of thiols to squaraines has also been used as a method of indirectly 
measuring other analytes of interest.  For example, our group used an organic-soluble 
squaraine and thiols to discriminate metal ions based on their thiophilicity.27    In the 
presence of thiol, the squaraine decolors due to nucleophilic addition of the thiol. Upon 
addition of mercury(II), palladium(II), or another thiophilic metal ion to the solution, the 
blue color returns as the metal binds to the thiol and pushes the equilibrium toward intact 
squaraine.  This reaction with metal ions demonstrates the reversible nature of the thiol-
squaraine reaction.  Many researchers have used squaraines as probes for mercury(II) based 
on these general reactivity properties.28–30  Likewise, a squaraine has been used to detect 
the inhibition of acetylcholinesterase, which converts the thioester in acetylcholine into a 
free thiol.31  If the enzyme is turning over, thiol is generated in the solution, and the 
squaraine decolors.  However, if the enzyme is inhibited, no thiol is generated, and the 
squaraine remains intact.   
 While the addition of thiols to squaraines is a well-known reaction, not all 
squaraines are susceptible to nucleophilic attack.  Typically, the squaraines employed for 
the addition are of the N,N-dialkylaniline type.  Squaraines derived from indoles, 
benzothiazoles, and other heterocyclic compounds have not been shown to react with 
nucleophiles and are stable in solution.  Phenol-derived squaraines can be electrophilic if 
the phenols are substituted with electron withdrawing groups such as halogens.32   
For the N,N-dialkylaniline-derived squaraines, electron-donating hydroxyl groups 
placed ortho to the four-membered ring of the squaraine render it much less electrophilic.  
Squaraines with these hydroxyl groups exhibit significantly greater stability in aqueous 
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solution compared to squaraines lacking hydroxyl groups.19  Furthermore, these hydroxyl-
functionalized squaraines are essentially not reactive with thiols.33   
4.1.4 Binding of Squaraines to Serum Albumin 
The binding of squaraines to serum albumin has been investigated primarily for 
protein detection and non-covalent labeling,34–38 but also for in vitro cell imaging.39  In 
these examples, typically the indole- and benzothiazole-derived squaraines have been 
investigated, although one research group has used phenol-derived squaraines.37,38  
Aniline-derived squaraines have not been studied in terms of their binding to serum 
albumin. 
In the studies of indole-, benzothiazole-, and phenol-based squaraines (Scheme 
4.1), researchers have invariably found that, when these squaraines bind to serum albumin, 
large increases in emission are observed.  These increases are generally on the order of 10- 
to 200-fold enhancement in intensity and are accompanied by bathochromic shifts in the 
λmax of emission.   
 
Scheme 4.4 Structures of the squaraines studied in their binding to serum albumin.   
The effect of serum albumin binding on the absorption spectra of squaraines is more 
variable.  In the case of the 3-dicyanomethylene-substituted indolenine dye synthesized by 
Yarmoluk and coworkers (Scheme 4.4), the absorption of the squaraine increases about 
three-fold in the presence of BSA.35  However, Ramaiah and coworkers observed more 
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complex absorbance behavior with their phloroglucinol-derived squaraine (Figure 4.3, 
Scheme 4.4).37  As BSA is added, the absorbance decreases up to 0.5 equivalents of BSA 
and then increases up to about three equivalents of BSA.  The authors attribute this 
phenomenon to site selectivity, which they further tested with lifetime and indicator 
displacement experiments with dansyl amide (DNSA) and dansyl proline (DP) as Sudlow 
Site I and II-specific ligands, respectively.  They postulate that at low concentrations of 
serum albumin, the squaraine binds in Sudlow Site I, forming a tight complex through 
hydrophobic and π-stacking interactions.  At more than 0.5 equivalents of BSA, the 
squaraine binds in Sudlow Site II, a more spacious binding site and one lacking in a 
tryptophan residue for π-stacking.  Thus, the binding in this site is looser than in Site I.   
 
 
Figure 4.3 Addition of BSA to phloroglucinol-derived squaraine of Ramaiah et al.  A) 
Change in absorbance of the squaraine (3 µM) with increasing BSA in 
phosphate buffer a) 0 µM BSA, g) 1.5 µM BSA, h) 1.8 µM BSA, and l) 7 
µM BSA. B) Visible detection of BSA a) squaraine alone b) squaraine + 
BSA.  (Reproduced from Ref. 37: © American Chemical Society 2006) 
 
Similarly, Belfield and coworkers observed an initial decrease in absorption of their 
benzoindolenine-based squaraine upon addition of BSA (Figure 4.4, Scheme 4.4).39  Upon 
addition of 0.4 equivalents of BSA, the absorption decreased and exhibited a bathochromic 
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shift.  Another addition (0.8 equivalents total) of BSA caused the absorption to be further 
red-shifted and to increase.  Further additions did not exhibit shifts but did increase the 
absorption up to about two equivalents of BSA.  The authors did not provide a physical 
explanation for this behavior.  They did observe that the peak at 590 nm, which corresponds 
to the dimer of the squaraine, diminished as serum albumin was added, implying that only 
the monomer binds and that the BSA breaks up the dimers.   
 
 
Figure 4.4 Addition of BSA to benzoindolenine-derived squaraine of Belfield et al.  
Titration of BSA (0-12 µM) to squaraine (5 µM) a) absorbance spectra and 
b) fluorescence spectra.  (Reproduced from Ref. 39: © American Chemical 
Society, 2013) 
4.1.5 Project Goals and Design 
We hypothesized that squaraines could be used in conjunction with thiol-
functionalized recognition units and serum albumin to build dynamic, multivalent 
receptors.  The squaraines bind to the protein non-covalently, and thiol-containing units 
such as peptides reversibly add to the squaraines (Figure 4.5).  The receptor would self-
assemble and could be templated against large, multivalent analytes such as proteins or cell 
surfaces.  Thus, we wanted to identify a squaraine that 1) binds to serum albumin with high 
stoichiometry (n > 1) and good affinity (Ka ≥ 105 M-1) and 2) reversibly adds thiols.   
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Figure 4.5 Cartoon representation of the squaraines and peptides assembled on the 
serum albumin scaffold.  
While our ultimate goal was to build receptors, we realized quickly upon beginning 
the project that we needed to first investigate squaraine structure and function in more 
depth than had previously been done in the context of thiol addition and serum albumin 
binding.  Therefore, we synthesized a series of squaraines and used spectroscopic methods 
to study their properties. 
4.2 SYNTHESIS OF SQUARAINES 
The squaraines synthesized were all water soluble or able to be dissolved in water 
with a small amount (< 10%) of acetonitrile, methanol, or dimethyl sulfoxide (DMSO).  
Yields varied significantly based on the squaraine. 
4.2.1 Indolenine-Based (SQ2) 
The indolenine-derived squaraine (SQ2) was synthesized by first attaching a 
sulfonate group to the benzoindolenine precursor with 1,3-propanesultone.  The resultant 
compound was refluxed with squaric acid in n-butanol with azeotropic removal of water 
by a Dean-Stark trap according to a literature procedure (Scheme 4.5).39  The product was 
purified by recrystallization from methanol (12% yield). 
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Scheme 4.5 Synthesis of SQ2. 
4.2.2 Phloroglucinol-Based (SQ3 and SQ3Br) 
 These squaraines were also synthesized according to a literature procedure 
(Scheme 4.6).37,38  SQ3 was synthesized by reacting phloroglucinol and squaric acid in 
acetic acid and purified by recrystallization from acetic acid.  SQ3 was brominated in acetic 
acid to yield SQ3Br.  The product precipitated from the reaction and required no further 
purification.  These squaraines were obtained in moderate yield (SQ3- 41%, SQ3Br- 35%). 
 
 
Scheme 4.6 Synthesis of SQ3 and SQ3Br. 
4.2.3 Aniline-Based (SQ1, SQ4-9) 
Most of the squaraines that were made for this work were aniline-derived.  These 
types of squaraines are synthesized by heating squaric acid and the aniline in n-butanol and 
benzene to 100°C with azeotropic removal of water.  In the literature, toluene is sometimes 
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used in place of benzene; however, we had no success using toluene.  The optimum ratio 
of butanol to benzene varies by aniline.  Yields for aniline-based squaraines vary widely 
from less than 10% to more than 90% depending on the aniline used.2  Since we wanted 
water soluble dyes, aniline precursors with carboxylates (SQ1), alcohols (SQ6), and 
sulfonates (SQ4, 5, 7-9) were used.   
SQ1 was synthesized according to a literature procedure (Scheme 4.7).40  First, 3-
benzyloxyaniline was alkylated with t-butylbromoacetate. Next, the benzyl protecting 
group was removed by transhydrogenation.  The squaraine was formed by refluxing in 
butanol/benzene (1:2) and was purified by silica chromatography (65% yield).  The t-butyl 
protecting groups were removed with TFA, and this final product required no further 
purification (92% yield).  
 
 
Scheme 4.7 Synthesis of SQ1. 
SQ6 was synthesized according to a literature procedure (Scheme 4.8).25  The pure 
product precipitated from the reaction, requiring no further purification (22% yield). 
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Scheme 4.8 Synthesis of SQ6. 
The rest of the squaraines contained sulfonate groups for water solubility (SQ4, 5, 
7-9).  We wanted to investigate the effect of aniline substitution, so we synthesized a series 
of squaraines with different substituents in the benzene ring at the ortho position to the 
four-membered ring (Scheme 4.9).  To do so, the appropriate aniline derivative was 
monoalkylated with iodoethane, and then sulfonated with 1,3-propanesultone.  Then, the 
squaraine was formed with azeotropic removal of water.  This procedure was based on the 
protocol described by Ghazarossian and coworkers to synthesize SQ4.41  We followed their 
procedure for the synthesis of SQ4 exactly but modified it for the synthesis of the other 
squaraines.  In their protocol, the sulfonated anilinium was used directly in the squaraine 
formation reaction, and they used sodium bicarbonate in situ to obtain the free base.  The 
researchers also used DMSO in the squaraine formation reaction to improve solubility of 
the charged aniline species in the solvent.   
While this protocol yielded a small amount of SQ4, we could not make SQ5 in this 
way.  The sodium bicarbonate interferes with the squaraine formation by deprotonating 
squaric acid (pKa 1.5, 3.4),
42 rendering it insufficiently electrophilic to be attacked by 
aniline.  Thus, we obtained the free base of the sulfonated aniliniums by carefully adjusting 
an aqueous solution of the compound to pH 7 and then removing the water to isolate the 
sodium salt.  The salt was used to form the squaraine. Additionally, we found that the 
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formation of SQ5 would not occur in the presence of DMSO, so it was omitted from the 
synthesis of the other squaraines as well.   
 
Scheme 4.9 Synthesis of SQ4, 5, 7, 8, and 9. 
The yields were generally very low (< 8%), although SQ9 was synthesized in a 
surprisingly good yield (62%).  There were several reasons for the low yields.  First, the 
squaraine formation reaction was performed at a high temperature (100°C) for extended 
periods (18-48 hours) which resulted in a large number of products, the distribution of 
which is determined by the stability of the various species.43  Less stable squaraines (X = 
H, CH3) in particular form in smaller amounts.  These reaction conditions are necessary to 
overcome the poor nucleophilicity of aniline, but they result in many unwanted byproducts.  
Furthermore, the solubility of the sulfonated anilines is poor in butanol/benzene.  While 
Ghazarossian et al. successfully used ethylene glycol and DMSO to ameliorate this 
solubility problem, we found that the presence of these solvents hindered the formation of 
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squaraine rather than improving it.  We found that using a larger proportion of butanol to 
benzene (closer to 1:1 rather than 1:2) did seem to improve yield, although we did not 
investigate this factor systematically.  Finally, the squaraines, with the exception of SQ9, 
had to be purified by reverse-phase chromatography, which resulted in poor recovery of 
pure product.  SQ9 precipitated from the reaction mixture and required no further 
purification.  SQ4 was purified by RP-HPLC in water/acetonitrile, 0.1% TFA.  SQ5, 7, 
and 8 were purified on a C-18 column in water/acetonitrile with a CombiFlash.  They were 
not stable under acidic conditions, so TFA was not used.  Even after method optimization, 
resolution on the column was poor, resulting in loss of product.  Despite the poor yields, 
enough material was obtained for us to carry out the necessary experiments. 
4.3 OPTICAL PROPERTIES OF THE ANILINE-BASED SQUARAINES 
 The absorbance spectra for SQ4, 5, 7, 8, and 9 are shown in Figure 4.6, and their 
optical properties are summarized in Table 4.1.   These squaraines exhibit typical squaraine 
absorbance properties: absorption bands around 500- 700 nm and extinction coefficients 
around 105 M-1cm-1.  The squaraines are fluorescent in aqueous solution, but the intensity 
is relatively low.   
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Figure 4.6 Absorbance spectra of SQ4, 5, 7, 8, and 9.  The squaraines (10 µM) were 
dissolved in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3.  4 = OH, 
5 = H, 7 = CH3, 8 = OCH3, and 9 = NH(CO)CH3. 
Table 4.1 Summary of optical properties of aniline-based squaraines. 
Squaraine λmax (nm) λemission (nm) ε (M-1cm-1) 
SQ4 585, 640 670 1.10 x 105 (585 nm) 
1.16 x 105 (640 nm) 
SQ5 595, 645 680 2.60 x 104 (595 nm) 
1.12 x 105 (645 nm) 
SQ7 605, 660 690 3.51 x 104 (605 nm) 
9.35 x 104 (660 nm) 
SQ8 595, 645 675 1.56 x 104 (595 nm) 
6.10 x 104 (650 nm) 
SQ9 595, 675 695 1.08 x 105 (595 nm) 
2.93 x 104 (675 nm) 
From the absorbance spectra, we can see that these squaraines exist as monomer 
and dimer in solution.  The dimer peak is around 595 nm, and the monomer peak is around 
650 nm.  Only the monomer is emissive.  These dimers are H-type aggregates, which are 
common for squaraines.16  SQ5, 7, and 8 appear to exist primarily as the monomer in 
aqueous solution.  SQ4 seems to be a mixture of the two forms, while SQ9 is mostly dimer.   
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4.4 STUDIES OF THIOL ADDITION TO SQUARAINES 
 In order to test the addition of thiols to the squaraines, N-acetylcysteine (NAC) was 
used for the thiol.  Most of the studies undertaken entailed absorbance and fluorescence 
measurements, because these methods require considerably less material than 1H-NMR.  
The decoloration of squaraines upon thiol addition can easily be followed visually or with 
UV-vis spectroscopy (Figure 4.2).  The characteristic emission of squaraines also 
diminishes upon thiol addition.  In the 1H-NMR spectrum, desymmetrization of the dyes 
can be observed as well. 
4.4.1 SQ2 
While there was no specific evidence in the literature that indicated thiols will add 
to indolenine-derived squararines, we wanted to confirm for ourselves whether or not this 
reaction would occur.  These types of squaraines are much easier to make than the aniline-
based dyes, so it would be desirable to use them if possible.  To test this reaction, an excess 
of NAC was added to a solution of squaraine, and the absorbance was monitored over time 
(Figure 4.7).  Even in the presence of 50 equivalents of thiol, the squaraine did not decolor.   
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Figure 4.7 Addition of thiol to SQ2.  Absorbance spectra of SQ2 (5 µM) before and 
after NAC addition (250 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 
0.02% NaN3.   
Next, we tested whether a selenol could add to SQ2, since selenols are more 
nucleophilic than the corresponding thiols.  The only selenol we had on hand was 
benzeneselenol, which is not very water soluble, so precipitation and cloudiness were 
problematic for our measurements (Figure 4.8).  The absorbance did initially decrease (1 
min) before the solution became too cloudy to obtain reliable measurements (2+ min).  Due 
to the toxicity of selenols and the difficulties associated with working with them (e.g. 
oxidation), we decided not to pursue selenol addition further.   
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Figure 4.8 Addition of selenol to SQ2.  A) Absorbance spectra of SQ2 before (5 µM) 
and after addition of benzeneselenol (5 µL, 24 mM) in 10 mM phosphate 
buffer, H2O, pH 7.00, 0.02% NaN3.  B) Left: SQ2 alone; Right: SQ2 after 
addition of selenol.   
4.4.2 SQ3Br 
 SQ3Br has been reported in the literature to react with thiols.32  We tested this 
reaction for ourselves by adding NAC to a solution of SQ3Br and monitoring the 
absorbance over time (Figure 4.9).   The solution did decolor, but it was not buffered, so 
we were aware that these changes could be attributed to changes in pH.  We dissolved the 
squaraine in a buffered solution (pH 7) and titrated NAC into it while monitoring the 
emission of the squaraine (Figure 4.10).  In this experiment, the emission initially 
increased, and then shifted to a lower wavelength and decreased.  Repeating the experiment 
gave a different result in which the emission only decreased.  At this point, we became 
concerned about the stability of the squaraine in ambient conditions, since we were getting 
inconsistent results from repetitions of the same experiment.  When working with SQ3Br, 
the solutions would change color from blue to purple or decolor while simply sitting on the 
bench.  To test the photostability of SQ3Br, a solution of it was placed in the fluorimeter 
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and periodically excited (Figure 4.11).  The emission decreased with each excitation, 
implying that the squaraine was either reacting (e.g. hydrolysis) over time or being 
photobleached by the excitation light.  In either case, while SQ3Br may react with thiols, 
this squaraine is too unstable to be sure that this is the only reaction occurring in solution.     
 
 
Figure 4.9 Absorbance monitoring of thiol addition to SQ3Br.  Addition of NAC (3 
mM) to SQ3Br (4 µM) in water, <1% ethanol. 
 
Figure 4.10 Addition of thiol to SQ3Br with fluorescence monitoring.  Thiol (0-22 µM) 
was added to SQ3Br (20 µM) in 10 mM phosphate buffer, H2O, pH 7.0, 
0.02% NaN3, 2% ethanol, λex = 575 nm, λex = 630 nm. 
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Figure 4.11 Fluorescence monitoring of SQ3Br alone over time.  SQ3Br (2 µM) in 10 
mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3, < 1% ethanol, λex = 575 
nm. 
4.4.3 SQ6 
SQ6 was reported by Liu and coworkers as a thiol probe,25 so we expected to find 
that it would react with thiols.  NAC (5 equiv.) was added to SQ6, and the solution 
decolored almost immediately (Figure 4.12).  Indeed, SQ6 reacts readily with thiols. 
 
 
Figure 4.12 Absorbance monitoring of thiol addition to SQ6.  Addition of NAC (12.5 
µM) to SQ6 (2.5 µM) in 50 mM phosphate buffer, 10 mM EDTA, H2O, pH 
7.5, < 1% DMSO.   
0
5000
10000
15000
20000
25000
30000
600 650 700 750
E
m
is
si
o
n
Wavelength (nm)
0 min
1 min
3.5 min
5 min
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
400 500 600 700 800
A
b
so
rb
an
ce
Wavelength (nm)
SQ6
+ 5 eq NAC after 30 s
+ 5 eq NAC after 1 min
 168 
4.4.4 Thiol Addition to the Aniline-Derived Squaraine Series (SQ4, 5, 7, 8, and 9) 
One of the main things that we wanted to investigate with these aniline-based 
squaraines was if we could tune their reactivity toward thiols through the substitution at 
the ortho position on the benzene ring (X in Scheme 4.8).  We knew from the literature 
that squaraines with no ortho substitution (X = H, SQ5) will react readily with thiols.  
However, these dyes also hydrolyze readily, which is a problem for working with 
squaraines in aqueous solutions.  On the other hand, squaraines with a hydroxyl group in 
the ortho position (X = OH, SQ4) are essentially not reactive to thiols, presumably because 
the hydroxyl group donates electron density to the squaraine core, making it much less 
electrophilic.  We hypothesized that placing other donating groups at the ortho position 
would result in intermediate reactivity between a hydrogen and a hydroxyl group.  We 
synthesized squaraines with X = CH3, OCH3, and NH(CO)CH3 (SQ7, 8, and 9) in order to 
test this hypothesis.  NAC was titrated into each squaraine while monitoring the absorbance 
(Figure 4.13-4.18). 
 
  
Figure 4.13 Absorbance titration of thiol into SQ4. NAC (0-2.59 mM) was added to 
SQ4 (10 µM) in 10 mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3, 25°C, 
5 min. equilibration between additions. 
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Figure 4.14 Absorbance titration of thiol into SQ5. NAC (0-138 µM) was added to SQ5 
(10 µM) in 10 mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3, 25°C, 3 
min. equilibration between additions. 
  
Figure 4.15 Absorbance titration of thiol into SQ7. NAC (0-138 µM) was added to SQ7 
(10 µM) in 10 mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3, 25°C, 3 
min. equilibration between additions. 
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Figure 4.16 Absorbance titration of thiol into SQ8. NAC (0-394 µM) was added to SQ8 
(10 µM) in 10 mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3, 25°C, 30  
min. equilibration between additions. 
  
Figure 4.17 Absorbance titration of thiol into SQ9. NAC (0-864 µM) was added to SQ9 
(10 µM) in 10 mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3, 25°C, 15  
min. equilibration between additions. 
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Figure 4.18 Isotherms for thiol addition to SQ4, 5, 7, 8, and 9 overlaid.  The decrease in 
absorbance for the monomer peak is described as a percentage of the initial 
absorbance of each squaraine.  See Figures 4.13-4.17 for experimental 
details. 
From Figure 4.18 and Table 4.2, it is clear that SQ5 and SQ7 react with thiols 
readily, while SQ8 and SQ9 do not react as readily.  SQ4 is essentially not reactive, as 
expected.  The reactivity of SQ7 appears to be slightly greater than for SQ5, which is 
unexpected because a methyl group is electron-donating.  Furthermore, SQ8 is expected to 
be less reactive than SQ9, but we observe the opposite order of reactivity.  The observed 
trends do not seem to agree particularly well with σ values (Table 4.3), although the σ+ 
values appear to be more appropriate than σpara, which implies that resonance effects are 
more significant than inductive effects from the substituent for this reaction.  A methyl 
group would not provide resonance stabilization, which would be consistent with the 
similar reactivity of SQ5 and SQ7.  Furthermore, perhaps SQ7 is more reactive than SQ5 
due to relief of steric strain between the methyl group and the oxygen when planarity is 
broken.  While a methoxy group should be more donating than an amide group, perhaps 
the monomer-dimer equilibrium for SQ9 can explain its extra stability compared to SQ8.  
SQ9 shows a strong tendency to dimerize compared to the other squaraines.  A dimer 
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would be less susceptible to nucleophilic attack statistically (i.e. two sides per two 
squaraines rather than two sides per one squaraine).  Additionally, if the SQ9 dimer is more 
stable than or similar in stability to the SQ9-thiol complex, then the equilibrium would not 
clearly favor the SQ-thiol complex.  These factors could make the σ value for amide 
inapplicable in this case. 
Table 4.2 Fitting of binding curves of NAC added to SQ to 1:1 regime. 
Squaraine Binding constant 
(M-1) 
Asymptotic Error 
(%) 
Covariance of 
Fit 
RMS of Residuals 
SQ7 8.57 x 105 5.2 0.017 0.032 
SQ5 4.00 x 105 2.0 0.005 0.012 
SQ8 1.92 x 104 0.7 0.003 0.006 
SQ9 2.62 x 103 0.6 0.009 0.015 
SQ4 6.44 x 102 1.3 0.038 0.019 
 
Table 4.3 Relevant σ values for the squaraine series.44 
Substituent σpara σ+ 
CH3 -0.14 -0.31 
NH(CO)CH3 0.00 -0.6 
OCH3 -0.12 -0.78 
OH -0.38 -0.92 
 
4.4.5 1H NMR of Thiol Addition to SQ5 
The desymmetrization of the squaraine upon thiol addition can also be observed by 
1H NMR.  Due to the small amounts of squaraine material we synthesized, we did not 
perform extensive 1H NMR studies.  However, we did examine the addition of NAC to 
SQ5 using this method.  The original spectra described here can be found in section 4.11.1.  
First, a spectrum of SQ5 in D2O alone was taken for a baseline.  In the aromatic region, 
there were two doublets from the aromatic protons of SQ5 (7.74, 6.66 ppm), as well as 
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additional small doublets from the hydrolyzed SQ5 (7.62, 6.70, 6.67 ppm), indicating that 
hydrolysis had already begun even after only a few minutes in solution.   
Then, one equivalent of NAC was added, and another spectrum was taken.  The 
solution had decolored completely immediately upon mixing the sample.  The doublets at 
7.74 and 6.66 ppm for intact SQ5 had disappeared completely, and several new doublets 
had appeared from the asymmetric SQ5-thiol product (7.42, 7.30, 6.77, and 6.73 ppm).  
Finally, this same sample was analyzed again 18 hr later.  The spectrum showed that the 
peaks for SQ5-thiol (7.42, 7.30, 6.77, and 6.73 ppm) had diminished relative to the peaks 
for SQ5-water (7.62, 6.70, 6.67 ppm).  This evidence is indicative of the reversibility of 
thiol addition to squaraines.  The SQ5-thiol peaks diminish over time because the thiols 
are constantly leaving and re-adding to SQ5, and the free thiols in solution are also being 
oxidized to disulfides in a separate reaction.  Over time, the thermodynamic sink for the 
system is the state in which the thiols are oxidized to disulfides and the squaraines are 
hydrolyzed.   
4.4.6 Testing Reactivity of Squaraines to Amines 
The selectivity of squaraines for thiols over amines at pH 6 has been demonstrated 
in the literature.23  However, we wanted to be sure that this selectivity was still observed at 
pH 7 with our squaraines.    A large excess of Boc-α-lysine (175 equivalents of amine) was 
added to a solution of SQ7, which was the most reactive squaraine with thiols in our series 
(Figure 4.19).  The solution did not decolor, even after one hour.  In fact, the absorbance 
of the squaraine appeared to increase slightly, perhaps due to the change in ionic strength 
of the solution due to the lysine.   
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Figure 4.19  Addition of an amine to SQ7.  Boc-α-lysine (2 mM) was added to SQ7 
(11.4 µM) in in 10 mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3.  
4.5 STUDIES OF SQUARAINE BINDING TO SERUM ALBUMIN 
The other major component of this work was to investigate the binding behavior of 
the squaraines to serum albumin.  In order to do this, BSA was titrated into each squaraine 
while monitoring the absorbance and fluorescence of the squaraine.  Furthermore, we used 
indicator displacement studies with dansyl amide (DNSA) and dansyl proline (DP) to probe 
the site-specificity of the binding of some of the squaraines.   
4.5.1 SQ1 
BSA was titrated into SQ1 (Figure 4.20).  The emission at 675 nm decreased as 
BSA was added, while the emission at 685 nm increased.  Saturation was reached at about 
three equivalents of protein.   
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Figure 4.20  Fluorescence titration of BSA into SQ1.  Addition of BSA (0-100 µM) to 
SQ1 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex 
= 640 nm.  Top: Spectra, Middle: λem = 675 nm, Bottom: λem = 685 nm. 
The new peak at 685 nm is likely due to binding of the squaraine into a hydrophobic 
pocket in serum albumin.  Binding stabilizes the excited state of SQ1 resulting in a smaller 
HOMO-LUMO gap, which leads to a lower energy, higher wavelength emission.   
0
100000
200000
300000
400000
500000
650 670 690 710 730 750
E
m
is
si
o
n
Wavelength (nm)
-160000
-120000
-80000
-40000
0
0 1 2 3 4 5 6
C
h
an
g
e 
in
 e
m
is
si
o
n
 @
 
6
7
5
 n
m
Equivs BSA
-50000
0
50000
100000
150000
200000
0 1 2 3 4 5 6C
h
an
g
e 
in
 e
m
is
si
o
n
 @
 
6
8
5
 n
m
Equivs BSA
 176 
4.5.2 SQ3Br 
BSA was titrated into SQ3Br (Figure 4.21).  The emission of the squaraine 
increased with the addition of BSA and saturated at about one equivalent of BSA.  The 
results from this experiment are consistent with the work by Ramaiah et al.38 Our binding 
isotherm is consistent with their 2:1 SQ3Br/BSA binding stoichiometry.   
 
 
Figure 4.21  Fluorescence titration of BSA into SQ3Br.  Addition of BSA (0-100 µM) 
to SQ3Br (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02 NaN3, 
λex = 575 nm. 
4.5.3 SQ4 
BSA was titrated into SQ4, and the absorbance and fluorescence spectra were 
recorded (Figure 4.22 and 4.23).  SQ4 dimerizes to a significant extent in aqueous solution 
(Figure 4.6), and this monomer-dimer equilibrium leads to complex absorbance and 
fluorescence behavior of the squaraine upon addition of BSA.  In the absorbance titration, 
the dimer peak at 585 nm consistently decreases, while a new peak (605 nm) grows in.  
This new peak then diminishes after about 0.7 equivalents of BSA are added.  This new 
peak could represent the bound dimer.  The monomer peak increases up to about 0.2 
equivalents of BSA, and the decreases up to 0.7 equivalents of BSA.  After that, the 
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absorbance at that wavelength increases up to at least 6 equivalents of protein.  The 
fluorescence titration also showed complex behavior: the emission decreases up to 0.5 
equivalents of BSA and then increases.  These results are indicative of a binding 
stoichiometry greater than 1:1.  Probably both the monomer and dimer can bind to serum 
albumin.   
  
Figure 4.22  Absorbance titration of BSA into SQ4.  Addition of BSA (0-129 µM) to 
SQ4 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3. 
  
Figure 4.23  Fluorescence titration of BSA into SQ4.  Addition of BSA (0-50 µM) to 
SQ4 (10 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex 
= 640 nm. 
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As a comparison, we performed the same titration with HSA (Figure 4.24).  Similar 
absorbance behavior to the addition of BSA was observed; however, small differences 
indicate that the binding of SQ4 is different to HSA than it is to BSA. 
 
 
Figure 4.24  Absorbance titration of HSA into SQ4.  Addition of HSA (0-129 µM) to 
SQ4 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3. 
4.5.4 SQ5 
BSA was titrated into SQ5, and the absorbance and fluorescence spectra were 
recorded (Figure 4.25 and 4.26).  As BSA is added, the absorbance decreases but the 
fluorescence increases.  We were puzzled by the observation of these two apparently 
opposing phenomena occurring.  The absorbance decrease implies that the squaraine is 
becoming desymmetrized by reaction with a nucleophile, or the charge transfer band is 
otherwise being disrupted by steric or electronic factors upon binding.  At the same time, 
the emission of the squaraine is increasing, which implies that binding improves the 
quantum yield of fluorescence.  However, the squaraine is absorbing less light at the 
excitation wavelength, so the quantum yield increase must be quite large.  For example, at 
three equivalents of BSA, the emission had increased by about fivefold, while the 
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absorbance at the excitation wavelength had decreased by about fivefold.  It is likely that 
we are observing the net effect of multiple factors.  Perhaps SQ5 is reacting with 
nucleophilic amino acids in the protein (e.g. lysine, serine), resulting in the decoloration.  
At the same time, the intact squaraine that remains binds to the protein and experiences a 
huge increase in its emission due to binding in the hydrophobic pocket/s. 
 
 
Figure 4.25  Absorbance titration of BSA into SQ5.  Addition of BSA (0-50 µM) to 
SQ5 (10 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3. 
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Figure 4.26  Fluorescence titration of BSA into SQ5.  Addition of BSA (0-50 µM) to 
SQ5 (10 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex 
= 640 nm. 
In order to test if the squaraine was reacting with the one free cysteine residue of 
BSA, we prepared a sample of BSA in which that cysteine had been blocked with 
iodoacetamide (c-BSA).  This c-BSA was titrated into SQ5, and the binding isotherm 
was compared with that of BSA (Figure 4.27).  The two isotherms are similar, which 
indicates that blocking the thiol does not significantly change the emission behavior of 
SQ5 in the presence of serum albumin.  Of course, SQ5 could be reacting with other 
amino acids like lysine.  We found with SQ7 that nearly 200 equivalents of amine did not 
decolor the solution, which indicates that amines will not react with the squaraines.  
However, the lysines in BSA have an average pKa of 9.2,
45 and some individual lysines 
in the protein could have even lower pKas than that.  These lysines would be more 
nucleophilic than a free lysine in solution like the one we used to test amine reactivity. 
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Figure 4.27  Fluorescence titration of BSA and c-BSA into SQ5.  Addition of BSA (0-
100 µM) to SQ5 (20 µM) and of c-BSA (0-100 µM) to SQ5 (20 µM) in 
10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex = 640 nm, λex = 
680 nm. 
 
To determine the binding stoichiometry of SQ5 to BSA, we used the method of 
continuous variation to generate a Job plot (Figure 4.28).  The Job plot indicates a 1:1 
stoichiometry, which is consistent with the fluorescence binding isotherm as well as the 
indicator displacement experiments with DNSA and DP that follow.  
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Figure 4.28  Job plot of BSA and SQ5.  BSA (100 µM) and SQ5 (100 µM) were mixed 
in different mole fractions in 10 mM phosphate buffer, H2O, pH 7.00, 
0.02% NaN3, λex = 640 nm, λem = 675 nm. 
To probe which site SQ5 might be binding in, solutions of BSA with dansyl 
amide (DNSA, Site I-specific) and with dansyl proline (DP, Site II-specific) were titrated 
with SQ5 while measuring the emission of DNSA and DP (Figure 4.29).  Both probes 
experienced a decrease in their emission, which is indicative of their displacement from 
BSA.  DP experienced a larger decrease than DNSA, so SQ5 is probably binding in 
Sudlow Site II, which is consistent with the results for SQ2 reported by Belfield et al.39  
Site II generally prefers aromatic molecules with peripherally-located negative charges,45 
so it makes sense that these sulfonate-functionalized squaraines would bind in Site II. 
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Figure 4.29  Fluorescence titrations of SQ5 into BSA/DNSA and BSA/DP.  SQ5 (0-47 
µM) was added to a solution of BSA (10 µM) and DNSA (9 µM) in 10 
mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex =360 nm, λem =485 
nm.  SQ5 (0-49 µM) was added to a solution of BSA (10 µM) and DP (9 
µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex =350 
nm, λem 490 nm.   
 As a way of further investigating the bizarre absorbance/emission behavior of SQ5, 
we titrated a solution of BSA/SQ5 with DNSA and DP (Figures 4.30-4.33).  If these probes 
displaced SQ5 from BSA, we would expect to see a decrease in SQ5’s emission.  If the 
absorbance behavior we observe is due to SQ5 reacting with lysines in the protein, we 
would expect the probes to have no effect on this reaction, so the absorbance would not 
change (Scenario 1).  However, if the absorbance behavior of SQ5 can be attributed to 
some non-covalent effect of being bound in the hydrophobic pocket, then displacing SQ5 
would restore its absorbance (Scenario 2). While these were the scenarios we hypothesized, 
we did not exactly observe either of these outcomes.   
 The addition of DNSA slightly increased the emission of SQ5, which implies that 
DNSA has a small cooperative effect on SQ5 binding to BSA.  From the other indicator 
displacement experiments, we determined that SQ5 probably binds in Site II, so perhaps 
the binding of DNSA in Site I induces allosteric changes in BSA that render the Site II 
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more hospitable to SQ5.  The absorbance data echoes this apparent cooperative effect of 
DNSA.  The decrease in absorbance of SQ5 upon addition of DNSA tends to suggest that 
the decrease observed upon SQ5 binding to BSA is not due to reaction with lysines.  DNSA 
would not be expected to affect that reaction.   
 
  
Figure 4.30  Absorbance titration of DNSA into BSA/SQ5.  Addition of DNSA (0-100 
µM) to BSA (10 µM) and SQ5 (10 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3. 
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Figure 4.31  Fluorescence titration of DNSA into BSA/SQ5.  Addition of DNSA (0-100 
µM) to BSA (10 µM) and SQ5 (10 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3, λex = 640 nm, λem = 670 nm. 
From both the absorbance and fluorescence data, DP displaces SQ5 starting at 
about two equivalents, which is consistent with our Site II binding model and our Scenario 
2 for indicator displacement.  The increase in emission from 0-2 equivalents of DP matches 
with the decrease in the dimer peak in the absorbance spectrum.  The presence of the DP 
seems to break up the dimer into monomer, which leads to the initial increase in emission 
upon addition of DP.   
These experiments provided some insight into how SQ5 interacts with BSA.  
However, it is still unclear exactly what phenomenon the decoloration of SQ5 in the 
presence of BSA can be attributed to. 
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Figure 4.32  Absorbance titration of DP into BSA/SQ5.  Addition of DP (0-100 µM) to 
BSA (10 µM) and SQ5 (10 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3. 
 
  
Figure 4.33  Fluorescence titration of DP into BSA/SQ5.  Addition of DP (0-100 µM) 
to BSA (10 µM) and SQ5 (10 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3, λex = 640 nm, λem = 670 nm. 
4.5.5 SQ6 
BSA was titrated into SQ6, and the fluorescence spectra were recorded (Figure 
4.34).  As with SQ5, the emission increased upon addition of BSA, and the isotherm 
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implies a 1:1 binding stoichiometry as well.  An absorbance titration was not performed, 
but we did observe that the SQ6 solution decolored upon the addition of BSA as well. 
 
  
Figure 4.34  Fluorescence titration of BSA into SQ6.  Addition of BSA (0-50 µM) to 
SQ6 (10 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, < 
1% DMSO, λex = 640 nm, λem = 675 nm. 
4.5.6 SQ7 
BSA was titrated into SQ7, and the absorbance and fluorescence spectra were 
recorded (Figure 4.35 and 4.36).  Again, the same behavior was observed for SQ7 as for 
SQ5 and 6: the absorbance decreases as BSA is added.  However, the shape of the 
fluorescence binding isotherm is different.  The emission increases to about 0.5 equivalents 
of BSA and then begins to decrease.  The shape is similar to the binding isotherm of SQ4, 
but in this titration the emission initially increases rather than decreasing as with SQ4.  
Thus, perhaps either the dimer or two separate monomers can bind to serum albumin.  We 
postulate that in the case of SQ7, two monomers bind separately to BSA, which leads to 
the increase in emission up to 0.5 equivalents.  As more BSA is added, there are more 
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binding sites available and one monomer/protein, and the emission decreases relative to 
the peak emission when two squaraines are bound. 
Figure 4.35  Absorbance titration of BSA into SQ7.  Addition of BSA (0-129 µM) to 
SQ7 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3. 
 
Figure 4.36  Fluorescence titration of BSA into SQ7.  Addition of BSA (0-100 µM) to 
SQ7 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex 
= 640 nm, λem = 690 nm. 
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 4.5.7 SQ8 
BSA was titrated into SQ8, and the absorbance and fluorescence were monitored 
(Figure 4.37 and 4.38).  The results were consistent with SQ5.  At very small additions of 
BSA (< 0.2 equivalent), a small blip in the isotherms are observed.  This phenomenon is 
probably due to some higher stoichiometry of binding occurring when very little BSA is 
present (e.g. dimer or two monomers binding).  Clearly, this effect is much smaller for SQ8 
than for SQ7 or SQ4.  
 
Figure 4.37  Absorbance titration of BSA into SQ8.  Addition of BSA (0-129 µM) to 
SQ8 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3. 
 
Figure 4.38  Fluorescence titration of BSA into SQ8.  Addition of BSA (0-100 µM) to 
SQ8 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex 
= 630 nm, λem = 675 nm. 
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4.5.8 SQ9 
 Finally, BSA was titrated into SQ9, and the absorbance and fluorescence data was 
obtained (Figure 4.39 and 4.40).  From SQ9’s absorbance spectrum, we know that it exists 
primarily as the dimer in solution.  Perhaps the amide groups stabilize the dimer by 
hydrogen bonding, making it the dominant form for SQ9 but not for SQ5, 7, or 8.  As BSA 
was added to SQ9, the dimer peak diminished and the monomer peak increased.  The two 
isotherms cross at two equivalents of BSA, although we are not sure what the significance 
of this crossing point is.  This titration implies that the BSA only binds the monomer and 
so breaks up the dimer.  The fluorescence titration supports this notion as the isotherm 
seems to show a 1:1 binding stoichiometry.   
 
Figure 4.39  Absorbance titration of BSA into SQ9.  Addition of BSA (0-129 µM) to 
SQ9 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3. 
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Figure 4.40  Fluorescence titration of BSA into SQ9.  Addition of BSA (0-100 µM) to 
SQ9 (20 µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex 
= 650 nm, λem = 695 nm. 
Since SQ9 does not exhibit a decrease in its monomer peak upon BSA addition as 
SQ5, 7, and 8 do, we wanted to use the same tests as we did for SQ5 to test the effect of 
displacement by DNSA and DP to compare to SQ5 (Figures 4.41-4.44).  When DNSA 
was added to SQ9/BSA, almost no change in the absorbance spectrum of SQ9 occurred, 
which matches the small effect of DNSA on SQ5/BSA.  A cooperative binding effect to 
BSA by DNSA and DP was apparent for SQ9 in the fluorescence titrations.  The emission 
of SQ9 increased as DNSA and DP are added.  The increase steadily continued at a lower 
magnitude for DNSA, which was consistent with the allosteric model proposed previously 
for SQ5.  For DP, the binding isotherm implies a 1:1:1 stoichiometry of DP/SQ9/BSA, 
suggesting that the DP could be sharing Site II with SQ9 rather than displacing the 
squaraine.   
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Figure 4.41  Absorbance titration of DNSA into BSA/SQ9.  Addition of DNSA (0-100 
µM) to BSA (10 µM) and SQ9 (10 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3. 
 
 
Figure 4.42  Fluorescence titration of DNSA into BSA/SQ9.  Addition of DNSA (0-100 
µM) to BSA (10 µM) and SQ9 (10 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3, λex = 670 nm, λem = 695 nm. 
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Figure 4.43  Absorbance titration of DP into BSA/SQ9.  Addition of DP (0-100 µM) to 
BSA (10 µM) and SQ9 (10 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3. 
 
 
Figure 4.44  Fluorescence titration of DP into BSA/SQ9.  Addition of DP (0-100 µM) 
to BSA (10 µM) and SQ9 (10 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3, λex = 670 nm, λem = 695 nm. 
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4.5.9  Summary 
The series of sulfonated squaraines exhibit complex binding behavior to serum 
albumin, in part due to the monomer-dimer equilibrium.  Some of the squaraines bind with 
greater than 1:1 stoichiometry (SQ4, 7) to BSA.  The dominant binding site for these 
squaraines seems to be Sudlow Site II as evidenced by indicator displacement titrations 
with DNSA and DP.   
For SQ5, 6, 7, and 8, the puzzling phenomenon of a decrease in absorbance with a 
concomitant increase in emission was observed.  Our best hypothesis to explain these two 
apparently opposing effects is that they are the net of multiple effects.  The emission of the 
squaraines increases upon binding to serum albumin due to the hydrophobic environment 
of the binding pocket.  The absorbance of the squaraines decreases for SQ5, 7, and 8 due 
to reaction with lysines in the protein or perhaps due to steric or electrostatic effects from 
the binding site.   
4.6 THIOL ADDITION TO SQUARAINES IN THE PRESENCE OF SERUM ALBUMIN 
Toward the goal of building receptors from serum albumin, squaraines, and thiols, 
we wanted to test the binding of the squaraine/thiol complex to serum albumin.  To do so, 
we performed indicator displacement experiments with DNSA and DP.  A solution of BSA 
and DNSA (or DP) was titrated with SQ5, SQ5/NAC, and SQ5/VVKLKC (Figure 4.45 
and 4.46).  VVKLKC is a thiol-containing peptide (see Chapter 5 for the synthesis and 
characterization).  The emission of the DNSA or DP was monitored to measure 
displacement of these probes by the titrants.  DP was displaced somewhat less by 
SQ5/NAC and SQ5/VVKLKC compared to SQ5 alone, while DNSA was displaced the 
same amount by all three titrants.  Based on our Site II binding model, this result makes 
sense.   
 195 
One interpretation of the result is that the SQ5-thiol complexes bind less well to 
Site II because of the change in shape of the squaraine and added bulk of the thiol that 
could be extending out of the pocket into solution.  Another interpretation is that the 
apparently lower affinity of the SQ5-thiol complex is actually indicative of the complex 
not binding at all to serum albumin.  The thiol adds reversibly to the squaraine, and the 
squaraine binds reversibly to the protein.  These two equilibria may be functioning in 
parallel such that the SQ-thiol complex itself never binds.  This interpretation would 
explain why SQ5/VVKLKC appears to bind better than SQ5/NAC.  If the complex was 
binding, the extra bulk of an entire peptide would logically be more cumbersome than 
cysteine alone.  However, VVKLKC is probably less nucleophilic than NAC, so at any 
given time less squaraine is sequestered as the complex and more is available for binding.   
 
Figure 4.45  Titration of SQ5, SQ5/NAC, SQ5/VVKLKC, and NAC into BSA/DP.  A 
solution of BSA (10µM) and DP (9 µM) was titrated with SQ5 (0-49 µM), 
SQ5/NAC (0-46 µM), SQ5/VVKLKC (0-47 µM), and NAC (0-43 µM) in 
10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex = 350 nm.   
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Figure 4.46  Titration of SQ5, SQ5/NAC, SQ5/VVKLKC, and NAC into BSA/DNSA.  A 
solution of BSA (10µM) and DNSA (9 µM) was titrated with SQ5 (0-47 
µM), SQ5/NAC (0-47 µM), SQ5/VVKLKC (0-47 µM), and NAC (0-48 
µM) in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3, λex = 360 
nm.   
To further explore these phenomena, we investigated whether serum albumin exerts 
a protective or cooperative effect on thiol addition to squaraines.  Ramaiah and coworkers 
identified a protective effect on phloroglucinol-derived squaraines by β-cyclodextrin, 
although the cyclodextrin did not protect aniline-derived squaraines from thiol addition.32  
To test our squaraines, solutions of BSA/SQ were titrated with thiol while monitoring the 
absorbance.  The decrease in absorbance was standardized by expressing it as the percent 
decrease of the initial absorbance to compare the squaraines to one another (Figure 4.47- 
monomer, Figure 4.48- dimer).  The original spectra and titration details for the 
experiments can be found in 4.10.2.  The order of reactivity from Figure 4.18 is largely 
retained in the presence of serum albumin. 
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Figure 4.47  Isotherms for thiol addition to all of the SQ/BSA combinations overlaid 
(monomer).  The decrease in absorbance for the monomer peak is 
described as a percentage of the initial absorbance of each squaraine.  See 
Figures 4.57-4.61 for experimental details and original spectra. 
 
Figure 4.48  Isotherms for thiol addition to all of the SQ/BSA combinations overlaid 
(dimer).  The decrease in absorbance for the dimer peak is described as a 
percentage of the initial absorbance of each squaraine.  See Figures 4.57-
4.61 for experimental details and original spectra. 
-10
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10
%
 A
b
so
rb
an
ce
Equivs thiol
SQ9 (amide)
SQ8 (Ome)
SQ5 (H)
SQ7 (Me)
SQ4 (OH)
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10
%
 A
b
so
rb
an
ce
Equivs thiol
SQ9 (amide)
SQ8 (Ome)
SQ5 (H)
SQ7 (Me)
SQ4 (OH)
 198 
 In order to try to detect a protective or cooperative effect by the serum albumin, we 
plotted the isotherms for the addition of thiol to squaraine together with the addition to 
BSA/SQ using the percent absorbance (Figures 4.49-4.53).  In each case, the BSA seems 
to exert a cooperative effect on thiol addition to the squaraines.  One way that BSA could 
appear to have a cooperative effect is by breaking up the dimers of the squaraines and 
increasing the relative concentration of monomer.  Another explanation for these results is 
that the squaraines are reacting with lysines in the protein, which decreases the 
concentration of free squaraine in solution.  In that case, the true starting concentration of 
squaraine is not known, and the equivalents of thiol added cannot be calculated accurately.   
 
Figure 4.49  Isotherms for thiol addition to SQ4 and SQ4/BSA.  The decrease in 
absorbance is described as a percentage of the initial absorbance of SQ4 or 
SQ4/BSA.  See Figures 4.13 and 4.57 for experimental details and 
original spectra. 
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Figure 4.50  Isotherms for thiol addition to SQ5 and SQ5/BSA.  The decrease in 
absorbance is described as a percentage of the initial absorbance of SQ5 or 
SQ5/BSA.  See Figures 4.14 and 4.58 for experimental details and 
original spectra. 
 
Figure 4.51  Isotherms for thiol addition to SQ7 and SQ7/BSA.  The decrease in 
absorbance is described as a percentage of the initial absorbance of SQ7 or 
SQ7/BSA.  See Figures 4.15 and 4.59 for experimental details and 
original spectra. 
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Figure 4.52  Isotherms for thiol addition to SQ8 and SQ8/BSA.  The decrease in 
absorbance is described as a percentage of the initial absorbance of SQ8 or 
SQ8/BSA.  See Figures 4.16 and 4.60 for experimental details and 
original spectra. 
 
Figure 4.53  Isotherms for thiol addition to SQ9 and SQ9/BSA.  The decrease in 
absorbance is described as a percentage of the initial absorbance of SQ9 or 
SQ9/BSA.  See Figures 4.17 and 4.61 for experimental details and original 
spectra. 
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4.7 CONCLUSIONS 
Squaraines are organic chromophores with absorption and emission in the red to 
near-IR region of the spectrum, making them useful dyes for a variety of applications.  For 
our purposes, we were interested in the properties of some squaraines to 1) add thiols 
through a conjugate addition reaction and 2) bind in the hydrophobic pockets of serum 
albumin.  We wanted to exploit these two properties to build dynamic and multivalent 
receptors from serum albumin, squaraines, and thiol-containing recognition units.  As a 
starting point toward achieving this goal, we synthesized a series of water soluble 
squaraines and investigated their reactivity to thiols and their affinity for serum albumin.   
Aniline-derived squaraines with no ortho substitution are known to be very reactive 
with thiols and other nucleophiles to the point that they are unstable in aqueous solution.  
On the other hand, squaraines with an ortho hydroxyl group are inert to nucleophiles.  We 
hypothesized that we could tune the reactivity of aniline-derived squaraines by the 
substitution at the ortho position of the benzene ring.  Thus, we synthesized squaraines 
with different electron-donating groups at the ortho position and studied their reactivity 
toward cysteine.  We found that the different substitution did indeed change the reactivity 
of the squaraine, and we achieved intermediate reactivity between the H-substituted 
squaraine and the OH-substituted squaraine.  Although the specific order of reactivity that 
we found did not conform to σ values for these groups.  We were able to rationalize these 
inconsistencies based on additional factors for the squaraines that the σ values would not 
take into account. 
We also investigated the binding properties of these squaraines to serum albumin.  
The sulfonated squaraines exhibit an increase in their emission upon binding to BSA.  
Some of the squaraines bind with greater than 1:1 stoichiometry to BSA, which could be 
due to the dimer binding in one site or multiple monomers in different sites.  The dominant 
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binding site for these squaraines seems to be Sudlow Site II, as evidenced by indicator 
displacement titrations with DNSA and DP.  Finally, we tested the effect of serum albumin 
on the thiol addition to the squaraines and detected a cooperative effect by the protein. 
4.8  FUTURE WORK 
While we made significant progress toward understanding the properties of these 
squaraines, questions remain that could be answered by further investigation.  The 
reactivity trend of the substituted squaraines could be further elucidated by synthesizing 
more derivatives (e.g. X = C(CH3)3, F, or Ph) for testing.  Derivatives with substitution at 
both ortho positions could also be made to see if additive or blended effects could be 
achieved for further refinement of reactivity.  The origin of the decoloration of the 
squaraines in the presence of serum albumin is still unclear.  The squaraines could be 
titrated with other proteins to test if the decrease in absorbance is due to lysine addition 
rather than non-covalent effects due to binding, although the exact reactivity of the lysines 
in serum albumin might not be represented by other proteins.  Crystal structures of the 
serum albumin-squaraine complex could be obtained.  Finally, the squaraines could be 
combined with serum albumin and thiol-containing recognition units in the presence of an 
analyte of interest to test if receptors will assemble as we had envisioned.  A specific 
signaling or characterization method will need to be devised to measure the purported 
template effect.   
4.9 CONTRIBUTIONS 
J. Logan Bachman, an undergraduate student, assisted in the synthesis of several of 
the squaraines.   
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4.10  EXPERIMENTAL METHODS 
4.10.1 General 
Unless otherwise indicated, chemicals and reagents were obtained from Sigma 
Aldrich and used without further purification.  Dansyl amide and dansyl proline 
piperidinium salt were obtained from TCI America.   
HPLC-grade solvents were prepared with 0.1% TFA (v/v) and filtered through 0.2 
micron filter.  HPLC was performed on a Shimadzu instrument with a preparative C-18 
column using a water and acetonitrile mobile phase.  Other reverse-phase separation was 
performed on a Teledyne Isco CombiFlash instrument using a water and acetonitrile mobile 
phase without TFA.  RediSep C-18 columns were used (4.3 gram flash column). 
LC-MS analysis was performed on an Agilent 1200 Series HPLC with an Agilent 
6130 single quadrupole mass spectrometer (ESI and APCI ionization).  NMR spectra were 
obtained on a 400 MHz Varian instrument. 
The fluorescence experiments were performed with a PTI fluorimeter using an 814 
photomultiplier detection system and a 75W xenon short arc lamp.  The data for the Job 
plot was obtained from a Biotek Synergy 2 Multimode Microplate Reader.  The absorbance 
experiments were performed with a Beckman Coulter DU 800 Spectrophotometer or an 
Agilent Cary 100 UV-VIS.   
The binding constants were calculated using Open Data Fit by the Centre for Bio-
Nano Science (CBNS) at http://supramolecular.org/. 
4.10.2 Synthesis 
The literature source for each compound is indicated next to the compound name.  
If there is no source given, it is a new compound.  For these squaraines that had not 
previously been synthesized, 1H NMR and high-resolution MS data were obtained.  These 
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squaraines have relatively low solubility in any solvent (< 1 mM) and are unstable in their 
best solvent (water), decomposing over the course of several hours.  Thus, it was not 
possible to obtain 13C NMR data due to the high concentrations and long scan times 
necessary.   
4.10.2.1 SQ1 
Di-tert-butyl 2,2'-((3-(benzyloxy)phenyl)azanediyl)diacetate (4.2)40 
 To 10 mL of acetonitrile was added 3-benzyloxyaniline (500 mg, 2.5 mmol, 1 eq) 
and proton sponge (1.18 g, 5.5 mmol, 2.2 eq).  Then t-butylbromoacetate (0.78 mL, 5.3 
mmol, 2.1 eq) was added, and the reaction was refluxed for 20 hr.  After 20 hr, another 0.4 
mL of t-butylbromoacteate (2.7 mmol) and 0.59 g of proton sponge (2.75 mmol) were 
added, and the reaction was refluxed for an additional 5 hr.  The reaction mixture was 
allowed to cool and was filtered to remove insoluble material.  Water was added and the 
solution was extracted four times with ethyl acetate and washed three times with brine.  
The organic layer was dried with Na2SO4, and the solvent was removed under reduced 
pressure.  The crude material was purified by silica chromatography with 10-50% ethyl 
acetate in hexanes.  The compound was a yellow oil (1.0 g, 94% yield).  1H-NMR (400 
MHz, CDCl3, ppm): δ 1.44 (s, 18H, CH3), 3.97 (s, 4H, CH2), 6.19 (d, 1H, Ar-H), 6.22 (s, 
1H, Ar-H), 6.39 (d, 1H, Ar-H), 7.09 (t, 1H, Ar-H), 7.36 (m, 5H, Ar-H of benzyl). 
Di-tert-butyl 2,2'-((3-hydroxyphenyl)azanediyl)diacetate (4.3)40 
 To a flask was added 4.2 (1g, 2.34 mmol, 1 eq), Pd/C (1.51 g), cyclohexene (17.45 
mL, 271 mmol, 116 eq), and 100 mL of ethanol. The reaction was refluxed for 2 hr.  The 
reaction mixture was cooled and filtered through Celite.  The solvent was removed under 
reduced pressure to yield a clear oil.  The product required no purification (0.75 g, 95% 
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yield).  1H-NMR (400 MHz, CDCl3, ppm): δ 1.42 (s, 18H, CH3), 3.98 (s, 4H, CH2), 6.13 
(s, 1H, Ar-H), 6.16 (d, 1H, Ar-H), 6.25 (d, 1H, Ar-H), 7.09 (t, 1H, Ar-H). 
t-Butyl-Protected SQ1 (4)40 
 To a flask was added squaric acid (70 mg, 0.61 mmol, 1 eq), 4.3 (440 mg, 1.30 
mmol, 2.1 eq), 16 mL benzene, and 8 mL n-butnaol (2:1).  A Dean-Stark trap was attached, 
and the reaction was refluxed at 100°C for 18 hr.  The reaction was allowed to cool, and 
the reaction mixture was concentrated under reduced pressure.  The crude material was 
purified on a silica column with DCM/MeOH.  The product was a blue solid (300 mg, 65% 
yield).  1H-NMR (400 MHz, CDCl3, ppm): δ 1.46 (s, 36H, CH3), 4.08 (s, 8H, CH2), 6.06 
(s, 2H, Ar-H), 6.24 (d, 2H, Ar-H), 7.90 (d, 2H, Ar-H).  MS (ESI): 753.3 (M+1). 
SQ140 
 The t-butyl-protected squararine (100 mg, 1.33 mmol) was placed in 3.75 mL 
DCM, 11 mL TFA, and 150 µL water.  The solution was stirred for 18 hr at room 
temperature.  The solvent was removed under reduced pressure.  The product required no 
purification and was a green iridescent solid (66 mg, 92% yield).  1H-NMR (400 MHz, d-
DMSO, ppm): δ 4.35 (s, 8H, CH2), 6.08 (s, 2H, Ar-H), 6.54 (d, 2H, Ar-H), 7.76 (d, 2H, 
Ar-H).  MS (ESI): 528.4 (M+1). 
4.10.2.2 SQ2 
3-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)propane-1-sulfonate (4.1)39 
 To 1,1,2-trimethyl-1-benz[e]indole (2g, 9.56 mmol, 1 eq) was added 15 mL of p-
xylene and 1,3-propane sultone (1 mL, 11.17 mmol, 1.2 eq).  The reaction was refluxed for 
6 hr and then cooled.  The reaction mixture was filtered to collect the solid.  The solid was 
washed with DCM and diethyl ether and dried.  The product required no further purification 
(2.66 g, 84% yield).  1H-NMR (400 MHz, d-DMSO, ppm): δ 1.75 (s, 6H, CH3), 2.21 (m, 
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2H, CH2), 2.67 (t, 2H, CH2), 2.93 (s, 3H, CH3), 4.77 (t, 2H, CH2), 7.72 (t, 1H, Ar-H), 7.78 
(t, 1H, Ar-H), 8.24 (m, 3H, Ar-H), 8.35 (m, 1H, Ar-H).   
SQ239 
 To a flask was added squaric acid (25 mg, 2.19 mmol, 1 eq), 4.1 (1.5 g, 4.52 mmol, 
2.1 eq), pyridine (3 mL), and n-butanol (10 mL).  A Dean-Stark trap was attached, and the 
reaction was refluxed for 5 hr.  After the reaction cooled, ether was added to precipitate the 
product.  The product was isolated by filtration and recrystallized three times in methanol.  
The product was a green solid (236 mg, 12% yield, pyridinium salt).  1H-NMR (400 MHz, 
d-DMSO, ppm): δ 1.95 (s, 12H, CH3), 2.06 (m, 4H, CH2), 2.58 (t, 4H, CH2), 4.35 (m, 4H, 
CH2), 5.88 (s, 2H, CH), 7.44 (t, 2H, Ar-H), 7.61 (t, 2H, Ar-H), 7.81 (d, 2H, Ar-H), 7.98 (d, 
8H, Ar-H), 8.28 (m, 2H, Ar-H), 8.50 (m, 2H, Ar-H), 8.79 (s, 4H, Ar-H).  MS (ESI): 739.2 
(M+1). 
4.10.2.3 SQ3Br 
SQ31 
To a flask was added squaric acid (250 mg, 2.19 mmol, 1 eq), phloroglucinol (552 
mg, 4.38, 2 eq), and 5 mL of acetic acid.  The reaction was refluxed for 4 hr.  The reaction 
was cooled, and the product was collected by filtration.  The crude product was 
recrystallized from acetic acid.  The product was a purple solid (300 mg, 41% yield).  MS 
(ESI): 329.2 (M-1). 
SQ3Br46 
 SQ3 (100 mg, 0.3 mmol, 1 eq) was placed in 70 mL of acetic acid. The solution 
was stirred and gently heated (up to 50°C) to dissolve SQ3.  To this solution was added a 
solution of bromine (0.07 mL, 13.6 mmol, 4.5 eq) in acetic acid dropwise over 1 hr.  The 
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reaction turned from purple to green.  The precipitate was collected.  The product required 
no further purification (68 mg, 35% yield).  MS (ESI): 644.7 (M-1). 
4.10.2.4 SQ4 
3-(ethylamino)phenol (4.5)47 
 To a flask was added 3-aminophenol (4.0 g, 37 mmol, 1 eq), potassium carbonate 
(5.0 g, 37 mmol, 1 eq), and 20 mL of DMF.  Then iodoethane (2.9 mL, 37 mmol, 1 eq) was 
added, and the reaction was heated to 100°C for 2 hr.  The reaction was cooled to room 
temperature and filtered to remove any solid.  Then water (20 mL) was added, and the 
solution was extracted three times with ethyl acetate. The organic layer was washed three 
times with water to remove DMF.  The product was purified on a silica column with 0-
30% ethyl acetate in hexanes (1.25 g, 25% yield).  1H-NMR (400 MHz, CDCl3, ppm): δ 
1.25 (t, 3H, CH3), 3.14 (m, 2H, CH2), 6.13 (t, 1H, Ar-H), 6.18 (m, 1H, Ar-H), 6.23 (m, 1H, 
Ar-H), 7.02 (t, 1H, Ar-H). 
3-((3-hydroxyphenyl)(ethyl)ammonio)propane-1-sulfonate (4.8)41  
 To a flask was added 4.5 (1.25 g, 9.11 mmol, 1 eq), 1,3-propanesultone (0.88 mL, 
10.02 mmol, 1.2 eq), and 10 mL of isopropanol.  The reaction was refluxed for 3 hr.  The 
precipitate was collected and washed with isopropanol.  The product required no further 
purification (1.68 g, 71% yield). 1H-NMR (400 MHz, d-DMSO, ppm): δ 0.97 (t, 3H, CH3), 
1.73 (m, 2H, CH2), 2.58 (t, 2H, CH2), 3.60 (m, 4H, CH2), 6.90 (broad s, 1H, Ar-H), 7.05 
(broad s, 2H, Ar-H), 7.37 (broad s, 1H, Ar-H), 10.23 (broad s, 1H, OH), 11.44 (broad s, 
1H, NH). 
SQ441 
 To a flask was added squaric acid (103 mg, 0.9 mmol, 1 eq), 4.8 (490 mg, 1.89 
mmol, 2.1 eq), sodium bicarbonate (159 mg, 1.89 mmol, 2.1 eq), 10 mL butanol, 5 mL 
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benzene, and 3 mL DMSO.  The reaction was refluxed for 3 hr.  Ether was added to 
precipitate the product.  The product was very wet, so it was taken up in methanol.  The 
methanol was filtered to remove solid, and then the methanol was removed under reduced 
pressure to give a green solid.  The crude product was purified by RP-HPLC in 
water/acetonitrile with 0.1% TFA.  The product was a green iridescent solid (7.4 mg, 1.4% 
yield).  MS (ESI): 596.2, 297.1 (M-1).  HRMS (ESI): expected m/z 297.07, found m/z 
297.07 ((M-1)/2); expected m/z 617.12, found m/z 617.13 (M-1).   
4.10.2.5 SQ5 
Sodium 3-(ethyl(phenyl)amino)propane-1-sulfonate (4.9)48 
 To a flask was added N-ethylaniline (2.52 mL, 20.0 mmol, 1 eq), 1,3-
propanesultone (1.93 mL, 22.0 mmol, 1.2 eq), and 20 mL of isopropanol.  The reaction 
was refluxed for 24 hr.  The product was isolated by filtration.  The product was taken up 
in water, and the solution was carefully adjusted to pH 7 with 1M NaOH (aq).  The water 
was removed by lyophilization.  The sodium salt was obtained (3.18 g, 60% yield).  1H-
NMR (400 MHz, d-DMSO, ppm): δ 0.97 (t, 3H, CH3), 1.74 (m, 2H, CH2), 2.60 (t, 2H, 
CH2), 3.65 (m, 4H, CH2), 7.60 (broad s, 5H, Ar-H).  MS (ESI): 242.2 (M-1). 
SQ5 
 To a flask was added squaric acid (64 mg, 0.6 mmol, 1 eq), 4.9 (303 mg, 1.2 mmol, 
2.1 eq), 16 mL benzene, and 8 mL n-butanol.  A Dean Stark trap was attached, and the 
reaction was refluxed at 100°C for 30 hr.  The reaction was filtered, and the blue solid was 
washed with isopropanol.  The crude product was purified on a C-18 RediSep column with 
a CombiFlash instrument eluting with water/acetonitrile.  The product was a purple solid 
(5.51 mg, 1.6% yield).  1H-NMR (400 MHz, d-DMSO, ppm): δ 1.13 (t, 6H, CH3), 1.85 (m, 
4H, CH2), 2.45 (m, 4H, CH2), 3.53 (m, 4H, CH2), 3.60 (t, 4H CH2), 6.98 (d, 4H, Ar-H), 
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8.06 (d, 4H, Ar-H).  LRMS (ESI): 281.2 ((M-1)/2).  HRMS (ESI): expected m/z 281.07, 
found m/z 281.07 ((M-1)/2); expected m/z 585.13, found m/z 585.14 (M-1).   
4.10.2.6 SQ6 
SQ625 
 To a flask was added squaric acid (114 mg, 1.0 mmol, 1 eq), 2-(N-
ethylanilino)ethanol (0.3 mL, 1.9 mmol, 1.9 eq), 16 mL benzene, and 8 mL n-butanol.  A 
Dean-Stark trap was attached, and the reaction was refluxed at 100°C for 18 hr.  The 
product was filtered from the reaction and washed with DCM.  The product was a blue 
solid (88.4 mg, 22% yield).  1H-NMR (400 MHz, d-DMSO, ppm): δ 1.14 (t, 6H, CH3), 
3.27 (m, 4H, CH2), 3.59 (m, 4H, CH2), 4.98 (s, 1H, OH), 6.78 (d, 4H, Ar-H), 8.07 (d, 4H, 
Ar-H).  MS (ESI): 409.2 (M+1).   
4.10.2.7 SQ7 
Sodium 3-(ethyl(m-tolyl)amino)propane-1-sulfonate (4.10)48 
 To a flask was added N-ethyl-m-toluidine (2.1 mL, 14.8 mmol. 1 eq), 1,3-
propanesultone (1.8 g, 14.8 mmol, 1 eq), and 20 mL of isopropanol.  The reaction was 
refluxed for 18 hr.  The product did not precipitate from the reaction, so the solvent was 
removed under reduced pressure.  The residue was taken up in water and neutralized to pH 
7 with 1M NaOH (aq).  The aqueous solution became cloudy and was washed two times 
with ether.  The aqueous solution was lyophilized.  The product was a cream-colored solid 
(2.46 g, 65% yield).  1H-NMR (400 MHz, d-DMSO, ppm): δ 1.06 (t, 3H, CH3), 1.76 (m, 
2H, CH2), 2.21 (s, 3H, CH3), 2.43 (m, 2H, CH2), 3.30 (m, 4H, CH2), 6.36 (d, 1H, Ar-H), 
6.47 (m, 2H, Ar-H), 6.99 (t, 1H, Ar-H).  MS (ESI): 256.2 (M-1). 
SQ7 
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 To a flask was added squaric acid (100 mg, 0.9 mmol, 1 eq), 4.10 (489 mg, 1.8 
mmol, 2 eq), 16 mL benzene, and 8 mL n-butanol.  A Dean-Stark trap was attached, and 
the reaction was refluxed at 100°C for 24 hr.  The solvent was removed under reduced 
pressure.  The crude product was purified on a C-18 RediSep column with a CombiFlash 
instrument eluting with water/acetonitrile.  The product was a purple solid (6.8 mg, 1.2% 
yield).  1H-NMR (400 MHz, d-DMSO, ppm): δ 1.15 (t, 6H, CH3), 1.88 (m, 4H, CH2), 2.45 
(m, 4H, CH2), 2.76 (s, 6H, CH3), 3.53 (m, 4H, CH2), 3.58 (t, 4H CH2), 6.77 (d, 2H, Ar-H), 
7.09 (m, 2H, Ar-H), 8.06 (d, 2H, Ar-H).  LRMS (ESI): 295.1 ((M-1)/2), 591.1 (M-1).  
HRMS (ESI): expected m/z 295.09, found m/z 295.09 ((M-1)/2); expected m/z 613.17, 
found m/z 613.17 ((M-1)+Na).   
4.10.2.8 SQ8 
N-ethyl-3-methoxyaniline (4.6)49 
 To a flask was added m-anisidine (4.2 mL, 37.4 mmol, 1 eq), iodoethane (2.3 mL, 
29.9 mmol, 0.8 eq), potassium carbonate (4.0 g, 29.9 mmol, 0.8 eq), and 7 mL DMF.  The 
reaction was heated to 60°C for 24 hr.  Water was added to the reaction mixture, and the 
solution was extracted two times with ethyl acetate.  The organic layer was washed with 
water twice and with brine and then dried with MgSO4.  The solvent was removed under 
reduced pressure.  The crude product was purified on a basic alumina with 10-20% ethyl 
acetate in hexanes.  The product was a brown oil (1.74 g, 31% yield).  1H-NMR (400 MHz, 
CDCl3, ppm): δ 1.24 (t, 3H, CH3), 3.15 (m, 2H, CH2), 3.76 (s, 3H, CH3), 6.18 (s, 1H, Ar-
H), 6.25 (m, 2H, Ar-H), 7.09 (t, 1H, Ar-H).   
Sodium 3-(ethyl(3-methoxyphenyl)amino)propane-1-sulfonate (4.11)48 
 To a flask was added 4.6 (1.74 g, 11.5 mmol, 1 eq), 1,3-propanesultone (1.5 mL, 
17.1 mmol, 1.5 eq), and 10 mL isopropanol.  The reaction was refluxed for 3 hr.  The 
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reaction mixture was concentrated and neutralized with 1M NaOH (aq).  The solvent was 
removed under reduced pressure and lyophilized.  The crude product was recrystallized 
from acetone.  The product was a white solid (1.86 g, 55% yield).  1H-NMR (400 MHz, d-
DMSO, ppm): δ 1.01 (t, 3H, CH3), 1.72 (m, 2H, CH2), 2.41 (m, 2H, CH2), 3.27 (m, 4H, 
CH2), 3.65 (s, 3H, CH3), 6.10 (d, 1H, Ar-H), 6.15 (s, 1H, Ar-H), 6.22 (d, 2H, Ar-H), 6.97 
(t, 1H, Ar-H).  MS (ESI): 272.2 (M-1). 
SQ8 
 To a flask was added squaric acid (70 mg, 0.61 mmol, 1 eq), 4.11 (381 mg, 1.29 
mmol, 2.1 eq), 10 mL benzene, and 5 mL n-butanol.  A Dean-Stark trap was attached, and 
the reaction was refluxed at 100°C for 48 hr.  The reaction mixture was filtered to collect 
the product, washing with ethyl acetate and allowing to dry thoroughly.  The crude product 
was purified on a C-18 RediSep column with a CombiFlash instrument eluting with 
water/acetonitrile.  The product was a purple solid (26.5 mg, 6% yield).  1H-NMR (400 
MHz, d-DMSO, ppm): δ 1.12 (t, 6H, CH3), 1.82 (m, 4H, CH2), 2.45 (m, 4H, CH2), 3.50 
(m, 4H, CH2), 3.65 (t, 4H CH2), 3.83 (s, 6H, CH3), 6.35 (s, 2H, Ar-H), 6.51 (d, 2H, Ar-H), 
8.53 (d, 2H, Ar-H).  LRMS (ESI): 311.2 ((M-1)/2), 623.2 (M-1).  HRMS (ESI): expected 
m/z 311.08, found m/z 311.08 ((M-1)/2); expected m/z 645.16, found m/z 645.15 ((M-
1)+Na).   
4.10.2.9 SQ9 
N-(3-(ethylamino)phenyl)acetamide (4.7)50 
 To a flask was added 3-aminoacetanilide (4 g, 26.6 mmol, 1 eq), iodoethane (1.65 
mL, 21.3 mmol, 0.8 eq), potassium carbonate (3.59 g, 26.6 mmol, 1 eq), and 7 mL DMF.  
The reaction was heated to 60°C for 20 hr.  The reaction was filtered to remove solids.  
Water was added to the solution, and it was extracted three times with ethyl acetate.  The 
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organic layer was washed brine twice and then dried with MgSO4.  The solvent was 
removed under reduced pressure.  The crude product was purified on basic alumina with 
20-100% ethyl acetate in hexanes.  The product was a brown oil (1.42 g, 30% yield).  1H-
NMR (400 MHz, CDCl3, ppm): δ 1.23 (t, 3H, CH3), 2.13 (s, 3H, CH3), 3.13 (m, 2H, CH2), 
6.44 (s, 1H, Ar-H), 6.73 (m, 1H, Ar-H), 7.08 (t, 2H, Ar-H), 7.35 (s, 1H, NH).  MS (ESI): 
179.2 (M+1). 
Sodium 3-((3-acetamidophenyl)(ethyl)amino)propane-1-sulfonate (4.12) 
 To a flask was added 4.7 (0.5 g, 2.8 mmol, 1 eq), 1,3-propanesultone (0.3 mL, 3.4 
mmol, 1.2 eq), and 10 mL acetonitrile.  The reaction was refluxed for 18 hr.  The reaction 
mixture was concentrated.  Water was added to the residue, and the solution was 
neutralized with 1M NaOH (aq).  The solution was washed with DCM and then 
lyophilized.  The product was a white solid (620 mg, 68% yield).  1H-NMR (400 MHz, d-
DMSO, ppm): δ 1.02 (t, 3H, CH3), 1.74 (m, 2H, CH2), 1.96 (s, 3H, CH3), 2.35 (m, 2H, 
CH2), 3.23 (m, 4H, CH2), 6.33 (d, 1H, Ar-H), 6.84 (m, 2H, Ar-H), 6.97 (t, 1H, Ar-H), 9.65 
(s, 1H, NH).  13C-NMR (400 MHz, d-DMSO, ppm): δ 11.09 (CH3), 22.55 (CH3), 22.68 
(CH2), 27.82 (CH2), 48.67 (CH2), 60.41 (CH2), 104.06 (Ar-C), 107.75 (Ar-C), 108.57 (Ar-
C), 129.07 (Ar-C), 139.37 (Ar-C), 148.02 (Ar-C), 170.18 (C=O).  LRMS (ESI): 299.2 (M-
1). HRMS (ESI): expected m/z 299.11, found m/z 299.11 (M-1)  
SQ9 
 To a flask was added squaric acid (70 mg, 0.61 mmol, 1 eq), 4.12 (416 mg, 1.3 
mmol, 2.1 eq), 5 mL benzene, and 5 mL n-butanol.  A Dean-Stark trap was attached, and 
the reaction was refluxed at 100°C for 48 hr.  The reaction mixture was filtered to collect 
the product, washing with ethyl acetate and isopropanol and allowing to dry thoroughly.  
The product was a green solid and required no further purification (212 mg, 49% yield).  
1H-NMR (400 MHz, d-DMSO, ppm): δ 1.24 (t, 6H, CH3), 1.86 (m, 4H, CH2), 2.17 (s, 3H, 
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CH3), 2.39 (m, 4H, CH2), 3.36 (m, 4H, CH2), 3.55 (m, 4H CH2), 6.76 (d, 2H, Ar-H), 8.06 
(s, 2H, Ar-H), 8.28 (d, 2H, Ar-H) 11.94 (s, 1H, NH).  LRMS (ESI): 338.2 ((M-1)/2).  
HRMS (ESI): expected m/z 338.09, found m/z 338.09 ((M-1)/2); expected m/z 699.18, 
found m/z 699.18 ((M-1)+Na).   
4.10.2.10 c-BSA 
 BSA (332 mg, 5 µmol, 1 eq) was dissolved in 15 mL of 50 mM phosphate buffer, 
10 mM EDTA, H2O, pH 7.5.  Iodoacetamide (9.24 mg, 50 µmol, 10 eq) was added, and 
the reaction was stirred for 5 hr.  The reaction mixture was filtered to remove any insoluble 
components and purified against 10 mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3 with 
10 kDa MWCO centrifugal filter units.  The concentration of the protein in the solution 
was measured by the Bradford method (Section 5.9.6.1).  The thiol content was measured 
by Ellman’s test (Section 5.9.6.2) and was found to be zero. 
4.10.3 Titrations 
The procedure for each titration is described in the caption of the figure that 
displays the results.   
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4.11 ADDITIONAL FIGURES AND EXPERIMENTS 
4.11.1 1H NMR Monitoring of Thiol Addition 
 
Figure 4.54 1H NMR of SQ5 in D2O.  SQ5 800 µM. 
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Figure 4.55 1H NMR of SQ5 and thiol in D2O taken immediately after preparation.  SQ5 
800 µM, NAC 800 µM. 
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Figure 4.56 1HNMR of SQ5 and thiol in D2O .taken 24 hr after the sample was 
prepared.  SQ5 800 µM, NAC 800 µM 
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4.11.2 Titrations of Thiol into BSA/SQ 
  
Figure 4.57  Titration of thiol into SQ4/BSA.  A solution of BSA (10µM) and SQ4 (10 
µM) was titrated with NAC (0-254 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3.   
 
Figure 4.58  Titration of thiol into SQ5/BSA.  A solution of BSA (10 µM) and SQ5 (10 
µM) was titrated with NAC (0-14 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3.   
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Figure 4.59  Titration of thiol into SQ7/BSA.  A solution of BSA (10 µM) and SQ7 (10 
µM) was titrated with NAC (0-14 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3.   
 
  
Figure 4.60  Titration of thiol into SQ8/BSA.  A solution of BSA (10 µM) and SQ8 (10 
µM) was titrated with NAC (0-92 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3. 
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Figure 4.61  Titration of thiol into SQ9/BSA.  A solution of BSA (10 µM) and SQ9 (10 
µM) was titrated with NAC (0-86 µM) in 10 mM phosphate buffer, H2O, 
pH 7.00, 0.02% NaN3.   
4.11.3 Titrations of G5 PAMAM Dendrimer into SQ5 
Amine-terminated PAMAM dendrimers are known to bind numerous anionic dyes, 
so we tested such a dendrimer (G5) for binding to SQ5 as a potential alternative scaffold 
to serum albumin.51,52  Ultimately, we were concerned, as we were with serum albumin, 
that the squaraine could be reacting with amines in the dendrimer. 
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Figure 4.62 Fluorescence titration of G5 dendrimer into SQ5.  Addition of G5 (0-85 
µM) to SQ5 (2 µM) in 50 mM HEPES buffer, H2O, pH 7.4, λex = 640 nm.  
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Figure 4.63 Displacement of carboxyfluorescein from G5 dendrimer by SQ5, SQ5/NAC, 
and SQ/VVKLKC.  To carboxyfluorescein (2 µM) and G5 dendrimer (0.67 
µM) was added SQ5 (0-32 µM), SQ5/NAC (0-33 µM), and SQ5/VVKLKC 
(0-33 µM) in 50 mM HEPES buffer, H2O, pH 7.4, λex = 485 nm. 
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Chapter 5: Development of Dynamic Receptors from Serum Albumin 
and Thia-Michael Addition Chemistry 
5.1 INTRODUCTION 
 As another strategy for building dynamic receptors, we sought to construct large, 
multivalent receptors from serum albumin by reversible covalent attachment of recognition 
units.  Rather than relying on non-covalent association of the units with serum albumin, as 
was the case with the fatty acid-peptides (Chapter 3) and squaraines (Chapter 4), the units 
in this design would be covalently anchored to the protein.  Thus, the bulk of our work 
went toward developing a suitable protein-labeling protocol that incorporated a reversible 
covalent linkage.   
5.1.1 Dynamic Combinatorial Chemistry 
 Dynamic combinatorial chemistry (DCC) uses reversible covalent bonding to 
generate libraries of compounds under thermodynamic control.1–3  In the presence of a 
guest molecule, the distribution of the species in the dynamic combinatorial library (DCL) 
will change as a function of the affinity of each species for the guest, according to Le 
Chatelier’s principle.  In this way, the species with the highest affinity for the guest will be 
selected for, while poor binders will be sacrificed (Figure 5.1).  The best receptors for the 
guest are not only identified but also amplified in this process.  This technique has been 
used to identify receptors for a variety of molecules, most notably biologically significant 
ones.4–10  
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Figure 5.1 Illustration of a small dynamic combinatorial library (DCL) and the effect 
of a template on the free energy of library species.  (Reprinted from Ref- 
Otto Science paper: © Association for the Advancement of Science, 2002). 
5.1.1.1 Reversible Covalent Bonding 
Chemical reactions that have been used for building DCLs for biological targets 
include C=N, S-S, and S-C bond-forming reactions.3,11  Chemical reactions that are suitable 
for DCC must be readily reversible and thus be under thermodynamic control.  Many 
organic reactions require heating to high temperatures and extended reaction times to 
achieve thermodynamic control.12  DCLs for biological targets such as proteins must be 
able to function under physiological or near physiological conditions (e.g. neutral pH, 
ambient pressure, mild temperatures).  Other biologically-relevant targets such as peptides 
or natural products could theoretically survive a more extreme environment.  However, the 
context of receptor identification is important for future utility of the receptor or receptors 
identified.  For instance, a good receptor for a target compound at pH 12 might not be such 
a good receptor for that compound at pH 7.4, depending on the binding interactions at 
work.  Thus, there are relatively few reactions suitable for constructing DCLs for 
biologically-relevant targets.   
In this work, we sought to develop the use of thia-Michael reactions as the basis for 
DCLs (Scheme 5.1).  Conjugate addition reactions are relative newcomers to the DCC tool 
box,11 and studies are still ongoing with respect to developing specific conjugate acceptor 
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substrates and reaction conditions that meet the criteria described above.13,14  Therefore, 
we chose the thia-Michael reaction for our work because this type of reversible covalent 
reaction has not been as thoroughly studied or widely used as other reactions such as 
disulfide exchange.  By incorporating thia-Michael chemistry into our protein receptors, 
we aimed to expand our basic understanding of these reactions for use in DCLs.   
 
 
Scheme 5.1 Thia-Michael reaction. 
5.1.2 Protein Modification and Conjugation  
 Proteins are common targets for modification and conjugation for a variety of 
purposes.15  Proteins can be modified to introduce a specific functionality (e.g. thiol, amine, 
carboxylate), to block a specific native functionality, or even to link the protein to another 
species (e.g. a fluorescent tag, another protein). The amino acids within proteins that are 
typically used for modification and conjugation purposes are the ones with ionizable side 
chains: aspartic acid, glutamic acid, lysine, arginine, cysteine, histidine, and tyrosine.  
When deprotonated, these side chains can be sufficiently nucleophilic to add to 
electrophiles.  A variety of electrophilic reagents are commercially available for reacting 
with these side chains.  Some considerations in protein modification include the selectivity 
of the reaction, the reaction conditions necessary (e.g. temperature, pH, solvent), the 
solvent accessibility of the targeted side chains, and the effect of the modification on the 
secondary, tertiary, and quaternary structure of the protein.   
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5.1.3 Characterization of Modified Proteins and Protein Conjugates 
 Once a protein has been chemically modified, this new species must be 
characterized to determine if the desired modification occurred at all, and if so, to what 
extent.  Common methods for characterizing organic small molecules such as 1H NMR are 
difficult to apply to modified proteins due to the complexity of the data generated.  If a 
specific functionality of the protein has been blocked or a specific functionality has been 
added to the protein, then chemical tests are often used to measure these modifications.15  
These tests utilize a reagent that reacts with the functionality of interest with some known 
stoichiometry, resulting in a fluorescent or colorimetric byproduct that can be quantified 
spectrophotometrically.  For example, Ellman’s test is used to quantify thiol.16–18  In this 
chemical test, 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) reacts with thiols to produce 2-
nitro-5-sulfidobenzoate, a yellow compound that can be quantified spectrophotometrically 
(Scheme 5.2).  Another example is the ninhydrin test, which quantifies primary amines by 
the purple byproduct of their reaction with ninhydrin (Scheme 5.3).19,20 
 
 
Scheme 5.2 Ellman’s test for thiol using DTNB reagent.   
 
Scheme 5.3 Ninhydrin test for primary amines.  
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For protein conjugates, the characterization can be case-specific.  For instance, if a 
protein is conjugated to a fluorophore, the emission of that moiety is measured to detect 
the modification.  However, if the conjugated species does not provide a simple and 
selective detection method, then more general procedures are applied.  In order to measure 
the approximate molecular weight of the modified protein, SDS-PAGE or gel-filtration 
chromatography with molecular weight markers are used.21   
Tandem mass spectrometry has found extensive use as a bottom-up proteomics tool 
for detecting and characterizing modified amino acids in proteins.22–25  In bottom-up 
protein analysis, the protein is first digested by a protease into peptides (Figure 5.2).  The 
peptides are separated by liquid chromatography (LC) and then ionized, usually by 
electrospray (ESI).  Then the peptides are subjected to tandem mass spectrometry with one 
or more dissociation steps (MSX, where X ≥ 2 since one mass spectrometer is always 
necessary for the ion analysis at the end of the fragmentation step/s).  Each peptide is 
fragmented along the amide backbone.  Collision-induced dissociation by a neutral gas is 
the most common fragmentation method (Figure 5.3).26,27  In this process, the amide 
backbone is broken to yield b- and y-type cations (Figure 5.4).  These fragmentation 
patterns are used to identify modified amino acids by comparison to the peptide fragments 
expected from the native protein.  In this way, both the type and location of the conjugated 
groups are determined.  It is also possible to obtain some quantitative or semi-quantitative 
information about the number of modifications of each type at each location.   This 
methodology is a powerful tool for obtaining detailed information about protein 
conjugates.   
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Figure 5.2 Bottom-up mass spectrometric analysis of proteins. (Image by Drs. Jared 
Shaw and Jennifer Brodbelt) 
 
Figure 5.3 Collision-induced dissociation by helium gas. (Image by Drs. Jared Shaw 
and Jennifer Brodbelt) 
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Figure 5.4 Collision-induced dissociation yields b- and y-ions. (Image by Drs. Jared 
Shaw and Jennifer Brodbelt) 
5.2 PARTIAL REDUCTION OF SERUM ALBUMIN 
Bovine serum albumin contains 35 cysteine residues in 17 disulfide bonds and one 
additional free cysteine.28  As a way of generating more thiols on serum albumin, some of 
these disulfide bonds were reduced.  Following the procedure of Grinnell et al.,21 
dithiothreitol (DTT) was used as a reducing agent (Scheme 5.4).  The buffer was 
deoxygenated by sparging with nitrogen to prevent reoxidation of the thiols.  A sample of 
BSA was exposed to DTT under nitrogen, and then any excess DTT was removed by 
dialysis.   
 
Scheme 5.4 Reduction of disulfides by dithiothreitol (DTT). 
The thiol was quantified by Ellman’s test.17   An average of 20 thiols per BSA 
molecule were obtained from the reduction.  The reduced BSA (r-BSA) was prone to 
reoxidation in air, readily precipitating or forming a gel due to disulfide crosslinking 
between proteins.29  Nevertheless, r-BSA was reacted with alkylating agents, including 
iodoacetamide and maleimide, to cap the thiols.  Eventually we wanted to use conjugate 
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acceptor-appended recognition units, but at this point we just needed to cap the thiols with 
something to obtain a stable sample.  However, the alkylated r-BSA became insoluble in 
water.  Such problems with reduced serum albumin samples have been reported,21,29,30 and 
we decided to abandon this approach.  
5.3 THIOLATION OF SERUM ALBUMIN 
As an alternative strategy to reduction of serum albumin, we next explored 
thiolation of the protein.  The ε-amine of lysine residues can be thiolated using N-
acetylhomocysteine thiolactone (AHTL) or N-succinimidyl S-acetylthioacetate (SATA).15  
We investigated the use of both thiolating agents, and also synthesized our own derivative 
of SATA with an S-trityl rather than an S-acetyl group (STTA).   
5.3.1 N-acetylhomocysteine thiolactone (AHTL) 
AHTL is activated by silver ion coordination.31,32  The amine attacks the activated 
carbonyl of the thiolactone, opening the ring to yield a free thiolate (Scheme 5.5).  The 
silver then coordinates to this free thiolate and must be removed by acidification and ion 
exchange chromatography to yield the thiol. 
 
 
Scheme 5.5 Thiolation of BSA by AHTL and silver nitrate. 
5.3.1.1 Capping with Iodoacetamide 
A sample of BSA was thiolated with AHTL and silver nitrate (t-BSA), and the thiol 
content was measured by Ellman’s test (18 thiols per BSA).  The pH of the sample was 
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adjusted back up to 7, and iodoacetamide was added to alkylate the t-BSA (c-t-BSA) 
(Scheme 5.6).  Alkylation was confirmed by a negative Ellman’s test.  With the c-t-BSA 
sample in hand, we wanted to determine if the protein had been significantly denatured by 
the chemical modification.  Thus, we titrated several fluorescent indicators with native 
BSA and c-t-BSA to compare (Figures 5.5-5.7).  We used NBD-FA (Chapter 2, 3, and 4), 
carboxyfluorescein (CF), and 2-anthracenecarboxylate (AC, Chapter 2 and 3).   In each 
case, we observed that c-t-BSA binds the indicators less strongly than native BSA, 
indicating that some denaturation of the protein occurred upon modification.  However, the 
indicators did still bind to c-t-BSA, so we knew that we had not completely denatured the 
protein by modifying it.   
 
 
Scheme 5.6 Alkylation of thiol by iodoacetamide. 
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Figure 5.5  Titration of BSA and c-t-BSA into NBD-FA.  BSA (0-68 µM) and c-t-BSA 
(0-73 µM) were added to NBD-FA (15.3 µM) in 10 mM phosphate buffer, 
H2O, pH 7.00, 0.02% NaN3, λex = 470 nm. 
 
Figure 5.6  Titration of BSA and c-t-BSA into CF.  BSA (0-52 µM) and c-t-BSA (0-52 
µM) were added to CF (10 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3, λex = 490 nm. 
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Figure 5.7  Titration of BSA and c-t-BSA into AC.  BSA (0-39 µM) and c-t-BSA (0-39 
µM) were added to AC (10 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3, λex = 386 nm. 
5.3.1.1 Capping with Methyl Vinyl Ketone 
Since we ultimately wanted to react the new thiols that we were installing on BSA 
with conjugate acceptors, we switched to methyl vinyl ketone (MVK) for our capping 
agent.  A sample of BSA was thiolated with AHTL (17 thiol per BSA by Ellman’s test), 
and the thiols were reacted with MVK (Scheme 5.7).  We titrated this sample (k-t-BSA) 
into 1,8-anilinonaphthalene sulfonate (ANS, Chapter 2 and 3) in order to study the state of 
the serum albumin’s structure (Figure 5.8).  ANS binds in the crevices between domains 
of serum albumin, so it is a good indicator of denaturation of the protein.33  From our 
titration, we observed that the k-t-BSA was unfolded somewhat compared to native BSA.  
However, some ANS could still bind, so the protein was not completely unfolded.  
 
 
Scheme 5.7 Alkylation of thiol by methyl vinyl ketone (MVK). 
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Figure 5.8  Titration of BSA and k-t-BSA into ANS.  BSA (0-42 µM) and c-t-BSA (0-
46 µM) were added to ANS (10 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3, λex = 400 nm. 
At this point we began to explore characterization of the modified protein samples 
by mass spectrometry.  To prepare the sample for analysis, the protein was fully reduced 
with DTT, and the exposed thiols were capped with iodoacetamide. Then, the protein was 
digested with endoproteinase Glu-C, which cleaves primarily at glutamic acid residues but 
also, to a lesser extent, at aspartic acid (Scheme 5.8).34  The resultant peptide mixture was 
separated on a C-18 column and then introduced to the mass spectrometer by electrospray 
ionization (ESI).  Collision-induced dissociation was used to fragment the peptides in order 
to sequence them (MS2).  In this way, the exact lysines that had been modified were 
identified by a protein database search.   
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Scheme 5.8 Cleavage of endoproteinase Glu-C. 
 Thirteen lysines were identified as having been thiolated and then capped with 
MVK (Lys-12, 41, 159, 173, 232, 239, 280, 294, 322, 350, 465, 544, and 573).  Two lysines 
had been thiolated but were alkylated with iodoacetamide during the MS sample 
preparation (Lys-41, 285), and several lysines were alkylated directly by MVK (Lys-57, 
93, 132, 136, 159, 294, 499, and 544).  Only 60% sequence coverage was achieved, 
probably due to incomplete digestion, so this data likely represents only some of the 
modifications present.  
5.3.2 N-succinimidyl S-acetylthioacetate (SATA) 
We also tested SATA for thiolating serum albumin.  The amine of lysine adds to 
the activated ester of SATA, forming an amide bond and installing an S-acetyl protected 
thiol (Scheme 5.9).35  The thiol is deprotected by treatment with hydroxylamine.   
 
 
Scheme 5.9 Thiolation of BSA by SATA and hydroxylamine. 
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 BSA was reacted with 30 equivalents of SATA.  The resultant sample (p-t-BSA) 
was subjected to a quantitative ninhydrin test to determine how many lysine residues had 
been thiolated.  The test indicated that 19 lysines,per BSA had been thiolated.  The 
solubility of this p-t-BSA sample was problematic, presumably because many of the 
charged groups on the protein surface had been blocked with a neutral species.  However, 
using a small amount of DMSO (4% v/v) helped the protein to fully dissolve in buffer.  
Before we deprotected the thiol and created the opportunity for disulfide formation 
and aggregation of the proteins, the p-t-BSA sample was titrated it into NBD-FA to probe 
its structure (Figure 5.9).  From this experiment, we could see that the modified protein 
was somewhat denatured compared to native BSA, which was consistent with our t-BSA 
samples prepared from AHTL. 
 
 
Figure 5.9  Titration of BSA and p-t-BSA into NBD-FA.  BSA (0-51 µM) and p-t-BSA 
(0-51 µM) were added to NBD-FA (10 µM) in 10 mM phosphate buffer, 
H2O, pH 7.00, 0.02% NaN3, λex = 470 nm. 
The p-t-BSA was deprotected with hydroxylamine, but the Ellman’s test of the t-
BSA indicated only 4 thiols per BSA, which is much lower than the ninhydrin test for 
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amine indicated.  Furthermore, the MS analysis found only that some lysines had been 
acetylated by SATA, and none had the expected S-acetylthioglycolate modification.   
A new batch of SATA was purchased from a different vendor, and the procedure 
was repeated with BSA and 50 equivalents of SATA to yield a new p-t-BSA sample.  A 
portion of the sample was submitted for MS analysis, and the rest was deprotected with 
hydroxylamine to free the thiols.  An Ellman’s test of this t-BSA sample indicated 13 thiols 
per BSA.  Furthermore, the MS analysis of p-t-BSA identified 11 lysines that had an S-
acetylthioglycolate moiety (Lys- 41, 64, 93, 131, 159, 239, 499, 520, 537, 544, and 573).  
The t-BSA sample was reacted with MVK to alkylate the thiols.  This k-t-BSA sample was 
also analyzed by MS: 21 lysines were found to have been thiolated and then reacted with 
MVK (Lys- 12, 41, 64, 93, 127, 131, 132, 136, 159, 211, 221, 224, 294, 322, 350, 414, 
520, 523, 524, 544, and 573).  This result, while positive, was rather inconsistent with the 
MS analysis and Ellman test of the corresponding p-t-BSA sample, which indicated fewer 
modifications.   
Thus, new k-t-BSA samples were prepared in the same way to study the 
reproducibility of the modification procedure.  The Ellman test indicated only 6 thiols per 
BSA and 10 thiols per BSA for theses t-BSA samples; however, the MS results for the 
corresponding k-t-BSA samples found many of the same modifications as the first k-t-BSA 
(Table 5.1).  One of the replicate samples (#2) was used for binding studies (Figures 5.10-
5.12).  As with the other modified serum albumin samples, k-t-BSA did not bind the 
fluorescent indicators as strongly as native BSA, indicating some degree of denaturation 
due to the modification.  
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Table 5.1 Summary of the lysine modifications of the p-t-BSA replicate samples. 
Modification Type Sample 1 Sample 2 Sample 3 
 
(lysine was thiolated, 
deprotected, and reacted 
with MVK) 
Lys-12, 41, 64, 
93, 127, 131, 
132, 136, 159, 
211, 221, 224, 
294, 322, 350, 
413, 520, 523, 
524, 544, 573 
Lys-12, 41, 64, 
93, 131, 132, 
136, 159, 211, 
221, 224, 294, 
322, 350, 413, 
520, 523, 524, 
544, 573 
Lys- 12, 41, 64, 
93, 127, 131, 
132, 136, 159, 
294, 322, 350, 
465, 499, 520, 
523, 524, 544, 
573 
 
(lysine was thiolated but 
not deprotected) 
280, 537 280, 322 12, 173, 285, 
520, 533, 535, 
573 
 
(lysine was thiolated and 
deprotected but did not 
react with MVK) 
136 322, 544 51, 180 
 
 
Figure 5.10  Titration of BSA and k-t-BSA into NBD-FA.  BSA (0-69 µM) and k-t-BSA 
(0-68 µM) were added to NBD-FA (10 µM) in 10 mM phosphate buffer, 
H2O, pH 7.00, 0.02% NaN3, λex = 470 nm. 
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Figure 5.11  Titration of BSA and k-t-BSA into ANS.  BSA (0-62 µM) and k-t-BSA (0-
68 µM) were added to ANS (10 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3, λex = 400 nm. 
 
 
Figure 5.12  Titration of BSA and k-t-BSA into AC.  BSA (0-43 µM) and k-t-BSA (0-50 
µM) were added to ANS (8.3 µM) in 10 mM phosphate buffer, H2O, pH 
7.00, 0.02% NaN3, λex = 386 nm. 
As we continued to repeat the thiolation with SATA and subsequent reaction with 
MVK, we observed a significant amount of acetylation of lysines (around 20 lysines) and 
fewer of the desired modifications (around 8 lysines) with new samples.  We also detected 
many more lysines that had been thiolated and deprotected but had not reacted with MVK, 
0
50000
100000
150000
200000
250000
-1 1 3 5 7
C
h
an
g
e 
in
 e
m
is
si
o
n
 @
 4
7
0
 n
m
Equivs serum albumin
BSA
ktBSA
-250000
-200000
-150000
-100000
-50000
0
0 2 4 6
C
h
an
g
e 
in
 e
m
is
si
o
n
 @
 4
2
0
 n
m
Equivs serum albumin
BSA
ktBSA
 242 
presumably because these thiols were tied up in disulfide bonds during the alkylation 
procedure (around 17 lysines).   
5.3.3 N-succinimidyl S-tritylthioacetate (STTA) 
 We synthesized our own variant of SATA with a trityl protecting group that could 
be removed by acid (Scheme 5.10).  This modification was desirable because we were 
concerned with disulfide bond formation during the deprotection of SATA, which was 
performed as neutral pH.  If the deprotection could be done under acidic conditions, then 
disulfide bond formation would be inhibited, at least until the pH was brought back up for 
the alkylation of t-BSA by MVK.  Thioglycolic acid was trityl protected according to a 
literature procedure.36  Then the acid was esterified with N-hydroxysuccimide.35  
 
 
Scheme 5.10 Synthesis of STTA. 
 BSA was reacted with 100 equivalents of STTA, and the protected sample was 
submitted for MS analysis (Scheme 5.11).  The p-t-BSA had only a few of the desired 
modifications (Lys-20, 41, 64, 159, 242, 294, 350, 544, and 573).  The removal of the trityl 
group was attempted by acidifying the p-t-BSA solution with HCl to a pH of 2.  However, 
the protein began to precipitate at this low pH, and the trityl group did not appear to have 
been removed according to a negative Ellman’s test.  This procedure was repeated with 
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TFA instead of HCl, but again no Ellman-positive thiol was generated.  We concluded that 
the acidity necessary to remove the trityl group precipitates the protein, so this reagent is 
not suitable for use with proteins. 
 
 
Scheme 5.11 Thiolation of BSA by STTA and subsequent deprotection and reaction 
with MVK. 
5.3.4 Synthesis of a Conjugate Acceptor 
While most of our efforts went toward generating more thiol groups on serum 
albumin, we did begin to synthesize a conjugate acceptor partner to react with these thiols.  
We designed the synthesis of an α,β-unsaturated ketone with an azide (Scheme 5.12).  We 
wanted to use an α,β-unsaturated ketones because they are more reactive than their 
corresponding ester or amide.13  The desired recognition units (e.g. peptides, boronic acids) 
could be attached to the conjugate acceptor by copper-catalyzed alkyne-azide 
cycloaddition (CuAAC).37,38  However, the Stille coupling to install the vinyl group was 
unsuccessful.  The azide was reduced to the amine instead, probably by a Staudinger 
reduction.   
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Scheme 5.12 Attempted synthesis of the conjugate acceptor. 
5.3.5 Summary 
While our initial strategy to partially reduce serum albumin resulted in unstable and 
insoluble samples, we were able to use both AHTL and SATA to thiolate serum albumin, 
adding as many as twenty thiols per protein.  We further demonstrated that these thiols 
could be alkylated with a conjugate acceptor.  We characterized these modified BSA 
samples using chemical tests (Ellman, ninhydrin) and by mass spectrometry.  However, we 
became concerned that the thiolated proteins were aggregating and then crosslinking 
through disulfide bond formation.  Additionally, the thiolation reactions with SATA 
became inconsistent in later samples.  Finally, we were struggling with the synthesis of an 
α,β-unsaturated ketone that could be easily conjugated to recognition units.  Thus, we 
switched to an alternative strategy. 
5.4 LABELLING OF SERUM ALBUMIN BY A CONJUGATE ACCEPTOR (EVACA) 
As an different approach to labeling serum albumin, we became interested in the 
chemistry of 5-alkylidene-2,2-dimethyl-1,3-dioxane-4,6-dione derivatives such as the one 
shown in Scheme 5.13.  The particular derivative shown, which we dubbed EvaCA, was 
reported by Wentrup and coworkers to add amines.39,40  EvaCA was synthesized according 
to their procedure from Meldrum’s acid, carbon disulfide, and methyliodide (Scheme 
5.13).  While Wentrup et al. observed that EvaCA added two amines, we hypothesized that 
the addition of one amine deactivates the conjugate acceptor to further addition due to 
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resonance donation by the nitrogen.  Then, a thiol would add more readily than a second 
amine to EvaCA, due to its greater nucleophilicity.  Thus, EvaCA could be used as a 
selective crosslinking agent for amines and thiols.   
 
Scheme 5.13 Synthesis of EvaCA. 
5.4.1 Reactions of EvaCA with Lysine and Cysteine 
5.4.1.1 Lysine and Cysteine 
First, we wanted to test our hypothesis about the reactivity of EvaCA.  EvaCA was 
reacted with α-Boc-lysine (Scheme 5.14).  Nitrogen was bubbled through the solution to 
aid in removing methyl mercaptan gas from the solution.  The reaction progress was 
monitored by LC-MS.   
 
Scheme 5.14 Reaction of EvaCA with α-Boc-lysine to form LysEva. 
 For these reactions, aqueous phosphate buffer at pH 7.2 or 7.5 was used, and there 
was no measurable difference in the speed of the reaction between the two pHs.  We found 
a strong concentration dependence on the speed of the reaction.  For example, a reaction 
that was 37 mM in EvaCA and α-Boc-lysine completed in about 18 hours, while a reaction 
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that was 8 mM in EvaCA and α-Boc-lysine completed in about 72 hours.  One equivalent 
of lysine was used, and no diaddition product (LysEvaLys) was observed under these 
conditions, which supports our hypothesis about EvaCA’s reactivity.   
 Next, NAC was added to LysEva at the same pH (Scheme 5.15).  The nitrogen flow 
was continued, and the reaction was again monitored by LC-MS.  The reaction took over 
about a week to reach 90% conversion of LysEva to LysEvaCys.   
 
 
Scheme 5.15 Reaction of LysEva with N-acetylcysteine (NAC) to form LysEvaCys. 
5.4.1.2 Lysine 
Looking toward reacting EvaCA with serum albumin, we wanted to know if two 
amines would be able to add to EvaCA under our conditions.  If two amines could readily 
add, then there could be crosslinking between proteins, which would be undesirable.  
EvaCA was reacted with five equivalents of α-Boc-lysine at pH 8 and 45 °C (Scheme 
5.16).  After 18 hours, an aliquot of the reaction was taken and analyzed by LC-MS.  The 
analysis showed that only a small amount of LysEvaLys had formed.  Thus, under the 
conditions we would be using for BSA labeling, we expected only one lysine to add to each 
EvaCA. 
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Scheme 5.16 Reaction of EvaCA with excess α-Boc-lysine to form LysEvaLys. 
5.4.1.2 Cysteine 
Due to the relatively slow addition of cysteine to LysEva, we wanted to explore 
other approaches to using EvaCA to label the protein.  If we could essentially exchange 
out methyl mercaptan for other thiols, then we could use the resultant CysEvaCys to label 
the lysines of serum albumin in one step.  To test this hypothesis, EvaCA was reacted with 
two equivalents of NAC at pH 7.5 and room temperature (Scheme 5.17).  After 18 hours, 
the EvaCA was converted entirely to CysEvaCys.  Then, one equivalent of α-Boc-lysine 
was added to the reaction.  After three days, the CysEvaCys had largely been converted to 
LysEvaCys.  While the approach worked, it is wasteful in terms of thiol because one of the 
thiols from each CysEvaCys is lost, and the reaction with an amine takes several days to 
complete. 
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Scheme 5.17 Reaction of EvaCa with NAC to form CysEvaCys and then with α-Boc-
lysine to form LysEvaCys. 
5.4.2 Synthesis of an EvaCA Derivative 
Since LysEva reacted slowly with cysteine, we postulated that a derivative of 
EvaCA from pyridin-2-ylmethanethiol (Scheme 5.18, PyrCA) could be synthesized and 
used for a faster alternative to EvaCA.  If an ion such as copper(II) or zinc(II) was present 
during the reaction of PyrCA with lysine and cysteine, then the pyridin-2-ylmethanethiol 
would be a better leaving group by coordination to the ion (Scheme 5.18).   
 
 
Scheme 5.18 Structure of PyrCA (left) and pyridin-2-ylmethanethiol coordinated to 
copper(II) (right). 
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5.4.2.1 Synthesis of PyrCA via 2-(Bromomethyl)pyridine 
Meldrum’s acid was reacted with carbon disulfide and then with 2-
(bromomethyl)pyridine (BMP) (Scheme 5.19).  However, the reaction did not produce 
PyrCA.  From the TLC and LC-MS analysis, several products were formed, but we were 
unable to identify most of them from their masses.  The reaction was attempted again with 
the free base of BMP.  This time, the mass of the product was identifiable from LC-MS 
analysis of the reaction mixture.  We attempted to isolate the PyrCA by column 
chromatography but were never successful.  The compound seemed to be oxidizing or 
otherwise degrading on the column.   
 
 
Scheme 5.19 Synthesis of PyrCA via 2-(bromomethyl)pyridine. 
5.4.2.2 Synthesis of BenzCA via Benzylbromide 
We synthesized BenzCA from Meldrum’s acid and benzylbromide (BB) (Scheme 
5.20) to confirm that the problem with synthesizing PyrCA had to do with the pyridine.  
The crude product was not purified, but 1H NMR and LCMS analysis of the reaction 
mixture indicated the BenzCA had been produced. 
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Scheme 5.20 Synthesis of BenzCA via benzylbromide.  
5.4.2.3 Synthesis of QuinCA via 2-(Bromomethyl)quinolone 
 Since PyrCA was unstable under ambient conditions, we decided to try to make 
QuinCA from 2-(bromomethyl)quinolone instead (Scheme 5.21).  This derivative also has 
a nitrogen atom for coordinating metal ions, but we hoped that the quinolone would be less 
prone to oxidation.  First, 2-(chloromethyl)quinolin-1-ium chloride was converted to the 
free base and then to the bromide with LiBr.41  The 2-(bromomethyl)quinolone was 
obtained in 39% yield.  Then Meldrums’ acid and 2-(bromomethyl)quinolone were reacted 
together to make QuinCA.  1H NMR and LC-MS analysis of the crude material were not 
indicative of product formation.  As with PyrCA, a variety of products were formed, but 
we could not identify them.  Curiously, the 1H NMR had no peaks in the methylene region 
of the spectrum.  We tried the reaction again according to another procedure for making 
EvaCA that used potassium fluoride as the base instead of triethylamine.  Again, the 1H 
NMR and LC-MS of the crude material did not show product formation.  We attempted to 
isolate the species in the crude mixture to better characterize them, but none of the 
components that we were able to isolate were identifiable as QuinCA.   
 
 
Scheme 5.21 Synthesis of QuinCA via 2-(bromomethyl)quinolone. 
5.4.2.4 Synthesis of PyrCA via Pyridin-2-ylmethanethiol 
As an alternative approach to accessing PyrCA, we made 2-pyridinemethanethiol 
(PMT) and then reacted it with EvaCA.  PMT was synthesized according to a literature 
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procedure in 6.3% yield (Scheme 5.22).42  Then, the PMT was reacted with EvaCA 
(Scheme 5.23).  However, 1H NMR and LC-MS analysis of the crude material did not 
show any product.  Thus, we abandoned our attempts to synthesize PyrCA or QuinCA and 
continued forward with EvaCA.   
 
 
Scheme 5.22 Synthesis of 2-pyridinemethanethiol. 
 
 
Scheme 5.23 Synthesis of PyrCA via 2-pyridinemethanethiol. 
5.4.3 Synthesis of a Model BSA Peptide and Cysteine-Containing Peptides 
For MS analysis of modified BSA samples, the protein had to be digested, and the 
resultant peptides fragmented by CID.  However, since we found that EvaCA can be 
fragmented more easily than the peptide backbone by CID, a model peptide was necessary 
to characterize this fragmentation in order to develop an appropriate method for analysis 
of BSA samples.  Additionally, the model peptide allowed for further studies of EvaCA’s 
reactivity.   
A peptide sequence from BSA that would appear in Glu-C digestion and that 
contained one lysine was selected (IAHRFKDLGE) and synthesized via solid-phase 
peptide synthesis (SPPS).  The N-terminus was acetylated to prevent any reaction with 
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EvaCA (acIAHRFKDLGE).  Then, the crude peptide material was reacted with EvaCA to 
yield acIAHRFK(Eva)DLGE.  The peptide was purified by RP-HPLC, but 
acIAHRFK(Eva)DLGE was not resolved from acAHRFK(Eva)DLGE.  Thus, a mixture of 
the two peptides was obtained and used. 
A series of cysteine-containing peptides were also synthesized for attaching to BSA 
through EvaCA.  Previous work in our group toward the development of receptors built 
from a DNA scaffold used pentapeptides conjugated to a DNA intercalator.43  The same 
peptide motifs from the DNA study were used for initial testing of the serum albumin 
labeling procedure.  These motifs were selected in the DNA study because they were 
known in the literature to bind to specific cancer cell types or cancer cell surface features, 
and the goal of that project was to make receptors to target cancer cell surfaces.  In this 
case, we wanted to start by simply showing that cysteine-containing peptides could be 
appended to serum albumin through EvaCA.  Thus, we used the pentapeptide motifs plus 
a cysteine residue.  The nine peptides were synthesized via SPPS and purified by RP-
HPLC: VVKLKC, KGGRKC, KRGSKC, KRSSKC, KAGLKC, KYPYKC, PRGDKC, 
KDGRKC, and KGARCC.   
5.4.4 Reaction of the Model Peptide with a Cysteine-Containing Peptide 
The model peptides (acIAHRFK(Eva)DLGE and acAHRFK(Eva)DLGE) were 
reacted with VVKLKC (Scheme 5.24).  The resultant sample was analyzed by MS and 
was found to contain the expected crosslinked species.  The reaction took about two weeks 
to complete.  The sample was also used to determine the protocol necessary to analyze the 
peptides from a digest of a sample of BSA functionalized with EvaCA and cysteine-
containing peptides.  It was determined that an MS3 experiment was necessary.  In the first 
mass spectrometer, EvaCA was fragmented.  In the second mass spectrometer, both the 
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peptide from BSA and the cysteine-containing peptide were fragmented to allow for 
sequencing and identification of modified lysines.  The third mass spectrometer analyzed 
the peptide fragments. 
 
 
  
Scheme 5.24 Synthesis of MPEvaVVKLKC. 
5.4.5 Reaction of EvaCA with BSA 
Two samples of BSA were reacted with EvaCA to make BSAEva (Scheme 5.25).  
One of the samples was submitted for MS analysis at this stage, and the other sample was 
further reacted with VVKLKC to make BSAEvaVVKLKC (Scheme 5.26).  The 
BSAEvaVVKLKC was also submitted for MS analysis.  The BSAEva sample was also 
subjected to a ninhydrin test, and it was found that 12 lysines per BSA had been reacted.  
The MS analysis of BSAEva indicated that 14 lysines had been modified with EvaCA (Lys-
12, 20, 51, 64, 131, 159, 242, 261, 273, 312, 350, 362, 535, and 573).  BSAEvaVVKLKC 
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had 14 lysines modified with EvaCA (Lys-12, 20, 51, 64, 131, 173, 180, 273, 350, 362, 
377, 413, 535, and 573) but only two of those modifications also had VVLKLC (Lys-64, 
350).  Figure 5.13 shows the modified lysines of the samples. 
 
 
Scheme 5.25 Synthesis of BSAEva. 
 
Scheme 5.26 Synthesis of BSAEvaVVKLKC. 
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Figure 5.13 Crystal structure of native BSA with the modified lysines in BSAEva and 
BSAEvaVVKLKC highlighted. Key: red- EvaCa in both, orange- EvaCA in 
BSAEva only, blue- EvaCA in BSAEvaVVKLKC only, green- EvaCA and 
peptide in BSAEvaVVKLKC.44 
5.4.6 Alternative Thiols 
Since we were only able to modify two lysines in BSA with VVKLKC, we next 
investigated other thiols.   
5.4.6.1 2-Mercaptoethanol 
 We postulated that a smaller thiol would be more nucleophilic, so we tried reacting 
2-mercaptoethanol with LysEva (LysEvaBME, Scheme 5.27).  The reaction was 
monitored by LC-MS and was found to be complete after five hours.  As hypothesized, this 
reaction was much faster than the cysteine reaction, which took about a week to complete.  
We observed additional species that we could not identify based on their masses, which 
indicated that side reactions were occurring. 
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Scheme 5.27 Synthesis of LysEvaBME. 
5.4.6.2 2-Azidoethanethiol 
We chose a small thiol with an azide group (Scheme 5.28) that we could use 
CuAAC to attach additional units to in a second step.  Thus, 2-azidoethanethiol was 
synthesized according to literature procedure starting from the disulfide of 2-
mercaptoethanol.38,45   
 
 
Scheme 5.28 Synthesis of 2-azidoethanethiol. 
 The thiol was reacted with LysEva to form LysEvaAz (Scheme 5.29). LC-MS 
analysis of the reaction showed the desired product, but there were also other species 
present that could not be identified.  As with 2-mercaptoethanol, side reactions were 
occurring.  
 
 257 
 
Scheme 5.29 Synthesis of LysEvaAz. 
 Next, the LysEvaAz sample was subjected to CuAAC conditions to test if this 
reaction would work (Scheme 5.30).  However, the desired product was not observed.  We 
did observe the mass of the CuAAC product of 2-azidoethanethiol and 3-butyn-1-ol, which 
indicates that the CuAAC reaction was working.  We also did not observe the mass of 
LysEvaAz after the sample was subjected to the CuAAC conditions. 
 
 
Scheme 5.30 Click reaction of 3-butyn-1-ol with LysEvaAz. 
5.4.6.3 2-{2-[2-(2-Mercaptoethoxy)ethoxy]ethoxy}ethanol 
Due to the side reactions observed with the small thiols, we wanted to try a slightly 
larger thiol.  LysEva was reacted with 2-{2-[2-(2-mercaptoethoxy)ethoxy]ethoxy}ethanol 
(MEEEE) to make LysEvaMEEEE (Scheme 5.31).  The reaction proceeded cleanly within 
a day.   
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Scheme 5.31 Synthesis of LysEvaMEEEE. 
 Next, MEEEE was reacted with the model peptide (acIAHRFK(Eva)DLGE and 
acAHRFK(Eva)DLGE) to develop the MS method necessary for characterizing a protein 
modified in this way (Scheme 5.32).   
 
 
Scheme 5.32 Synthesis of MPEvaMEEEE. 
5.4.7 Reaction of EvaCA with Myoglobin 
 In order to simplify the MS analysis, we switched to myoglobin, a smaller protein 
than BSA, that has 19 lysines.  Three replicate reactions of myoglobin with EvaCA and 
then MEEEE were performed to form MyoEvaMEEEE.  The resultant samples were 
digested and analyzed by MS3.  There were five lysines that had been modified with EvaCA 
and MEEEE in all three samples (Lys-17, 46, 56, 134, 148, Figure 5.14).  Thus, using 
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MEEEE we were able to achieve much more efficient labeling of a protein compared to 
cysteine.   
 
 
Figure 5.14 Crystal structure of native myoglobin with the modified lysines 
highlighted.46  
5.4.8 Removal of Amine and Thiol from EvaCA with Dithiothreitol 
 Based on the reactivity of EvaCA that we had observed, we hypothesized that 
dithiothreitol (DTT) could be used to remove the amine and thiol from EvaCA (Scheme 
5.33).  Indeed, when LysEvaCys was reacted with DTT, α-Boc-lysine and NAC were 
liberated, and the DTT-EvaCA adduct shown in Scheme 5.33 was observed by MS.  A 
sample of LysEvaMEEEE was also reacted with DTT, and again we observed liberation of 
α-Boc-lysine and MEEEE and the presence of the DTT-EvaCA adduct.  However, a sample 
of LysEvaLys was inert to DTT, indicating that at least one of the species on EvaCA must 
be a thiol for DTT to effect removal of the groups.   
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Scheme 5.33 Removal of amine and thiol from EvaCA by DTT. 
5.4.8.1 Structure of DTT-EvaCA Adduct and Mechanism of Formation 
We further confirmed the structure of the DTT-EvaCA adduct by 13C NMR to be 
the five-membered ring shown in Scheme 5.33.  We propose that a seven-membered ring 
forms first by attack of both thiols, and then a rearrangement quickly occurs to the more 
stable five-membered ring.  We tested both 2-mercaptoethanol and 1,2-ethanedithiol to 
probe this proposed mechanism.  Neither compound formed a five-membered ring with 
EvaCA.  Thus, we propose that DTT is essential because it contains two thiols.  The alcohol 
of 2-mercaptoethanol is insufficiently nucleophilic to add to EvaCA on the time scale that 
we measured (up to 48 hours).  Furthermore, the thiols in DTT are more nucleophilic due 
to the adjacent electron-withdrawing alcohols compared to the thiols in 1,2-ethanedithiol.   
5.4.8.2 Removal of Label from MyoEvaMEEEE 
 With this knowledge in hand, we wanted to demonstrate that DTT could be used to 
remove the EvaCA label from a protein.   The MyoEvaMEEEE samples were reacted with 
DTT overnight, and then the protein sample was purified by a molecular-weight cutoff 
(MWCO) filter that retains the protein but through which small molecules can pass freely.  
The flow-through solution containing small molecule components of the sample was 
analyzed by MS and was found to contain both MEEEE and the DTT-EvaCA adduct.  
Furthermore, the protein portion of the sample was also analyzed by MS and compared to 
 261 
the spectrum for MyoEvaMEEEE.  The sample that had been subjected to DTT showed 
the mass for unmodified myoglobin (Figure 5.15) and did not match the spectrum for 
MyoEvaMEEEE (Figure 5.16), which showed higher molecular weight species than native 
myoglobin. 
 
 
Figure 5.15 ESI spectrum of MyoEvaMEEEE after DTT treatment. 
 
Figure 5.16 ESI spectrum of MyoEvaMEEEE. 
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5.5 TRIAMINE COMPOUND AS A SCAFFOLD 
Due to our success using EvaCA as a reversible protein label, we wanted to explore 
the use of EvaCA in the generation of DCLs on another scaffold.  We synthesized a 
triamine compound (1,3,5-benzenetrimethanamine) from the corresponding bromide 
according to literature procedure (Scheme 5.34).47,48  The spacing of the amine on the 
benzene ring was intended to prevent the possibility of two amines on the same molecule 
adding to EvaCA. 
 
 
Scheme 5.34 Synthesis of 1,3,5-benzenetrimethanamine. 
5.5.1 Reaction of the Triamine Compound with EvaCA and Cysteine 
The triamine compound was reacted with EvaCA to form PE3 (Scheme 5.35).  The 
solution was sparged gently with nitrogen to remove methyl mercaptan.  The product was 
not very soluble in water, so acetonitrile was added to help solubilize PE3.  Next, PE3 was 
reacted with NAC (Scheme 5.36).  The reaction was monitored over time by LC-MS.  After 
about two days, the reaction had equilibrated, converging on PE3C3.   
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Scheme 5.35 Synthesis of PE3. 
 
Scheme 5.36 Synthesis of PE3C3. 
 PE3C3 was further reacted with DTT to clip the triamine and the cysteine from 
EvaCA.  LC-MS analysis showed no masses corresponding to any of the PExCx 
compounds.  Also, the mass of the DTT-EvaCA adduct was observed.   
5.5.2 Reversibility of the Thiol Addition to PWEva 
  In order to use EvaCA in a dynamic combinatorial library, the addition of the thiol 
must be reversible.  Thus, we investigated the reversibility of the thiol addition to PE3 by 
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first synthesizing PE3C3 and then reacting it with another thiol of comparable 
nucleophilicity (2-mercaptopropionic acid, Scheme 5.37).  The reaction was monitored by 
LC-MS and was found to equilibrate after about five days.  As expected, at equilibrium a 
distribution of the possible species was observed: PE3C3, PE3C2M, PE3CM2, and PE3M3.   
 
 
Scheme 5.37 Thiol exchange on PE3C3 with 2-mercaptopropionic acid. 
5.5.3 Resin-Bound Triamine Compound 
 To aid in the analysis of DCLs generated from PE3, we decided to immobilize the 
triamine compound on a resin via one of the three amines.49  Then we could build a bivalent 
receptor via the remaining two amines using EvaCA and thiol-containing recognition units.  
This immobilization step would allow us to wash away any unattached recognition units 
as well as the analyte of interest after equilibration of the library.  In this way, the 
recognition units that were selected for in the equilibration of the library would remain 
attached to the resin.  These recognition units could then be removed from the resin by 
DTT and analyzed by LC-MS.   
 Thus, we began by attaching the triamine compound to a Tentagel-Br resin50 
according to a literature procedure (Scheme 5.38).51  The functionalization of the resin was 
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characterized by a Kaiser test, which is a colorimetric test for primary amines that uses 
ninhydrin.  After attachment of the triamine compound, the resin tested positive for amine 
by a Kaiser test.  Next, EvaCA was reacted with the resin.  After this reaction, the resin 
was negative for amine by a Kaiser test, indicating that the reaction had worked.   
 
Scheme 5.38 Immobilization of the triamine on a Tentagel S Br resin and subsequent 
reaction with EvaCA. 
 A portion of the functionalized resin was taken and reacted with NAC for about 
three days.  Then the resin was washed thoroughly with water and methanol to remove any 
unattached species.  Finally, the resin was reacted with DTT, and the reaction mixture was 
analyzed by LC-MS.  We found NAC and the DTT-EvaCA adduct, indicating that the 
reactions had worked as anticipated.  Furthermore, the resin tested positive for amine by a 
Kaiser test. 
5.5.4 Dynamic Combinatorial Libraries 
 We hypothesized that we could use the resin-bound EvaCA and thiol-containing 
peptides to make DCLs to template against proteins.52–54  To test our hypothesis, DCLs 
were set up from the functionalized resin and the thiol-containing peptides (KGGRKC, 
KRGSKC, KRSSKC, KAGLKC, KYPYKC, PRGDKC, KDGRKC, and KGARCC). One 
library contained BSA as a test analyte, and the other library contained no protein as a 
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comparison.  The library was allowed to equilibrate for six days, at which time the solution 
was removed from the resin, and the resin was washed thoroughly with water and methanol 
and then was reacted with DTT overnight.  The solution was collected for analysis.  The 
resin was subjected to a Kaiser test and was found to be positive for amine. 
 The same peptide mixture that was used in the libraries was made and used to 
develop a RP-HPLC method for resolving the peptides (Figure 5.17).  The resolution on 
the instrument used was not very good, but the libraries were analyzed with this method 
anyway as a preliminary determination of the content of each sample (Figure 5.18 and 
5.19). Some differences between the peaks in the two libraries were apparent; however, the 
poor resolution and inconsistent retention times made it difficult to draw any solid 
conclusions from this data about the templating effect of the BSA.  However, it was clear 
from the data that the peptides were immobilized on the resin, which confirmed that the 
reaction was working.   
 
Figure 5.17 Separation of the peptide mixture. Top: λ = 254 nm, bottom: λ = 190 nm. 
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Figure 5.18 Separation of the untemplated library. Top: λ = 190 nm, bottom: λ =254 
nm. 
 
 
Figure 5.19 Separation of the library templated against BSA. Top: λ = 190 nm, bottom: 
λ =254 nm. 
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5.6 CONCLUSIONS 
In this work, we developed protocols for chemically modifying proteins to contain 
either thiols or conjugate acceptors.  These functionalities were able to react via thia-
Michael chemistry to attach units to the protein.  We had the most success using EvaCA 
for this purpose.  Before working with proteins, we studied the reactivity of EvaCA and 
found that it reacts with an amine and then is rendered less electrophilic so that the second 
addition is selective for thiol.  Thus, EvaCA can be used as a general crosslinker of an 
amine and a thiol.  Furthermore, we found that DTT can be used to remove the amine and 
thiol from EvaCA, which makes the crosslinking a reversible process.  We used EvaCA to 
reversibly label a sample of myoglobin with a thiol with good reproducibility of the 
modifications.   
Furthermore, using a triamine scaffold, we demonstrated that the thiol addition to 
EvaCA is a dynamic reaction by observing the scrambling of different thiols on the 
triamine.  Then, we immobilized the triamine on a Tentagel S resin and built a DCL out of 
this resin, EvaCA, and thiol-containing peptides.  This DCL was tested for its templating 
effect against BSA as a test analyte.  Preliminary HPLC analysis of the library after removal 
of the peptides from the resin by DTT suggests that there is a template effect from the 
protein.   
5.7 FUTURE WORK 
Further work in the area of protein labeling could include taking the thiol MEEEE 
and transforming the alcohol to an azide, as we did with 2-mercaptoethanol to make 2-
azidoethanethiol.  Then, this thiol could be tested for addition to LysEva and for its 
reactivity toward CuAAC conditions with an alkyne.  If this process proved to be an 
efficient way to conjugate a protein to recognition units, then proteins labeled in this way 
could be used for DCC.   
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For the resin-bound triamine portion of the work, the DCLs should be analyzed 
with a more sophisticated LC-MS instrument to improve the resolution and allow for 
conclusive identification of the peptides.  If the apparent template effect is confirmed, then 
more DCLs could be set up from these peptides to template against different proteins.  The 
data for the DCLs for each protein could be used in conjunction with pattern recognition 
algorithms like LDA and PCA to differentiate the proteins.   
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5.9  EXPERIMENTAL METHODS 
5.9.1 General 
Unless otherwise indicated, chemicals and reagents were obtained from Sigma 
Aldrich and used without further purification.  The resins, amino acids, and coupling 
reagents were obtained from NovaBioChem.  N-succinimidyl S-acetylthioacetate (SATA) 
and 2-anthracene carboxylic acid were obtained from TCI America.  NBD-FA was 
synthesized according to the literature procedure described in Chapter 2.   
HPLC-grade solvents were prepared with 0.1% TFA (v/v) and filtered through a 
0.2 micron filter.  HPLC was performed on a Shimadzu instrument with a preparative C-
18 column using a water and acetonitrile mobile phase.  LC-MS analysis was performed 
on an Agilent 1200 Series HPLC with an Agilent 6130 single quadrupole mass 
spectrometer (ESI and APCI ionization).  1H NMR spectra were obtained on a 400 MHz 
Varian. 
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The fluorescence titration experiments were performed with a PTI fluorimeter 
using an 814 photomultiplier detection system and a 75W xenon short arc lamp.  
Absorbance measurements were taken using a Beckmann Coulter DU-800 UV/VIS 
Spectrophotometer. 
5.9.2 Synthesis 
5.9.2.1 N-succinimidyl S-tritylthioacetate (STTA) 
S-tritylthiolglycolic acid36 
 Thioglycolic acid (3 mL, 43 mmol, 1 eq) and triphenylmethanol (11.2 g, 43 mmol, 
1 eq) were placed in a flask with 30 mL DCM under argon.  Acetic acid (23 mL) and boron 
trifluoride diethyl etherate (7.4 mL, 60 mmol, 1.4 eq) were added to the reaction.  The 
reaction was stirred at room temperature for 1.5 hr.  The solvent was removed under 
reduced pressure, and the product was precipitated with water.  The solid was washed with 
water, acetonitrile, and cold diethyl ether.  The product required no further purification (9.9 
g, 69% yield).  1H-NMR (400 MHz, CDCl3, ppm): δ 3.05 (s, 2H, CH2), 7.30 (m, 9H, Ar-
H), 7.42 (m, 6H, Ar-H). LRMS (ESI): 333.2 (M-1).  
N-succinimidyl S-tritylthioacetate 
 S-tritylglycolic acid (6.7 g, 20 mmol, 1 eq) and N-hydroxylsuccinimide (2.3 g, 20 
mmol, 1 eq) were dissolved in 35 mL dry DCM.  Dicyclohexylcarbodiimide (4.2 g, 20 
mmol, 1 eq) was added, and the reaction was stirred for 18 hr under argon.  The reaction 
mixture was filtered to remove solids, and the solvent was removed under reduced pressure.  
The crude product was recrystallized from isopropanol.  The product was a white 
crystalline solid (3.0 g, 35% yield).  1H-NMR (400 MHz, CDCl3, ppm): δ 2.82 (s, 4H, 
CH2), 3.18 (s, 2H, CH2), 7.23 (m, 3H, Ar-H), 7.31 (m, 6H, Ar-H), 7.42 (m, 6H, Ar-H).  
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13C-NMR (400 MHz, CDCl3, ppm): δ 25.53 (CH2), 31.40 (CH2), 68.01 (C), 127.13 (Ar-
C), 128.23 (Ar-C), 129.48 (Ar-C), 143.52 (Ar-C), 165.05 (C=O), 168. 56 (C=O).   
5.9.2.2 1-(4-azidophenyl)prop-2-en-1-one (attempted) 
 To 4-azidobenzoic acid (1 g, 6 mmol, 1 eq) was added 27 mL of thionyl chloride.  
The reaction was refluxed for 2.5 hr, and the solvent was removed under reduced pressure. 
To this residue was added 10 mL of dry THF, and the flask was placed under argon.  
Tributyl vinyl tin (1.75 mL, 6.0 mmol, 1 eq) and a catalytic amount of 
tetrakis(triphenylphosphine)palladium were added to the reaction.  The reaction was heated 
to reflux for 3 hr.  Then ether was added to the reaction, and solids were removed by 
filtration.  The solution was washed repeatedly with a saturated KF solution (aq) to remove 
tin species.  The solution was washed with brine, dried with MgSO4, and the solvent was 
removed under reduced pressure.  The crude product was analyzed by LC-MS but did not 
contain the desired product. 
5.9.2.3 PyrCA via 2-(bromomethyl)pyridine (attempted) 
 Meldrum’s acid (200 mg, 1.4 mmol, 1 eq), carbon disulfide (0.13 mL, 2.2 mmol, 
1.2 eq), and trimethylamine (0.4 mL, 2.8 mmol, 2 eq) were placed in a flask with 5 mL 
acetonitrile.  The reaction was stirred for 1 hr.  Meanwhile the 2-(bromomethyl)pyridine 
hydrobromide was dissolved in 10 mL of a saturated sodium bicarbonate solution (aq), 
which was stirred briefly.  The solution was extracted three time with ether, and the solvent 
was removed under reduced pressure.  The above reaction was cooled in an ice bath and 
the 2-(bromomethyl)pyridine was added.  The reaction was stirred overnight at room 
temperature.  The solvent was removed under reduced pressure, yielding a black residue.  
Water was added, and the solution was extracted with chloroform three times. The organic 
layer was washed with brine and dried with MgSO4.  The solvent was removed under 
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reduced pressure to yield a reddish-black residue.  1H-NMR and LC-MS analysis did not 
indicate the presence of any product.  Attempts to separate the species present on alumina 
were unsuccessful. 
5.9.2.4 EvaCA40 
To a solution of Meldrum’s acid (10 g, 0.07 mol) in DMSO (30 mL) was added 
triethylamine (14.2 g, 0.14 mol) and carbon disulfide (5.3 g, 0.07 mol).  The reaction was 
stirred for 1 hr at room temperature under argon.  Then methyl iodide (19.9 g, 0.14 mol) 
was added dropwise.  The reaction was stirred for 18 hr.  Then ice was added to precipitate 
the product.  The crude product was recrystallized from methanol (9.5 g, 55% yield). 1H 
NMR (400 MHz, CD3CN, ppm): δ 1.71 (s, 3H, CH3), 2.62 (s, 3H CH3). 
5.9.2.5 BenzCA (attempted) 
Meldrum’s acid (0.5 g, 3.5 mmol, 1 eq), trimethylamine (1 mL, 7.3 mmol, 2.1 eq), 
and carbon disulfide (0.34 mL, 5.6 mmol, 1.6 eq) were placed in a flask under agon with 
10 mL of acetonitrile.  The reaction was stirred for 1 hr, and the benzylbromide (0.86 mL, 
6.9 mmol, 2.0 eq) was added.  The reaction was stirred for 18 hr.  A white precipitate 
formed and was collected by filtration.  The crude product was analyzed by NMR but not 
purified.  1H NMR (400 MHz, CDCl3, ppm): δ 0.63 (s, 3H, CH3), 3.45 (s, 2H, CH2), 7.21 
(m, 5H, Ar-H).  LRMS (ESI): 308.8 (M-1). 
5.9.2.6 QuinCA (attempted) 
2-(bromomethyl)quinolone41 
To 100 mL of water was added 2-(chloromethyl)quinoline hydrochloride (10 g, 
46.7 mmol, 1 eq).  To this solution was added 50 mL 1 M NaOH (aq).  A white precipitate 
formed and was collected.  The solid was recrystallized from hexanes.  The purified solid 
was dissolved in 200 mL THF, and LiBr (40 g, 46.7 mmol, 10 eq) was added. The reaction 
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was heated to reflux for 18 hr.  The reaction was concentrated under reduced pressure.  
Water was added, and the solution was extracted twice with ether.  The ether was washed 
with brine and removed under reduced pressure.  The produce was an orange solid (4.0 g, 
39% yield).  1H NMR (400 MHz, CDCl3, ppm): δ 4.65 (s, 2H, CH2), 7.52 (m, 2H, Ar-H), 
7.66 (t, 1H, Ar-H), 7.76 (d, 1H, Ar-H), 7.99 (d, 1H, Ar-H), 8.10 (d, 1H, Ar-H).   
QuinCA (attempted) 
Meldrum’s acid (650 mg, 4.5 mmol, 1 eq), carbon disulfide (0.33 mL, 5.6 mmol, 
1.6 eq), and trimethylamine (1.25 mL, 9.0 mmol, 2.1 eq) were placed in a flask with 10 mL 
acetonitrile.  The reaction was stirred for 1 hr.  The above reaction was cooled in an ice 
bath and the 2-(bromomethyl)quinoline was added.  The reaction was stirred overnight at 
room temperature.  A yellow precipitate had formed and was collected by filtration.  1H-
NMR and LC-MS analysis did not indicate the presence of any product.  Attempts to 
separate the components of the reaction mixture on alumina were unsuccessful. 
5.9.2.7 PyrCA via 2-pyridinemethanethiol (attempted) 
2-pyridinemethanethiol41 
 Thiourea (1.28 g, 15.2 mmol, 1.1 eq) and 2-(chloromethyl)pyridine hydrochloride 
(2.5 g, 15.0 mol, 1 eq) were dissolved in 20 mL of water.  The reaction was heated to 85 
°C for 1 hr.  The reaction mixture was cooled in an ice bath and sparged with nitrogen for 
2 hr.  With the flow of nitrogen continuing, NaOH was added (1.8 g, 45.0 mmol, 3 eq), and 
the reaction was stirred overnight at room temperature.  The reaction mixture was washed 
twice with t-butylmethylether.  The aqueous layer was cooled in an ice bath, and the pH 
was adjusted to 7 with 1 M HCl.  The solution was extracted three times with DCM.  The 
organic layers were dried with MgSO4, and the solvent was removed under reduced 
pressure.  The product was a white solid (119 mg, 6.3% yield).  1H NMR (400 MHz, CDCl3, 
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ppm): δ 2.00 (s, 1H, SH), 3.84 (s, 2H, CH2), 7.16 (m, 1H, Ar-H), 7.34 (m, 1H, Ar-H), 7.65 
(m, 1H, Ar-H), 8.53 (m, 1H, Ar-H).  
PyrCA via 2-pyridinemethanethiol (attempted) 
 EvaCA (118 mg, 0.48 mmol, 1 eq) and 2-pyridinemethanthiol (119 mg, 0.95 mmol, 
2 eq) were dissolved in acetonitrile.  DIPEA (165 µL, 0.95 mmol, 2 eq) was added, and the 
reaction was stirred under nitrogen for 24 hr.  Water was added to the reaction, and the 
solution was extracted twice with DCM.  The DCM layer was washed with brine and dried 
with MgSO4.  The solvent was removed under reduced pressure.  The crude material was 
analyzed by LC-MS and 1H NMR.  The desired product was not observed. 
5.9.2.8 2-Azidoethanethiol 
Bis-(2-bromoethydisulfide)45 
 Concentrated H2SO4 (10 mL) was added slowly to a solution of 48% HBr in an ice 
bath with stirring.  Then bis-(2-hydroxyethyl)disulfide (0.3 mL, 2.45 mmol) was added 
slowly to the acid mixture.  The reaction stirred overnight at room temperature.  DCM was 
added to the reaction and washed with water and 10% Na2CO3 (aq).  The DCM layer was 
dried with MgSO4 and removed under reduced pressure.  The product was a liquid (0.68 g, 
99% yield).  1H NMR (400 MHz, CDCl3, ppm): δ 3.08 (t, 4H, CH2), 3.59 (t, 4H, CH2).   
Bis-(2-azidoethyl)disulfide45 
 The bis-(2-bromoethyl)disulfide (0.23 g, 0.82 mmol, 1 eq) and sodium azide (0.26 
g, 4.0 mmol, 4.9 eq) were dissolved in 10 mL DMF.  The reaction was heated to 80 °C for 
18 hr.  Then water was added, and the product was extracted three times with ether.  The 
organic layer was dried with MgSO4 and removed under reduced pressure (0.14 g, 82% 
yield).  1H NMR (400 MHz, CDCl3, ppm): δ 2.87 (t, 4H, CH2), 3.60 (t, 4H, CH2).   
2-azidoethanethiol38 
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 Bis-(2-azidoethyl)disulfide (0.15 g, 0.75 mmol, 1 eq), dithiothreitol (0.34 g, 2.2 
mmol, 3 eq), and trimethylamine (0.6 mL, 4.3 mmol, 6 eq) were dissolved in THF under 
argon.  The reaction was stirred for 2 hr at room temperature and was monitored by TLC 
with an iodine stain.  Then 1 M HCl (aq) was added to acidify the solution.  The resultant 
solution was extracted twice with DCM.  The DCM was washed with 1 M HCl and water 
until the DTT spot on the TLC disappeared.  The DCM was allowed to evaporate.  The 
product was a volatile yellow liquid (74 mg, 49% yield).  1H NMR (400 MHz, CDCl3, 
ppm): δ 1.58 (t, 1H, SH), 2.70 (q, 2H, CH2), 3.46 (t, 2H, CH2).   
5.9.2.9 Triamine compound 
1,3,5-(azidomethyl)benzene48 
 To a flask was added 1,3,5-(bromomethyl)benzene (1 g, 2.8 mmol, 1 eq) in 5 mL 
DMF.  Sodium azide (1.1 g, 16.8 mmol, 6 eq) was added in portions over several minutes, 
and then the reaction was stirred at room temperature for 24 hr.  Water was added to the 
reaction, and the solution was extracted twice with DCM.  The DCM was washed with 
brine, dried with MgSO4, and removed under reduced pressure.   The product was a brown 
oil (459 mg, 67% yield).  1H NMR (400 MHz, CDCl3, ppm): δ 4.38 (s, 6H, CH2), 7.23 (s, 
3H, Ar-H).   
1,3,5-(aminomethyl)benzene47,48 
 To a flask was added 1,3,5-(azidomethyl)benzene (0.59 g, 2.3 mmol, 1 eq) and 
triphenylphospine (3.8 g, 14.5 mmol, 6.3 eq) in 10:1 THF/water.  The reaction was stirred 
at room temperature for 48 hr.  The solvent was removed under reduced pressure.  The 
residue was dissolved in a small amount of water and filtered to remove solids.  The water 
was removed by lyophilization to yield a yellow hygroscopic solid (0.25 g, 63% yield).  1H 
NMR (400 MHz, d-DMSO, ppm): δ 3.63 (s, 6H, CH2), 7.06 (s, 3H, Ar-H).   
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5.9.3 Peptide Synthesis 
The peptides were synthesized on an automated peptide synthesizer (Protein 
Technologies) using Fmoc chemistry and the Wang resin pre-loaded with Fmoc-12-
aminododecanoic acid.  For a 200 µmol-scale reaction, the Wang resin was swelled in 
DMF and then deprotected with 20% piperidine in DMF twice.  In between the resin was 
washed with DMF and DCM.  Each amino acid was dissolved in DMF (100 mM) and 
introduced to the resin after the deprotection step.  PyBOP (300 mM) and DIPEA (1.2 M) 
in DMF were added along with the amino acid to perform each coupling (twice).  The final 
residue was deprotected at the end.  The resin was then removed from the synthesizer.   
The resin was washed with DMF, DCM, MeOH, and glacial acetic acid and then 
dried overnight on the high vacuum line.  The peptides were cleaved from the resin with 
95% TFA, 2.5% TIPS, and 1% H2O for 4 hr.  The TFA solution was filtered from the resin, 
and the TFA was removed.  To the residue was added diethyl ether to precipitate the 
peptides.   
5.9.3.1 Model Peptide 
Before IAHRFKDLGE was cleaved from the resin, the N-terminus was acetylated 
by placing the resin in 5 mL of 50% acetic anhydride in DMF and 100 µL pyridine.  The 
reaction was allowed to proceed for 3 hr with shaking to mix.  Then the resin was washed 
and cleaved from the resin.  The crude peptide (100 µmol) was dissolved in 3 mL 
acetonitrile and 2 mL water.  DIPEA (120 µL, 600 µmol, 6 eq) and EvaCA (50 mg, 200 
µL, 2 eq) were added, and the reaction was stirred in an open vial for 24hr.  The presence 
of the product was confirmed by LC-MS.  The solvent was removed under reduced 
pressure. 
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5.9.3.2 Purification 
The crude peptides were dissolved in water/DMSO (no more than 50% DMSO) 
and purified by HPLC.  Fractions containing the desired peptide were verified by LC-MS, 
combined, and evaporated:   
 acIAHRFK(Eva)DLGE and acAHRFK(Eva)DLGE: 34.8 mg (25% yield); LRMS 
(ESI): 657.6, 714.1 ((M+1)/2), 1313.8, 1426.8 (M+1); HRMS (ESI): expected 
1314.58, found 1314.58, expected 1427.66, found 1427.66 (M+1) 
 VVKLKC: 59.3 mg (58% yield).  LRMS (ESI): 689.4 (M+1); HRMS (ESI): 
expected 689.44, found 689.44 (M+1) 
 KGGRKC: 61.9 mg (56% yield); LRMS (ESI): 648.4 (M+1); HRMS (ESI): 
expected 648.36, found 648.36 (M+1) 
 KRGSKC: 48.9 mg (43% yield); LRMS (ESI): 678.4 (M+1); HRMS (ESI): 
expected 678.37, found 678.37 (M+1) 
 KRSSKC: 64.3 mg (55% yield); LRMS (ESI): 708.4 (M+1); HRMS (ESI): 
expected 708.38, found 708.38 (M+1) 
 KAGLKC: 52.9 mg (55% yield); LRMS (ESI): 619.4 (M+1); HRMS (ESI): 
expected 310.18, found 310.18 ((M+1)/2) 
 KYPYKC: 56.6 mg (50% yield); LRMS (ESI): 801.4 (M+1); HRMS (ESI): 
expected 401.20, found 401.20 ((M+1)/2) 
 PRGDKC: 61.4 mg (60% yield); LRMS (ESI): 675.3 (M+1); HRMS (ESI): 
expected 338.17, found 338.17 ((M+1)/2) 
 KDGRKC: 65.0 mg (56% yield); LRMS (ESI): 706.3 (M+1); HRMS (ESI): 
expected 706.37, found 706.37 (M+1) 
 KGARCC: 40.7 mg (42% yield); LRMS (ESI): 637.3 (M+1); HRMS (ESI): 
expected 637.29, found 637.29 (M+1) 
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5.9.4 Small Molecule Test Reactions 
5.9.4.1 LysEvaCys 
 EvaCA (5 mg, 20 µmol, 1 eq) was dissolved in 100 µL acetonitrile.  The α-Boc-
lysine (5 mg, 20 µmol, 1 eq) was dissolved in 1 mL of 50 mM phosphate buffer, H2O, 10 
mM EDTA, pH 7.5.  The EvaCA solution was added dropwise to the lysine solution.  The 
reaction was stirred for 24 hr at room temperature.  LC-MS analysis indicated that the 
reaction had gone to completion (Figure 5.20 and 5.21).  LRMS (ESI): 445.2 (M-1).  Then 
NAC (3.6 mg, 22 µmol, 1.1 eq) was added to the solution.  The reaction was gently sparged 
with nitrogen and monitored by LC-MS over eight days, at which point the reaction had 
mostly completely (Figure 5.22).  LRMS (ESI): 560.2 (M-1). 
 
 
Figure 5.20 LC-MS analysis of LysEva reaction after 3 hr.  Top: TIC, positive mode, 
bottom: TIC, negative mode. 
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Figure 5.21 LC-MS analysis of LysEva reaction after 72 hr. Top: TIC, positive mode, 
bottom: TIC, negative mode. 
 
Figure 5.22 LC-MS analysis of LysEvaCys reaction after 8 days. Top: TIC, negative 
mode, bottom: UV trace, λ = 280 nm. 
5.9.4.2 LysEvaCys + DTT 
 LysEvaCys was prepared as described.  Then three equivalents of dithiothreitol was 
added to the solution, and the reaction was heated to 40 °C for 18 hr.  LC-MS analysis 
showed no LysEvaCys was present.   
5.9.4.3 CysEvaCys 
 EvaCA (6.0 mg, 24.2 µmol, 1 eq) was dissolved in 1 mL acetonitrile. NAC (8.3 
mg, 50.7 µmol, 2.1 eq) was dissolved in 5 mL of 50 mM phosphate buffer, H2O, 10 mM 
EDTA, pH 7.5.  The two solutions were combined.  The reaction was gently sparged with 
nitrogen and reacted overnight.  LC-MS analysis showed CysEvaCys (Figure 5.23).  
LysEva 
LysEvaCys 
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LRMS (ESI): 477.2 (M-1).  Then α-Boc-lysine (6.0 mg, 24.2 µmol, 1 eq) was added, and 
the reaction was stirred for 3 days.  It was monitored by LC-MS (Figure 5.24).  LRMS 
(ESI): 560.2 (M-1). 
 
 
Figure 5.23 LC-MS analysis of CysEvaCys after 18 hrs. Top: TIC, positive mode, 
bottom: TIC, negative mode. 
 
Figure 5.24 LC-MS analysis of LysEvaCys after 3 days. Top: TIC, positive mode, 
bottom: TIC, negative mode. 
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5.9.4.4 LysEvaBME 
 LysEva (19 µmol) was prepared as described.  Then 2-mercaptoethanol (BME, 
1900 µmol, 100 eq) was added, and the reaction was stirred for 5 hr. LRMS (ESI): 475.2 
(M-1). 
 
 
Figure 5.25 LC-MS analysis of LysEvaBME after 5 hr. TIC, negative mode. 
5.9.4.5 MPEvaVVKLKC 
 The peptides acIAHRFK(Eva)DLGE/acAHRFK(Eva)DLGE (1.9 mg, 1.15 µmol, 
1 eq) and VVKLKC (2.7 mg, 2.62 µmol, 2.3 eq) were dissolved in 10 mM carbonate buffer, 
pH 9.2.  The buffer capacity was exceeded, so 1 M NaOH (aq) was added to adjust the pH 
to 7.5.  The total reaction volume at the end of the adjustment was 1 mL.  The reaction was 
allowed to stir at room temperature for two weeks in an open Eppendorf tube.  The reaction 
was periodically replenished with H2O as it evaporated.  After this time, the solution was 
filtered and analyzed by LC-MS.  The desired products were present.  A sample was 
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submitted for MS analysis by our collaborators.  LRMS (ESI): 1034.7 ((M+1)/2), 978.2 
((M+1)/2), 690.3 ((M+1)/3), 652.6 ((M+1)/3), 518.0 ((M+1)/4), 489.7 ((M+1)/4). 
 
 
Figure 5.26 LC-MS analysis of MPEvaVVKLKC after 2 weeks. Top: TIC, positive mode, 
bottom: TIC, negative mode. 
5.9.4.6 MPEvaVVKLKC + DTT 
 To the solution of MPEvaVVKLKC (1.15 µmol, 1 eq) was added DTT (1 mg, 6.5 
µmol, 5.7 eq).  The reaction was stirred at room temperature in an open container for three 
days.  LC-MS analysis indicated that the reaction had occurred (Figure 5.27).  LRMS 
(ESI): VVKLKC- 230.7 ((M+1)/3), 345.2 ((M+1)/2), 689.4 (M+1); MP- 372.3 ((M+1)/3), 
410.0 ((M+1)/3). 
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Figure 5.27 MS analysis of MPEvaVVKLKC + DTT after 3 days.  
5.9.4.7 LysEvaLys and LysEvaLys + DTT 
 EvaCA (5.8 mg, 23.5 µmol, 1 eq) was dissolved in 300 µL acetonitrile, and α-Boc-
lysine (33.7 mg, 137 µmol, 5.8 eq) was dissolved in 2.5 mL of 50 mM phosphate buffer, 
H2O, 10 mM EDTA, pH 7.2.  The EvaCA solution was added to the lysine solution.  The 
reaction was heated to 45 °C for three days.  LC-MS analysis indicated some of the 
LysEvaLys product had formed (Figure 5.28).  LRMS (ESI): 643.2 (M+1). Then 
dithiothreitol (42 mg, 272 µmol, 11.6 eq) was added to the reaction, and the heating was 
continued for 24 hr.  LC-MS analysis indicated that the LysEva reacted with DTT, but the 
LysEvaLys did not react with DTT (Figure 5.29).   
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Figure 5.28 LC-MS analysis of LysEvaLys after 3 days. Top: TIC, positive mode, 
bottom: TIC, negative mode. 
 
Figure 5.29 LC-MS analysis of LysEvaLys + DTT after 24 hr. Top: TIC, positive mode, 
bottom: TIC, negative mode. 
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5.9.4.8 LysEvaAz and CuAAC reaction 
 EvaCA (4.7 mg, 19 µmol, 1 eq) was dissolved in 0.4 mL acetonitrile and added to 
a 2 mL solution of α-Boc-lysine (6.4 mg, 26 µmol, 1.4 eq) in 50 mM phosphate buffer, 
H2O, 10 mM EDTA, pH 7.5.  The reaction was gently sparged with nitrogen for 48 hr.  
Then 2-azidoethanethiol (5.9 mg, 57 µmol, 3 eq) was dissolved in 1 mL methanol and 
added to the reaction.  The reaction was stirred for 18 hr in an open vial, and then analyzed 
by LC-MS to confirm LysEvaAz (Figure 5.30). LRMS (ESI): 500.2 (M-1).  Then, 3-butyn-
1-ol (73 µL, 970 µmol), CuSO4•5H2O (36 mg, 144 µmol, 15%), and sodium ascorbate (38 
mg, 192 µmol, 20%) were added.  The reaction as stirred for 24 hr, and then a sample was 
taken and analyzed by LC-MS (Figure 5.31).  The reaction did not yield the desired 
product. 
 
 
Figure 5.30 LC-MS analysis of LysEvaAz after 18 hr. Top: TIC, positive mode, middle: 
TIC, negative mode, bottom: UV trace λ =300 nm. 
 
 286 
 
Figure 5.31 LC-MS analysis of Click reaction with LysEvaAz and 3-butyn-1-ol after 24 
hr. Top: TIC, positive mode, bottom: TIC, negative mode. 
5.9.4.9 LysEvaMEEEE and LysEvaMEEEE + DTT 
 LysEva was prepared as described (38 µmol).  To LysEva was added MEEEE (22 
µL, 115 µmol, 3 eq), and the reaction was stirred in an open container for 18 hr.  The 
reaction was analyzed by LC-MS to confirm LysEvaMEEEE (Figure 5.32). LRMS (ESI): 
607.2 (M-1).  Then, dithiothreitol (53 mg, 344 µmol, 9 eq) was added, and the reaction was 
stirred for 18 hr.  LC-MS analysis showed MEEEE and DTT-Eva adduct (Figure 5.33). 
LRMS (ESI): 305.2 (M-1). 
 
Figure 5.32 LC-MS analysis of LysEvaMEEEE reaction after 18 hr.  TIC negative mode. 
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Figure 5.33 LC-MS analysis of LysEvaMEEEE + DTT after 18 hr.  TIC negative mode. 
5.9.4.10 MPEvaMEEEE 
 The peptides acIAHRFK(Eva)DLGE/acAHRFK(Eva)DLGE (1.29 mg, 0.78 µmol, 
1 eq) were dissolved in 250 µL of water.  The pH of the solution was adjusted to 7 with 10 
mM NaOH (aq), resulting in a total volume of 1 mL.  MEEEE (2 µL, 10.4 µM, 13.3 eq) 
was added to the solution, and the reaction was stirred for 20 hr in an open vial.  LC-MS 
analysis showed the desired product (Figure 5.34).  LRMS (ESI): 738.9 and 795.4 
((M+1)/2). 
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Figure 5.34 MS analysis of MPEvaMEEEE after 20 hr.  Left: negative mode, Right: 
positive mode. 
5.9.4.11 DTT-Eva Adduct 
 EvaCA (3.37 mg, 1.5 µmol, 1 eq) and dithiothreitol (2.27 mg, 1.5 µmol, 1 eq) were 
dissolved in 1.5 mL CD3CN.  The reaction was stirred in an open vial for 24 hr.  
1H NMR 
(400 MHz, CD3CN, ppm): δ 1.66 (s, 6H, CH3), 2.82 (m, 2H, CH2), 3.41 (m, 2H, CH2), 3.59 
(m, 1H, CH), 3.81 (s, 1H, OH), 3.89 (s, 1H, OH), 5.36 (m, 1H, CH).  13C NMR (400 MHz, 
CD3CN, ppm): δ 26.01 (CH3), 27.33 (CH2-SH), 30.69 (CH2-SH), 72.45 (CH2-OH), 91.29 
(CH-OH), 103.45 (C-O, -CH3, -CH3), 103.45 (C=C, -C, -C), 158.13 (C=O), 163.95 (C=O), 
not observed (C=C,-S, -O). LRMS (ESI): 305.2 (M-1). 
5.9.4.12 EDT-Eva Adduct 
 EvaCA (6.7 mg, 27 µmol) and ethanedithiol (2 µL, 24 µmol) were dissolved in 0.75 
mL CD3CN.  The reaction was stirred in an open vial overnight.  
13C NMR (400 MHz, 
CD3CN, ppm): 20.73 (CH3-C), 25.93 (CH3-S), 26.12 (CH2-SH), 38.38 (CH2-S), 102.98 
(C=C, -C, -C), 103.67 (C-O, -CH3, -CH3), 159.74, 161.30 (C=O), not observed (C=C,-S, -
S).   
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5.9.4.13 PE3C3 
 The triamine (6.35 mg, 38 µmol, 1 eq) was dissolved in 4 mL of 0.1 M phosphate 
buffer, 0.15 M NaCl, H2O, pH 7.2.  EvaCA (29.5 mg, 119 µmol, 3 eq) was dissolved in 2 
mL acetonitrile.  The solutions were combined and stirred for 36 hr.  The solution became 
cloudy, so MeCN was added to dissolve the components.  NAC (39 mg, 239 µmol, 6.3 eq) 
was added, and the reaction was monitored over four days with LC-MS (Figure 5.35 and 
5.36).  LRMS (ESI): PE3 764.0 (M-1), PE3C 879.0 (M-1), PE3C2 994.0 (M-1), PE3C3 
1109.0 (M-1).   
 
 
Figure 5.35 LC-MS analysis of PE3 reaction with NAC after 48 hr.  UV trace λ = 300 
nm. 
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Figure 5.36 LC-MS analysis of PE3 reaction with NAC after 4 days.  UV trace λ = 300 
nm. 
5.9.4.14 PE3C3 + DTT 
 PE3C3 was prepared as described (41 µmol) in 36 hr by adding more MeCN to 
dissolved PE3 and gently sparging with nitrogen.  Then, DTT (63 mg, 408 µmol, 10 eq) 
was added and reacted for three days (Figure 5.37). LRMS (ESI): 305.2 (M-1).     
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Figure 5.37 MS analysis of PE3C3 reaction with DTT after 3 days.  Negative mode. 
5.9.4.15 PE3C3 + 3-Mercaptopropionic Acid 
 PE3C3 was prepared as described (16.3 µmol).  Then, 3-mercaptopropionic acid 
(8.7 µL, 100 µmol, 6 eq) was added, and the reaction was monitored by LC-MS for ten 
days (Figure 5.38).  LRMS (ESI): PE3 764.0 (M-1), PE3C 879.0 (M-1), PE3C2 994.0 (M-
1), PE3C3 1109.0 (M-1), PE3M3 938.0 (M-1), PE3M2C 994.8 (M-1), PE3MC2 1051.8 (M-
1), PE3M2 879.8 (M-1). 
. 
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Figure 5.38 MS analysis of reaction of PE3C3 with 3-mercaptopropionic acid.  Left: 
after 48 hr, negative mode, right: after 8 days, negative mode. 
5.9.4.16 Coupling of Triamine to Tentagel S Br (Resin-P) 
 Tentagel S Br (0.26 mmol/g, 107 mg, 27.8 µmol, 1 eq) was placed in 5 mL of 1:1 
water/MeCN and stirred for 15 min to swell the resin.  The triamine (14.1 mg, 85.5 µmol, 
3.1 eq), proton sponge (18.5 mg, 86.3 µmol, 3.1 eq), and NaI (16 mg, 107 µmol, 3.8 eq) 
were added to the solution.  The reaction was heated to 80 °C for 20 hr.  The beads were 
washed with water and methanol and subjected to a Kaiser test.  The test was positive for 
amine.  The resin was dried thoroughly under vacuum. 
5.9.4.17 Kaiser Test 
 Solutions: KCN (16.5 mg KCN in 25 mL H2O, then 1 mL of this solution was 
diluted to 50 mL total in pyridine).  Ninhydrin (1 g ninhydrin dissolved in 10 mL ethanol). 
Phenol (20 g phenol in 10 mL ethanol).  To a few beads of resin was added three drops of 
each of the three solutions.  The solution was heated to 100 °C for 10 minutes to develop 
the color.  Blue/purple = amine. 
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5.9.4.18 Resin-PE2 
 Resin-P (107 mg, 27.8 µmol, 1 eq) was placed in 3 mL of 0.1 M phosphate buffer, 
0.15 M NaCl, H2O, pH 7.  EvaCA (28 mg, 113 µmol, 2 eq) was dissolved in 2 mL MeCN 
and added to the resin.  The reaction was gently sparged with nitrogen for 24 hr.  Then the 
resin was washed with water and methanol and subjected to a Kaiser test (negative for 
amine).   
5.9.4.19 Resin-PE2C2 
 Resin-PE2 (11.67 mg) was placed in 1 mL of 0.1 M phosphate buffer, 0.15 M NaCl, 
H2O, pH 7.2, and NAC (2 mg, 12.14 µmol) was added.  The reaction was gently sparged 
with nitrogen for 2.5 days.  The resin was washed with water and methanol.  Then, a 
solution of DTT (6.15 mg, 40 µmol) was added to the resin.  The reaction was stirred for 
36 hr.  Then the solution was collected and analyzed by LC-MS (Figure 5.39 and 5.40).  
The resin was washed and subjected to a Kaiser test (positive for amine).   
 
 
Figure 5.39 LC-MS analysis of the flow-through from the DTT reaction with resin-
PE2C2.  TIC positive mode. 
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Figure 5.40 LC-MS analysis of the flow-through from the DTT reaction with resin-
PE2C2.  TIC negative mode. 
5.9.4.20 DCL 
The peptides were dissolved in 0.1 mM phosphate buffer, 0.15 mM NaCl, H2O, pH 
7.4 (Table 5.2).  Portions of resin-PE2 were weighed out (A- 1.79 mg, B- 1.40 mg).  To 
each resin was added the appropriate volume of each peptide solution (Table 5.2).  To 
reaction B was added BSA (16.44 mg, 0.25 µmol).  The total volume of each library was 
0.5 mL.  The libraries were allowed to react for six days.  Then the solutions were removed, 
and the resins were washed with water and methanol.  To each resin was added 1 mL of a 
2.96 mM DTT solution in 0.1 mM phosphate buffer, 0.15 mM NaCl, H2O, pH 7.4 (2.96 
µmol).  The reaction was stirred for 36 hr.  Then the solutions were collected and analyzed 
by RP-HPLC with 5% MeCN for 5 minutes, 5-95% MeCN for 30 minutes.  
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Table 5.2 Summary of peptide solutions and DCL setup. 
Peptide MW 
(g/mol) 
mg vol 
(mL) 
concentration 
(mM) 
vol added to 
library (µL) 
concentration in 
library (mM) 
KGGRKC 1103.89 61.9 5 11.2 44.6 0.8 
KRGSKC 1133.92 48.9 5 8.6 58.0 0.8 
KRSSKC 1163.94 64.3 5 11.0 45.3 0.8 
KAGLKC 960.86 52.9 5 11.0 45.4 0.8 
KYPYKC 1143.04 56.6 5 9.9 50.5 0.8 
PRGDKC 1016.84 61.4 5 12.1 41.4 0.8 
KDGRKC 1161.93 65.0 5 11.2 44.7 0.8 
KGARCC 978.86 40.7 5 8.32 60.1 0.8 
 
5.9.5 Protein Modification Reactions 
5.9.5.1 BSA Reduction by DTT21 
A 1.5-g portion of BSA was added to an argon-flushed flask.  To this flask 40 mL 
of deoxygenated buffer (20 mM PBS, 45 mM NaCl, 1.1 μM EDTA) was added.  A 0.55 M 
solution of DTT in buffer was prepared and deoxygenated and then added to the BSA 
solution.  The reaction was stirred for 45 min.  The reaction mixture was transferred to 
dialysis tubing under nitrogen and dialyzed against 6 L of 0.1 mM EDTA, 100 mM HCl, 
50 mM NaCl with two changes over 18 hr.  The solution was removed from the tubing 
under N2 and placed in a flask under Ar.  It was subjected to the Ellman test as described 
below. Ellman test results varied between samples with an average of 20 mol SH/mol BSA 
(s = 5) based on seven reaction products.   
5.9.5.2 BSA Thiolation with AHTL21 
In 10 mL of water 0.5 g BSA and 0.06 g N-acetylhomocysteine thiolactone (AHTL, 
50 eq) were dissolved.  A 100 mM silver nitrate solution was prepared in water (0.085 g in 
5 mL) and added dropwise to the BSA/AHTL solution over 15 min.  In order to maintain 
a pH of about 7 during the course of this addition, 1 M NaOH was added concurrently over 
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the 15 min.  The pH was monitored by narrow-range pH paper.  As the silver nitrate was 
added, a white precipitate formed in the solution.  To the reaction was added 3.25 mL of a 
500 mM thiourea solution in water, and then the reaction was acidified with 1 M HCl to 
pH 2.  During the acidification the solution first cleared and turned yellow and then turned 
a milky brown at pH 2.  The solution was filtered and passed through an ion exchange 
column to remove silver (Amberlite IR-120 H+ ion exchange resin) with a water mobile 
phase.  This process was repeated three times.  The solution was dialyzed against 24 L of 
5 mM HCl over 18 hr with two changes.  The product was subjected to the Ellman test as 
described below.  Ellman test registered an average of 17 mol SH per mol BSA (s = 2) 
based on five reaction products. 
5.9.5.3 BSA Thiolation with SATA and Deprotection15 
BSA (1.0 g, 15.04 μmol) was dissolved in 40 mL of 0.1M PBS buffer (0.15M NaCl, 
pH 7.2).  N-succinimidyl S-acetylthioacetate (172 mg, 752 μmol, 50 eq) was dissolved in 
4 mL DMSO and added to the BSA solution.  The reaction was stirred overnight (18 hr).  
The reaction mixture was dialyzed against 9 L total of 0.1M PBS, 50 mM EDTA, 0.2 w/v 
% NaN3, pH 7.5 with two changes for several days until the SATA smell was absent.  The 
protein solution was removed from the dialysis tubing and filtered.  The protein 
concentration was measured as described below to be 253 μM (n = 4, s = 5) with a total 
volume of about 33 mL.  A 20-mL portion of this solution was taken and to it was added 
2.53 mL of a 1 M solution of hydroxylamine in buffer (0.1M PBS, pH 7.2).  To adjust the 
pH back to 7.5, 1 M NaOH was used.  The reaction was stirred for 2.5 hr.  Next, the reaction 
was subjected to the Ellman test and then dialyzed against 0.1 M PBS, 50 mM EDTA, 0.2 
w/v % NaN3, pH 7.5 (5 L total with two changes over 24 hr).  The Ellman test registered 
an average of 11 mol SH per mol BSA (s = 4) from four reactions. 
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5.9.5.4 Reaction of t-BSA with Methyl Vinyl Ketone 
A portion of t-BSA solution in buffer (0.1 M PBS, 50 mM EDTA, 0.2 w/v % NaN3, 
pH 7.5) was made 5 mM in DTT.  The reaction was placed under nitrogen and half of the 
DTT was added.  After stirring for 30 min, the other half of the DTT was quickly added. 
To the protein solution was added methyl vinyl ketone.  The amount of MVK added was 
calculated by the following equation so that an appropriate excess would be achieved based 
on the approximate number of thiols on the protein and the thiols from unreacted DTT in 
the solution: 
 𝑚𝑜𝑙 𝑀𝑉𝐾 = [(𝑚𝑜𝑙 𝐵𝑆𝐴 ∗ 20) + (𝑚𝑜𝑙 𝐷𝑇𝑇 ∗ 2)] ∗ 50 
The reaction stirred overnight at which point the reaction had turned orange.  The 
reaction mixture was dialyzed against 6 L of water overnight (one change) until the smell 
of MVK was absent.  The solution was concentrated by about one third with Aquacide II.  
Then it was dialyzed against 4 L of 10 mM PBS, 0.2 w/v % NaN3, pH 7 overnight (one 
change).   Finally, the solution was filtered and the concentration measured. 
5.9.5.5 BSAEvaVVKLKC 
 EvaCA (17.4 mg, 70 µmol, 115 eq) was dissolved in 0.7 mL MeCN.  BSA (40.5 
mg, 0.6 µmol, 1 eq) was dissolved in 4.5 mL of 50 mM phosphate buffer, H2O, 10 mM 
EDTA, pH 7.5.  The EvaCA solution was added to the BSA solution.  The reaction was 
stirred in an open vial for 18 hr.  The reaction was filter and purified by 10 kDa MWCO 
centrifugal filter unit against 50 mM phosphate buffer, H2O, 10 mM EDTA, pH 7.5.  The 
concentration of the protein solution was found to be 107 µM by Bradford assay (0.11 
µmol, 1 mL).  To the BSAEva was added VVKLKC (2.18 mg, 2.11 µmol, 20 eq).  The 
reaction was stirred in an open vial for two weeks.  The reaction was filtered and purified 
by 10 kDa MWCO centrifugal filter unit against 50 mM phosphate buffer, H2O, 10 mM 
EDTA, pH 7.5.  The sample was digested and analyzed by LC-ESI-MS3 (see 5.8.6).   
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5.9.5.6 BSAEvaVVKLKC + DTT 
 BSAEvaVVKLKC was prepared as described (0.04 µmol).  To the protein solution 
was added dithiothreitol (4.5 mg, 29 µmol, 725 eq).  The reaction was heated to 40 °C for 
18 hr.  The protein solution was purified by 10 kDa MWCO centrifugal filter unit against 
50 mM phosphate buffer, H2O, 10 mM EDTA, pH 7.5.  The flowthrough was collected 
and subjected to LC-MS analysis, which showed VVKLKC and DTT-Eva adduct. 
5.9.5.7 BSAEvaCys 
 EvaCA (12 mg, 48 µmol, 1 eq) was dissolved in 0.5 mL acetonitrile and added to 
a 5 mL solution of NAC (16.6 mg, 102 µmol, 2.1 eq) in 0.1 M phosphate buffer, 0.15 M 
NaCl, H2O, pH 7.2.  The reaction was gently sparged with nitrogen for 24 hr.  Then BSA 
(64 mg, 0.96 µmol, 0.02 eq) was added, and the reaction was stirred for three days.  The 
reaction was filtered and purified by 10 kDa MWCO centrifugal filter unit against 0.1 M 
phosphate buffer, 0.15 M NaCl, H2O, pH 7.2.  The sample was digested and analyzed by 
LC-ESI-MS3 (see 5.8.6).   
Eva- 100, 156, 198, 204, 264, 297, 336, 340, 399, 402, 580 
EvaCys- 580, a few on 204, 336, 340 
5.9.5.8 MyoEvaMEEEE 
 Equine skeletal muscle myoglobin (14 mg, 0.82 µmol, 1 eq) was dissolved in 4 mL 
of 0.1 M phosphate buffer, 0.15 M NaCl, H2O, pH 7.2.  EvaCA (8.2 mg, 33 µmol, 40 eq) 
was dissolved in 0.5 mL acetonitrile and was added to the myoglobin solution.   The 
reaction was stirred in an open container for 24 hr.  The protein was filtered and purified 
against 0.1 M phosphate buffer, 0.15 M NaCl, H2O, pH 7.2 with 10 kDa MWCO 
centrifugal filter units.  Then the MEEEE (16 µL, 84 µmol, 102 eq) was added, and the 
reaction was stirred for another 24 hrs.  The protein was filtered and purified against 0.1 M 
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phosphate buffer, 0.15 M NaCl, H2O, pH 7.2 with 10 kDa MWCO centrifugal filter units.  
A sample was taken of MyoEvaMEEEE and submitted for LC-ESI-MS3 analysis (see 
5.8.6).  To the remainder was added dithiothreitol (12.8 mg, 83 µmol, 101 eq), and the 
reaction was stirred for 36 hr.  The protein was filtered and purified against 0.1 M 
phosphate buffer, 0.15 M NaCl, H2O, pH 7.2 with 10 kDa MWCO centrifugal filter units.  
The protein sample was submitted for intact ESI-MS, while the flow-through was collected 
and analyzed by LC-MS (Figure 5.41).  MEEEE and DTT-Eva adduct was observed. 
 
 
 
Figure 5.41 LC-MS analysis of flow-through from reaction of MyoEvaMEEEE and DTT.  
Top: TIC positive mode, bottom: TIC negative mode. 
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5.9.6 Protein Characterization 
5.9.6.1 BSA Concentration Measurement  
Lowry Method21 
To a quartz UV-VIS cuvette was added 2 mL of water, which was used to blank 
the spectrophotometer over 250-350 nm. Protein solution was added to the water, and the 
absorbance was measured over that range.  The reported extinction coefficient of 43,824 
cm-1M-1 at 280 nm for BSA was used to calculate the concentration of the protein solution 
in the cuvette.  The concentration of the original protein solution was calculated from the 
dilution.  Several trials were performed and averaged to obtain the protein concentration. 
Bradford Assay55 
A solution of Coomassie Blue G dye was prepared by dissolving 100 mg of dye in 
50 mL of methanol.  This solution was added to 100 mL of 85% H3PO4, and water was 
added to dilute to a total volume of 200 mL to yield a dark red solution.  Standard solutions 
of BSA were prepared in 10 mM phosphate buffer, H2O, pH 7.0, 0.02% NaN3 (2, 4, 6, 8, 
10, 12 µM).  Then, 1 part dye stock was diluted with 4 parts water (e.g. 10 mL dye solution 
+ 40 mL water).  The protein samples to be measured were generally diluted by 1/10 to 
bring them within the concentration range of the BSA standards.  The diluted dye solution 
(2 mL) was mixed with 30 µL of each BSA standard and each diluted sample to be 
measured.  The absorbance at 595 nm of each solution was measured to generate a 
calibration curve from the BSA standards.  From the calibration curve, the concentration 
of the unknown protein samples was determined based on their absorbance at 595 nm.   
5.9.6.2 Ellman test17,18  
A solution of DTNB was prepared by dissolving 20 mg in 5 mL of 0.1 M PBS, pH 
8.  The protein solution was diluted to a concentration of about 0.2 μM in 0.1 M PBS, pH 
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8.  To 3 mL of this protein solution was added 0.1 mL of DTNB solution.  It was allowed 
to react for 15 minutes.  A “blank” was also prepared by adding 0.1 mL of DTNB solution 
to 3 mL of 0.1 M PBS, pH 8.  The absorbance for each sample was read at 410 nm.  The 
“blank” absorbance was subtracted from the absorbance of each sample. The concentration 
of thiol was calculated from the extinction coefficient for 2-nitro-5-mercaptobenzoic acid, 
13,560 cm-1M-1.  Several trials were performed and averaged to obtain the concentration 
of thiol. 
5.9.6.3 Quantitative Ninhydrin Test19,56 
 The protein samples to be tested were diluted to approximately 10 µM in 10 mM 
phosphate buffer, H2O, pH 7.00, 0.02% NaN3.  A native BSA sample was used as a control 
for the total measurable amine content.  Amine standards were prepared from glycine (10 
µM- 500 µM in 10 mM phosphate buffer, H2O, pH 7.00, 0.02% NaN3).  The dye solution 
was prepared from ninhydrin (2 g) and hydrindantin (0.3 g) dissolved in 75 mL DMSO and 
25 mL 4 M acetate buffer, H2O, pH 5.5.  Each of the sample solutions (1 mL of protein or 
glycine solution) were mixed with dye solution (1 mL).  The solutions were heated to 100 
°C for 15 min.  The solutions were allowed to cool, and then 5 mL of a 1:1 water/ethanol 
solution were added.  The absorbance of the resultant solutions was measured at 570 nm.  
A calibration curve was constructed from the glycine standards absorbance values, and the 
amine content of the protein samples was determined from this plot.   
5.9.6.4 Mass Spectrometric Analysis 
Protein digestion 
A 200-µg portion of protein was reduced with a 100-fold excess of dithiothreitol 
(DTT) with respect to protein for 60 minutes at 60 °C then incubated with a 400-fold excess 
of iodoacetamide with respect to protein at 37 °C for 30 minutes in the dark. Excess 
 302 
iodoacetamide was quenched with additional DTT. Then a 1 µg/ µL solution of GluC in 1 
mM HCl was added giving a protein-to-enzyme ratio of 20:1. The digestion solution was 
incubated over night at 37 °C. The digest was desalted using C18 cartridges then dried and 
reconstituted in water to a concentration of 1 µg/µL. 
MS analysis 
The LC instrument used was a Dionex Ultimate 3000.  Mobile phase A was water 
with 0.1% formic acid, and mobile phase B was acetonitrile with 0.1% formic acid.  The 
gradient was 5% to 40% mobile phase B over 60 min.  The ion source was electrospray 
ionization. The mass analyzer used was a Bruker Daltronics HCT quadropole ion trap.  
Collision-induced dissociation with helium gas was used for ion fragmentation.  The 
algorithm used was MassMatrix (MassMatrix.net). 
5.9.7 Titrations 
The experimental details for the titrations can be found in the corresponding figure 
captions. 
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